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Type 2 diabetes mellitus plays a crucial role in causing bone impairments and 
fragility fractures.  Incretin hormones such as glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are known to augment 
insulin secretion from pancreatic beta-cells. There is mounting evidence which 
points out that these incretin hormones do have positive effects on bone.  Especially, 
GIP is known to have dual action on bone as it enhances osteoblasts which are bone 
forming cells and reduces bone resorption by osteoclasts. There are mixed results 
regarding effects of GLP-1 on the bone and the mechanism of action is less clear. 
However, one cannot rule out the positive findings of several studies highlighting 
beneficial effects of GLP-1 on the bone. The scientific community is taking an 
interest in designing oligopeptide as a promising approach in the treatment against 
bone fractures. The main focus of this thesis is to assess the potential beneficial 
effects of bone-specific oligopeptides and its analogues on sarcoma osteogenic 
SAOS-2 cells as well as assess the impact of these analogues on bone directly 
through in-vivo studies. Furthermore, the use of highly advanced sophisticated 
imaging techniques provides deeper understanding of bone tissue microarchitecture 
and bone integrity. (D-Ala2)GIP and bone-specific (D-Ala2)GIP-Asp enhanced bone 
biomarker-alkaline phosphatase activity in human osteoblastic SAOS-2 cells. Bone-
specific analogue (D-Ala2)GIP-Asp possessed similar insulin secretory actions as (D-
Ala2)GIP in BRIN-BD11 cells. Treatment with (D-Ala2)GIP-Asp improved glucose 
homeostasis and insulin sensitivity in high fat fed mice. (D-Ala2)GIP-Asp increased 
bone mineral content (BMC) in tibia highlighting positive effects of (D-Ala2)GIP-
Asp on bone. Bone matrix properties such as bone marrow diameter, total area and 
cortical thickness were increased in the mice treated with (D-Ala2)GIP-Asp. 
Collagen cross-linking was enhanced by (D-Ala2)GIP-Asp. The results of xenin 
analogue on bone were inconsistent. The bone-specific analogue namely, Xenin-
25[Lys13PAL]-Asp did not showed any beneficial effects on bone but overall, Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp showed beneficial metabolic effects in 
lean as well as high fat fed mice. Further studies need to be carried out to assess the 
positive impact of Xenin-25[Lys13PAL]-Asp on bone. Varying degrees of benefit of 
the bone-specific hybrid peptide, namely GIP/Xenin-Asp and GIP/Xenin-Glu, were 
found on bone in high-fat fed mice. Once daily administration of GIP/Xenin-Asp and 
xiv 
 
GIP/Xenin-Glu enhanced tibial bone mineral density. GIP/Xenin treatment increased 
trabecular bone volume and number of trabeculae in high fat fed mice.  No effects of 
GIP/Xenin-Asp and GIP/Xenin-Glu were seen on bone matrix and tissue material 
properties. This thesis sheds light upon immense potential of incretin-based 
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1. 1 DIABETES MELLITUS  
Diabetes mellitus is a metabolic disease where the pancreas 
cannot produce sufficient insulin, or bodily tissues cannot 
effectively utilise it (Effoe et al. 2017, Moon et al 2017 and 
Kodama et al. 2017). Hence, blood glucose levels are elevated in 
the body in diabetes. There are two major forms of diabetes 
mellitus; type 1 diabetes mellitus (T1DM) and type 2 diabetes 
mellitus (T2DM). Currently, there are more that 400 million 
people in the world affected by diabetes (International Diabetes 
Federation, 2015). It is projected that, in 2035, 592 million 
individuals will be affected with diabetes imposing tremendous 
burdens on health care systems. According to Diabetes UK, 
from November 2016, there are almost 3.6 million people who 
have been diagnosed with diabetes in United Kingdom 
(Northern Ireland-88,000; Wales-188644; England-3,033,529 
and Sctoland-280,023). There are various well-characterised 
complications associated with diabetes which include 
retinopathy, neuropathy, nephropathy, cardiovascular diseases. 
(Diabetes UK, 2014). As well as there is growing evidence to 
suggest that diabetes can cause bone fragility and increase the 
risk of bone fractures (Palmero et al. 2017, Westberg-
Rasmussen et al. 2017 and Sanches et al. 2017). Various studies 
have pointed out that diabetes can cause severe impairment of 
bone microarchitecture, reduce bone mineral density (BMD) and 
bone mineral content (BMC) in T1DM patients. In T2DM 
patients, BMD is found to be slightly elevated, but increased 
fracture risk still persists (Vestgaard 2007, Ponti et al. 2017 and 
Perez-Saez et al. 2017). There are inconsistencies with BMD, 
but without doubt diabetes plays an important role in causing 
bone fractures (Jiao et al. 2015). This whole new frontier of 
diabetes and bone fragility fractures needs to be studied 




1.1.1Type 1 diabetes mellitus (T1DM)  
  T1DM is mostly seen in young adults and accounts for 10% of 
the cases of diabetes worldwide (International Diabetes 
Federation, 2014). Type 1 diabetes mellitus is characterised by 
inability of body to produce sufficient insulin due to 
autoimmune destruction of pancreatic β cells (American 
Diabetes Association Definition). Therefore, the patient has to 
depend on exogenous insulin to maintain blood glucose 
concentration after ingestion. It is believed that over expression 
of CD4+ and CD8+ T cells by pancreatic β cells, ultimately leads 
to destruction of insulin producing β cells in T1DM (Graham et 
al. 2012). Genetic and environmental factors do play an 
important role in pathogenesis of T1DM. Genetic factors mainly 
include major histocompatibility complex human leukocyte 
antigen (HLA) alleles, such as DR3-DQ2 and DR4-DQ8 that 
strongly contribute to T1DM (Atkinson & Eisenbarth 2001). 
Environmental factors, such as viruses which can cause 
abnormal activation of immune system, has been shown to lead 
to the generation of β cell specific auto-antibodies (Napoli et al. 
2016). 
 1.1.2 Type 2 diabetes mellitus (T2DM)  
T2DM is characterised by inability of β cells to produce 
sufficient insulin coupled with an ineffective utilisation of 
insulin by peripheral tissues (Bolen et al. 2017, Powers et al. 
2017). T2DM accounts for 90% cases of diabetes worldwide and 
is generally reported in middle aged and older individuals 
(Fareed et al. 2017, Pan et al. 2017). In order to maintain normal 
blood glucose levels, compensatory bodily mechanisms come 
into action, which respond to insulin resistance by secreting 
more insulin to maintain steady blood glucose levels (Drucker 
2006). However, eventually beta-cell exhaustion occurs and the 
body cannot produce sufficient insulin, leading to overt 
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hyperglycemia. There are several environmental factors that 
contribute to T2DM that include pregnancy, ageing, obesity, 
physical inactivity and poor diet (Balcerczyk et al. 2017, 
Romieu et al. 2017). Genetic associations also exist, and genetic 
predisposition are linked to mutations in TCF7L2, PPARG, 
CAPN10, MC4R, FTO, KCNJ11 and KCNQ1 genes (Valeria et 
al. 2007, Taharani et  al. 2011, Basil et al. 2014, Prasad & 
Groop 2015). The biggest concern regarding T2DM is that it can 
progress symptom free for many years before clinical diagnosis 
(Wilmot & Idris 2014, Chaudhury et al. 2017). 
1.1.3 Diabetes and fracture risk  
Bone fracture risk is elevated in diabetes, and is considered to be 
higher in T1DM than T2DM (Moayeri et al. 2017). Several 
studies have clearly revealed reduced BMD in T1DM patients 
(Hampson et al. 1998, Miazgowski & Czekalsi 1998, 
Vestergaard 2007, Rakel et al 2008). In contrast, T2DM patients 
have normal or sometimes elevated BMD (Schwartz et al. 2000, 
Petit et al. 2010 and Asokan et al. 2017). Even though T2DM 
patients have elevated BMD, they are still at higher risk of bone 
fractures (Moseley 2012). As such, focus on potential for bone 
fracture should not be entirely dependent upon BMD, as there 
are many other factors such as neuropathy and retinopathy could 
lead to higher risk of falling in diabetic patients (Schwartz et al. 
2002) and postural instability (Moseley 2012). In addition, 
Yamagishi et al. reported interaction of advanced glycation end 
products (AGEs) and collagen in bone reduces bone strength, 
leading to osteoporosis in diabetic patients (Yamagishi et al. 
2005, Alikhani et al. 2007). Further, AGEs may stimulate 
apoptosis of osteoblasts, causing defective bone formation 
(Asokan et al. 2017). Some studies have pointed out that low 
levels of vitamin D and altered vitamin D metabolism may lead 
to osteoporosis and eventually increased fracture risk in diabetes 
(Wientroube et al. 1980, Vogt et al. 1997, Caprio et al. 2017).  
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BMD is strongly associated with body weight, ageing and lean 
mass, which are all important in the diagnosis and progression 
of diabetes (Ooms et al. 1993, De Laet et al. 2005, Hirschfeld et 
al. 2017). Figure 1.1 summarises the major factors that may be 
responsible for increased bone fracture risk in T2DM 
(Mosenzon et al. 2015). 
 1.1.4 Existing treatment for diabetes  
The current approved treatment for T1DM is daily injections of 
exogenous insulin (Heise et al. 2017). As well as insulin 
injection, there are other treatment options for T1DM which 
mainly include islet-cell transplantation. Transplantation is an 
issue in T1DM because of the altered immune systems in this 
individual and possible organ rejection (Kolb & Herrath 2017). 
In addition, drugs that are used to prevent organ rejection have 
been shown to have negative effects on beta-cell insulin 
secretion (Langsford et al. 2017). Moreover, there is short 
supply of organs, and until new sources of functional islets are 
found, the future remains uncertain. Regarding T2DM, several 
drugs, or drug combinations, have been approved. Although, 
there are some inconsistencies regarding effective dosing and 
related side effects, most of these drugs are fairly well tolerated 
by patients (Table 1.1). However, the impact of these drugs to 
help prevent bone fractures are not yet well established (Table 
1.2). In addition, it should be remembered that the normal 
measures of BMD to assess fracture risk, are likely not be 







Figure 1.1 Factors responsible for higher fracture 
risk 
 
Schematic representation of factors responsible for 
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Once a day 
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Once a day 
Albiglutide 30 mg Once a week 
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 Dapagliflozin 10 mg  
 
AMPK: AMP-Activated protein kinase; DPP-4: Dipeptidyl peptidase-4;; GLP-1r: Glucagon-like peptide 1 receptor; LAR: 
Long-acting release; SGLT2: Sodium–glucose co-transporter 2; PPAR: Peroxisome proliferator-activated receptor. 
 
Taken from (Tahrani et al. 2011, Inzucchi et al. 2012, 
Mabilleau et al. 2015)    
 
Metformin is now considered the first-line of treatment agent in 
T2DM (Upadhyay et al. 2017). It is an oral antidiabetic drug 
that belongs to biguanide class (WHO- Dept of Essential 
Medicines and Health Products). Its mechanism of action 
involves activation of AMP-activated protein kinase which 
results in suppression of hepatic glucose production and 
increases insulin sensitivity. Metformin directly inhibits the 
mitochondrial respiratory chain complex through inhibition of 
mitochondrial glycerophosphate dehydrogenas, which leads to 
suppression of gluconeogenesis (Madiraju et al. 2014). 
Interestingly, other recent evidence has suggested that 
metformin benefits in T2DM could be linked to suppression of 
hepatic glucagon signalling (Miller et al. 2013). There is 
controversial evidence when it comes to the action of metformin 
on bone. Metformin has been shown to enhance type I collagen 
and osteocalcin expression, increase alkaline phosphatase 
activity and promote the bone mineralisation process (Kanazawa 
et al. 2008). Metformin also reduces osteoclast activity by 
disrupting CaMKK and TAK1 (Mai et al. 2011). However, very 
few clinical studies have reported a reduced risk of fracture with 
metformin (Meier et al. 2008, Melton et al. 2008, Vestergaard et 
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al. 2009) and the majority of studies show no effect on fracture 
risk (Kanazawa et al. 2010, Colhoun et al. 2012 and Napoli et 
al. 2014).   
Sulphonylureas are also extensively used in the treatment of 
T2DM (Deacon & Lebovitz 2016). Their mechanism of action 
involves binding to sulfonylurea receptors, which leads to the 
closure of KATP channels on the β-cell plasma membrane. 
Subsequently, this leads to closure of potassium channels and 
opening of voltage-dependent calcium channels that stimulates 
insulin secretion (Roder et al. 2016, Baumgard et al. 2016). 
There is evidence which suggest that sulphonylureas has some 
positive effects on osteoblast and enhance alkaline phosphatase 
activity (Chandran 2017, Lecka-Czernik 2017). However, 
another most important aspect is that sulphonylureas are 
associated with higher incidences of hypoglycaemia that 
increases risk of fall in individuals, and therefore increased 
fracture risk (Badieh & Mary 2016, Pscherer et al. 2016 and 
Watts et al. 2016).    
Thiazolidinedione (TZD) mechanism of action involves 
activation of peroxisome proliferator activated receptor gamma 
(PPARγ), a transcription factor that facilitates mesenchymal 
stem cells to differentiate into adipocytes (Lecka-Czernik et al. 
2002).  Several clinical studies have reported a higher incidence 
of fractures with TZD (Meier et al. 2016), and this has been 
confirmed on numerous occasions (Fujita et al. 2016, 
Shanbhogue et al. 2016). Preclinical studies confirm that TZDs 
are detrimental to bone (Lecka-Czernik et al.2002). TZDs 
reduce the number of osteoblasts-bone forming cells and related 
bone volume (Rzonca et al. 2004). Preclinical studies have 
reported a neutral effect of SGLT-2 inhibitors on bone with 
some positive effects leading to increase in bone mineral density 
(Yokono et al. 2014). However, it is conceivable that the effect 
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of SGLT-2 inhibitors on the levels of circulating ions could 
ultimately have a negative impact on bone integrity.  
Glucagon-like peptide 1 (GLP-1) is secreted by intestinal L-cells 
in response to nutrient absorption (Steinert et al. 2017). GLP-1 
enhances glucose–stimulated insulin secretion through binding 
to specific GLP-1 receptors (GLP-1r) on beta-cells. The GLP-1r 
is also present in various tissues including the brain, heart, 
kidney and gastrointestinal tract (Holst et al. 2004, Green & 
Flatt 2007). GLP-1 also causes glucagon suppression, slows 
gastric emptying and reduces appetite (Amalia et al. 2017). 
Some controversy exists as to the presence of GLP-1rs on the 
bone, although GLP-1 mediated bone effects are acknowledged 
(Nuche-berrenguer et al. 2010). As such, studies in GLP-1r 
knockout (KO) mice reveal a reduction in osteoclasts (Yamada 
et al. 2008), but it has been reported that bone formation 
remains almost unaffected in GLP-1r KO mice (Yamada et al. 
2008).  However, others have shown that the GLP-1r is critical 
for optimal bone mechanical and material properties (Mabilleau 
et al. 2013). SGLLT2 inhibitors such as dapagliflozin and 
canagliflozin have no effect on the bone (Nauck 2014).  
Dipeptidyl peptidase-4 (DPP-4) is an enzyme that inactivates 
GLP-1, and its sister incretin hormone glucose-dependent 
insulinotropic polypeptide (GIP), by cleaving an N-terminal 
dipeptide from both hormones leaving the truncated metabolites 
GIP(3-42) and GLP-1(9-36) (Drucker 2007). Interestingly, both 
metabolites are considered to be receptor antagonists 
(Yanagimachi et al. 2017), and a very recent study has fully 
characterised the antagonistic properties of a DPP-4 cleaved GIP 
compound in man (Gasbjerg et al. 2017). Currently, there are 
many DPP-4 inhibitors available for clinical use, including 
Vildagliptin, Saxagliptin, Sitagliptin and Linagliptin (Duez et al. 
2007).  There is conflicting evidence regarding DPP-4 and its 
use as therapeutic treatment option for reducing bone fractures 
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in diabetes. Some studies suggest that there is no effect of DPP-
4 inhibition on osteoblast differentiation (Sbaraglini et al. 2014), 
while in another study it was found that 12 week treatment with 
saxagliptin caused a reduction in osteoblasts and osteocyte 
density and an increase in osteoclast numbers (Gallagher et al. 
2014). Taken together, the most exciting area in terms of 
diabetes medications and bone effects, with potential therapeutic 
implications, relates to the incretin hormones. As discussed 
above, GLP-1 mimetics have been shown to potentially 
positively impact bone (Mabilleau, et al. 2017). In addition, 
emerging evidence has revealed an extremely important role for 
GIP in the maintenance of normal bone function and quality. 
Therefore, this thesis will focus on the effects of incretin 
















Table 1.2 Effect of current T2DM treatment options for 
bone fracture risk  
Class of medication Potential mechanisms 
bone 
Effect on fracture 
risk 
Biguanide Conflicting results in 
animals and humans 
 
Thiazolidinediones Reduction in the 





Animal/human data is 
conflicting 
 
GLP-1R agonists Controversial findings; 
alterations in bone 
tissue material 
properties 
     or 
DPPIV inhibitors Conflicting results in 
preclinical rodent 
studies 
                  or 
SGLT2 inhibitors  Neutral/no effect  
 
Taken from Irwin & Flatt 2015 
1.2 BONE  
Bone is a living mineralised tissue that comprises of three major 
components - fibrous protein collagen, calcium phosphate-based 
hydroxyapetite and water (Weiner & Wanger 1998). There are 
many important physiological functions of bone, but the most 
important is to control mechanical function of the body and act 
as a storage vessel for calcium and phosphate (Hao et al. 2017). 
Bone undergoes continuous remodelling through sequential 
activity of bone-forming osteoblast cells and bone-resorbing 
osteoclast cells (Figure 1.2). This continuous process is 
governed by various autocrine and paracrine factors, such as 
IGF-1, IL-6, netrin 1, TGF-β (Bart Clarke 2008, Kini & 
Nandeesh 2012). Bones undergoes several changes throughout 
life that can be due to environment, age and disease status (Oishi 
& Manabe 2016). Some diseases, such as osteoporosis, may 
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cause alterations in the bone leading to fractures (El-Tawdy et 
al. 2017). However, early diagnosis can prevent further 
deterioration of the bone and there are several techniques that 
can be used for assessment of bone in more detail.  
Figure 1.2 Bone remodeling cycle 
 
(Taken from Encyclopedia Britannica Inc, 2010) 
 
Bone remodelling is a continuous process and is 
coordinated by the activity of osteoclasts and 




1.2.1 Assessment of bone mass  
The most commonly used technique to assess bone mass is dual-
energy X-ray absorptiometry (DEXA) (Ali et al. 2017, Leeuwen 
et al. 2017).  DEXA analysis can help in determining bone 
mineral density (BMD) and bone mineral content (BMC). Bone 
mineral content and bone mineral density can also be assessed 
by X-ray microradiograph imaging (Bassett et al. 2012). In the 
general population, increased BMD is considered to be good 
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thing as it is linked to a lower risk of bone fracture (Unnauntana 
et al. 2010). Unfortunately, this is not the case in diabetes, with 
both T1DM and T2DM having contradictory effects on BMD. 
As such, T1DM patients have reduced BMD while T2DM tend 
to present with unchanged or elevated BMD (Vestergaard 2007, 
Abdulameer et al. 2012, Jackuliak & Payer 2014). Since both 
forms of diabetes are linked to increased fracture risk, it is clear 
that BMD does not paint a true picture of fracture risk in these 
patients. Indeed, BMD is not the only parameter that reflects 
bone quality, and other characteristics such as bone 
microarchitecture, mineral matrix ratio, collagen maturity, 
collagen content and mineral composition can also play 
important role (Gourion-Arsiquad et al. 2009, Wen et al. 2015).  
1.2.2 Assessment of bone microarchitecture 
Microcomputed tomography (microCT) provides a deeper 
understanding of bone microarchitecture. Essentially, there are 
three different steps to assess bone microarchitecture. In the first 
step, the entire bone is scanned leading to a projection of 
overlaid X-ray images. In the second step, from this stack of X-
ray images, a 3D representation of the bone is reconstructed and 
then finally analysis can be performed (Van’t Hof 2012). The 
main advantage of microCT is that it provides deeper insight 
into the trabeculae of bone and assesses number of trabeculae, 
bone volume as well as trabecular thickness (Verdelis et al. 
2011, Manske et al. 2015). This information can provide a much 
clearer picture of bone quality than simple BMD and BMC 
measures. 
1.2.3 Biomechanical assessment of bone 
The two major factors that govern the biomechanics of bone are 
strength and stiffness (Osterhoff et al. 2016). Bone stiffness, or 
hardness, can be assessed using nanoindentation and ultimate 
strength by three-point bending (Nyman et al. 2016). 
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Nanoindentation was first used by Oliver and Pharr in 1962. The 
biggest advantage of nanoindentation is that it can measure 
mechanical properties of the bone in a very small scale (below 
micron level), to gain a more accurate reflection of the material 
properties in bone matrix (Olive & Pharr 1992).  The basic 
principle of three-point bending depends on the relationship 
between load applied at the midshaft of long bone and 
displacement of the bone until failure, which produces load 
displacement curve similar to well-established stress-strain 
curve (Iepsen et al. 2015). This stress-strain curve helps in 
assessing different variables of the bone, including ultimate 
load, ultimate displacement, stiffness and work-to-failure ratio 
(McNerny et al. 2016). 
1.2.4 Assessment of bone material properties 
Scanning electron microscopy can be used to assess bone 
mineral density distribution (Whitehouse et al 1971). Basically, 
backscattered electrons are reflected by the atoms present in the 
bone sample. The atoms with high atomic number have stronger 
interactions with the electrons and they appear brighter in the 
grey level image derived from the electron scan. The atoms with 
lower atomic numbers will have fewer interactions and will 
produce images of less intensity (Chappard et al 2011).  Another 
technique that can be employed for assessment of bone material 
properties is Fourier transformed infrared (FTIR) microscopy. 
Fundamentally, femurs are cut at mid-shaft and embedded in 
polymethylacrylate and further subjected to spectral analysis 
which is carried out by infrared microscope. FTIR is used for 
examination of mineral to matrix ratio, degree of mineralisation, 
mineral maturity, crystallinity and collagen maturity (Farley et 
al. 2010, Kourkoumelis et al. 2012, Wen et al. 2015), all of 




 1.3 INCRETIN EFFECT 
The term ‘incretin effect’ is used to describe the fact that oral 
glucose administration produces greater degree of insulin 
secretion as compared to intravenous infusion of the same 
amount of glucose (Nauck et al. 1986). Thus, it implies that gut 
derived factors have an important role to play in insulin 
secretion and glucose homeostasis (Yang et al. 2017). Indeed, 
the incretin effect is estimated to account for 50-70% of total 
insulin secretion after oral glucose administration (Kazafesos 
2011, Nauck et al. 2011). After food ingestion, the incretin 
hormones, GIP and GLP-1, are released into the blood and 
directly enhance glucose-mediated insulin secretion from 
pancreatic β-cells (Fu et al. 2013, Smith et al. 2014). Although 
there are many gastrointestinal hormones that can stimulate and 
release insulin, GIP and GLP-1 are believed to be the only 
molecules that can do this at physiologically relevant levels, 
meaning that these two hormones account for the full incretin 
effect in man (Seino et al. 2010).   
 
1.4 GLUCOSE-DEPENDENT INSULINOTROPIC 
POLYPEPTIDE (GIP) 
GIP was initially isolated from porcine small intestine and 
initially it was known as gastric inhibitory polypeptide, hence 
the acronym GIP, because of its ability to inhibit gastric acid 
secretion (Brown et al. 1969). However, the main biological role 
is now considered to be stimulation insulin release in response 
to food ingestion (Pederson et al. 1976), and so was later named 
glucose-dependent insulinotropic polypeptide to maintain its 





1.4.1 Synthesis, secretion and signaling  
GIP is a 42-amino acid peptide synthesised by intestinal K-cells, 
which are found in the upper duodenum and proximal jejunum 
(Fujita et al. 2016). The human GIP gene comprises of 6 exons 
(Figure 1.3), and most of the sequence for GIP lies in exon 3. 
The GIP sequence is highly conserved and human GIP shares 
more than 90% similarity in amino acid sequence with mouse, 
rat, porcine and bovine GIP (Baggio & Drucker 2007, Mells & 
Anania 2013). 








Structures of (A) ProGIP gene, (B) mRNA, and (C) 
GIP protein. (Taken from Baggio & Drucker 2007) 
 
1.4.2 GIP, β cell and diabetes 
The main role of GIP as incretin hormone is to regulate glucose 
homeostasis (Holst et al. 2017). Upon food intake, GIP is 
secreted by K-cells and then binds to its specific receptor on 
pancreatic islet β-cells to enhance glucose-mediated insulin 
secretion (Cavin et al. 2017). Activation of GIPR signaling 
increases cAMP levels and subsequent inhibition of KATP 
channels (Figure 1.4). Inhibition of KATP channels leads to 
influx of Ca2+ and stimulation of insulin secretion by exocytosis 
(Ding & Gromada 1997). Binding of GIP to its G-protein 
coupled receptor also activates cAMP-mediated 
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phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) 
and MAP kinase signaling pathways which are closely 
associated with promotion of proliferation, differentiation and 
inhibition of apoptosis of β -cells  (Ugleholdt et al. 2006).   
 
Figure 1.4 Signalling pathways of GIP  
 
 (Taken from Seino et al. 2010) 
 
 
1.4.3 Extrapancreatic action  
The main physiological action of GIP is in pancreas. However, 
the widespread expression of GIPRs in other tissues such as in 
adrenal cortex, brain, heart, lung, pituitary, adipose as well as 
bone suggests wider extrapancreatic actions of GIP in the body 
(Figure 1.5). There is firm evidence revealing that functional 
GIPRs are present in primary adipocytes and the adipose cell 


















Extrapancreatic effects of GIP by direct interaction with 
GIPRs on specific tissues. (Taken from Baggio & 
Drucker 2007) 
 
Effects of GIP have also been shown in the brain. GIPR 
mRNA and specific binding sites have been detected in the 
cerebral cortex and hippocampus, including the olfactory bulb 
(Usdin et al. 1993, Kaplan & Viagna 1994). Indeed, several 
studies have highlighted that GIP plays important role in 
regulating functions in the brain. In 2007, Nyberg and co-
workers demonstrated that administration of exogenous GIP in 
rats and incubation of GIP with cultured adult hippocampal 
progenitor cells stimulates the proliferation of hippocampal 
progenitor cells (Nyberg et al. 2007). In addition, GIP-
overexpressing transgenic mice display better memory 
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recognition than normal wild type mice (Ding et al. 2006, Li et 
al. 2016).  In 2011, Porter and colleagues demonstrated that, 
administration of a stable GIP analogue for 28 days improved 
cognitive function in high-fat fed diabetic mice that displayed 
cognitive dysfunction (Porter et al. 2011). Overall, these 
findings show that GIP does play an important role in 
regulating certain brain functions.   
In terms of bone, functional GIPRs are found on bone-forming 
osteoblast cells and bone-resorbing osteoclast cells (Bollag et 
al 2000, Zhong et al 2007). GIPRs are also expressed on 
osteocytes (Bollag et al 2001) and cultured bone marrow 
stromal cells (BMSCs) (Ding et al. 2008).  Genetic knockout 
of the GIPR in mice has been shown to negatively affect bone 
quality and strength (Greco et al. 2016, Mantelmacher et al. 
2017, Ramsey & Isales 2017) whereas administration of a 
stable GIP analogue improves bone quality in normal and 
diabetic rodents (Millar et al. 2016, Hansen et al. 2017, 
Mansur et al. 2017). Together, this also reveals an important 
role for GIP in normal bone physiology. 
 1.4.4 DPP-4 and GIP metabolism 
GIP is secreted immediately after food ingestion, but has a short 
half-life due to the action of the ubiquitous enzyme DPP-4 
(Chon & Gautier 2016, White & baker 2016). In rodents, the 
half-life of GIP is less than 2 mins (Kieffer et al. 1995) while in 
humans, the half-life of GIP is around 5-7 mins (Deacon et al. 
2000). DPP-4 is a specialised serine protease that cleaves the 
penultimate residues from the N-terminal of bioactive proteins 
that contain alanine or proline residues at position 2 (Mentlein et 
al. 1993). Thus, DPP-4 inactivates biologically active GIP by 
cleaving at its first two N-terminal amino acids (Tyr1-Ala2), 
leaving truncated metabolite, GIP(3-42) (Kieffer et al. 1995, 
Marvani & Patel 2017, Nongonierma & FitzGerald 2017, 
Sparre-Ulrich et al. 2017). The cleavage of active GIP (1-42) by 
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DPP-4 leads to eliminates biological activity, and possibly leads 
to the generation of a GIPR antagonist (Gault et al. 2003). In 
addition to rapid degradation by DPP-4, GIP is also subjected to 
renal excretion by kidney filtration (Meier et al. 2004). In order 
to overcome the inactivation of GIP by DPP-4, structurally-
modified DPP-4 resistant GIP molecules have been designed 
(Divya et al. 2014, Chaurasia et al. 2016, O'Harte et al. 2016). 
In addition, renal clearance can be reduced by conjugating the 
peptide to fatty acid moieties or polyethylene glycol residues 
(Muppidi et al. 2016, Yang et al. 2016, Han et al. 2017). 
Together these modifications prolong the pharmacokinetic 
profile of GIP and dramatically enhance its bioactivity, as 
detailed below. 
 1.4.5. Structurally modified GIP agonists  
In order to fully exploit the insulinotropic properties of GIP, a 
substantial number of DPP-4 resistant GIP molecules have been 
designed and tested (Table 1.3). One of the pharmacological 
approaches that is extensively used is modification of the N-
terminal amino acid residues of GIP to prevent DPP-4-mediated 
degradation (Irwin & Flatt 2009). Several Tyr1-substituted GIP 
molecules that have been generated and tested which include N-
acetyl, N-Fmoc, N-gluticol, N-pyroglutamyl and N-palmitate 
GIP. These analogues have been shown to be resistant to DPP-4 
and thus, have enhanced bioactivity as compared to that of 
native GIP (O’Harte et al. 2000, Gault et al. 2002, O’Harte et al. 
2002). Synthesis and characterisation of several Ala2-modified 
GIP analogues has also been carried out and these include 
[Abu2]GIP, [Gly2]GIP, [Sar2]GIP, [Ser2]GIP and [D-Ala2]GIP. 
However, it has been found that only [Gly2]GIP, [Ser2]GIP and 
[D-Ala2]GIP have notable biological activity and 
antihyperglycaemic properties as compared to native GIP 




Even though N-terminally-protected GIP analogues are resistant 
to DPP-4-, there is still another hurdle of renal filtration that 
needs to be addressed. Therefore, in order to overcome this 
problem, C-16 palmitate fatty-acid (PAL) chain has been 
attached covalently to the Lys16 or Lys37 residue of the GIP 
peptide. There are several fatty-acid GIP derivatives that have 
been developed to date. These include GIP(Lys37PAL), 
GIP(Lys16PAL), N-AcGIP(Lys37PAL), N-AcGIP(Lys16PAL), 
N-pGluGIP(Lys37PAL) and N-pGluGIP(Lys16PAL) (Irwin et al. 
2005a, Irwin et al. 2005b, Irwin et al. 2006a) (Table 1.3). The 
main advantage for attaching C-16 fatty acid is that it 
encourages non-covalent binding of the peptide to albumin, 
acting as a drug reservoir that cannot be filtered by the kidneys, 
thus prolonging biological activity (Irwin & Flatt 2009). 
Polyethylene glycol (PEG) derivatised GIP analogues have also 
been characterised and these molecules are also resistant to 
kidney filtration and display protracted pharmacodynamics 



























































(Adapted from Irwin et al. 2015) 
 
 
1.5 GLUCAGON -LIKE PEPTIDE (GLP-1) 
1.5.1 Synthesis, secretion and signaling 
The proglucagon gene has 6 exons and the entire GLP-1 coding 
sequence lies within exon 4 (Figure 1.6).  The proglucagon gene 
is expressed in pancreatic α-cells, intestinal L-cells and the 
central nervous system (Jiang et al. 2016). Posttranslational 
processing of the proglucagon gene product generates different 
peptides, depending on the tissue. In the pancreas, proglucagon 
is cleaved by prohormone convertase (PC2) to produce glucagon 
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(GLUC), glicentin-related polypeptide (GRPP), intervening 
peptide-1 (IP-1) and major proglucagon fragment (MPGF) 
(Rouille et al. 1997a). As a major product of proglucagon in α-
cells, glucagon is known to play its role by counteracting insulin 
action to maintain normal glucose levels (Mayfield et al. 2016, 
Muller et al. 2017 and Preiato et al. 2017). 
 
In the intestine and central nervous system, the 180-amino acid 
proglucagon peptide liberates oxyntomodulin, glicentin, GLP-1, 
intervening peptide-2 (IP-2) and GLP-2. GLP-1 is the major 
product of proglucagon gene in the intestine and it is one of the 
important glucoregulatory hormones that control glucose 
homeostasis (Albrechtsen et al. 2016, Drucker 2016). In 
addition to GLP-1, oxyntomodulin is also released 
postprandially and the peptide is believed to exert its effects by 
binding to both GLP-1 and glucagon receptors (Pocai 2012). 
Activation of glucagon receptor increases blood glucose 
concentration, whilst simultaneous GLP-1R activation 
counteracts this effect, thus balancing glucose metabolism in the 
body. However, there is a suggestion that central activation of 
glucagon receptors can alter energy turnover and lead to body 
weight loss (Pocai 2014). For this reason, oxyntomodulin has 
recently been speculated to have therapeutic potential for 
diabetes and obesity (Pocai 2014). Similar to GIP, processing of 
proglucagon precursor to yield GLP-1 is dependent on 
prohormone convertase PC1/3. Proglucagon is initially cleaved 
to glicentin and the major proglucagon fragment (MPGF). 
Subsequent cleavage of MPGF at the monobasic site Arg77 and 





















Structures of (A) the proglucagon gene, (B) mRNA, 
and (C) protein. (D) Posttranslational processing of 
proglucagon. (Taken from Baggio & Drucker 2007) 
 
1.5.2 Pancreatic actions 
The primary physiological action of GLP-1 in the pancreas is to 
stimulate insulin secretion from beta-cells in a glucose 
dependent manner (Mojsov et al. 1987). Two different 
signalling pathways are involved in GLP-1-mediated insulin 
release, either through cAMP-dependent PKA or Epac2 
activation, or via cAMP-independent phosphatidylinositol-3 
kinase (PI-3K)/protein kinase C (PKC) signalling pathways 
(Baggio & Drucker 2007). GLP-1 can also encourage insulin 
gene transcription and synthesis through effects on the pancreas 
duodenum homeobox 1 (PDX-1) gene (Amatya et al. 2017). 
PDX-1 is an essential transcription factor for pancreatic beta- 
cell function (Wang et al. 1999). GLP-1 also strongly suppresses 
glucagon secretion from pancreatic α-cells (Holst et al. 2011) 
and its inhibitory action is likely mediated through stimulation 
of somatostatin and activation of somatostatin subtype receptor 
2 (SSTR2) in pancreatic α-cells (de Heer et al. 2008, Piro et al. 
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2016, Otter & Lammert 2016, Gylfe 2017, Muller et al. 2017, 
Pradhan & Majhi 2017).  
 
 
 Extrapancreatic actions  
Several tissues have been shown to express glucagon-like 
peptide-1 receptors (GLP-1Rs), such as the heart, brain, liver, 
intestinal tract, muscle and adipose tissue (Wei & Mojsov 1996, 
Dunphy et al. 1998, Merchenthaler et al. 1999 and Green et al. 
2009). As shown in Figure 1.7, GLP-1Rs are present 
throughout the body. The glucoregulatory activity of GLP-1 
does not only take place in pancreas, but also in other tissues by 
reducing hepatic glucose production in liver and increasing 
glucose uptake in muscle and adipose tissue (Larsson et al. 
1997, Baggio & Drucker 2007). In the brain, activation of GLP-
1R signaling enhances neurogenesis, reduces apoptosis and 
protects neuronal function (Perry et al. 2002, Perry et al. 2003). 
It has been reported that GLP-1can also be used as a therapeutic 
option for treatment of chronic heart failure (McDermott et al. 
2016).  Moreover, improvements in learning and memory 
activities were observed in rodents when treated with stable 
GLP-1 mimetics (Cha et al. 2016, Millar et al. 2017, Palleria et 
al. 2017, Tramutola et al.2017). Therefore, GLP-1 could be 
useful in the treatment of neurodegenerative disorders (Dilan et 































Extrapancreatic effects of GLP-1 by direct interaction 
with GLP-1Rs on specific tissues. (Taken from 
Baggio & Drucker 2007) 
 
 
1.5.4 DPP4- and GLP-1 metabolism  
There are several forms of GLP-1 secreted in vivo that include 
GLP-1(1-37), GLP-1(1-36)amide, but only GLP-1(7-37) and 
GLP-1(7-36)amide are thought to be biologically active (Baggio 
& Drucker 2007). GLP-1 is rapidly secreted into the blood 
circulation following feeding; however, the half-life of intact 
GLP-1 is short, around 2 mins (Kieffer et al. 1995), due to the 
activity of DPP-4.  Native GLP-1 contains an alanine at position 
2 and therefore alanine acts as a good substrate for DPP-4 
(Mirošević et al. 2017). The specific cleavage of DPP-4 at N-
terminal dipeptides from GLP-1 produces GLP-1(9-36)amide 
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and GLP-1(9-37) with diminished biological activities (Mentlein 
et al. 1993, Kieffer et al. 1995). Similar to GIP, GLP-1 can also 
be eliminated from circulation by renal filtration (Meier et al. 
2004). The short half-life of GLP-1 has therefore prompted the 
need of generation of stable long-acting forms of GLP-1, if the 
peptide is to be employed therapeutically (Knudsen et al. 2000).  
1.5.5 Structurally modified GLP-1 agonists 
In order to exploit the highly significant glucose-lowering and 
insulin-releasing properties of GLP-1, various structurally 
modified GLP-1R agonists have been generated (Green et al. 
2001). These GLP-1 analogues possess modification of amino 
acid residues at N-terminus of the peptide, producing GLP-1R 
molecules that are resistant to DPP-4 activity (Deacon et al. 
1998). Biological activity of GLP-1 can also be prolonged by 
delaying renal filtration, and this can be achieved through fatty 
acid derivatisation (Green & Flatt 2007).  
 
1.5.6 Exendin-4 
Exendin-4 (Exenatide / Byetta) is a naturally occurring 39 
amino acid peptide which is isolated from the saliva of the lizard 
Heloderma suspectum (Furman BL 2012). Exendin-4 exhibits 
around 53% similarity in structure to that of mammalian GLP-1. 
It is resistant to DPP-IV action due to the presence of a glycine 
residue at position 2 in place of alanine (Drucker & Nauck 
2006). Therefore, exendin-4 remains in the blood for longer 
time as compared to that of native GLP-1 (Chen et al. 2017, 
Peter et al. 2017). The biological activity of exendin-4 is similar 
to that of GLP-1, since it binds and activates the GLP-1R (Koole 
et al. 2017). As such, exendin-4 enhances insulin secretion in 
glucose dependent manner, delays gastric emptying as well as 
reduces food intake thereby reducing body weight (Seino et al. 
2010, Duarte et al. 2013, Sharma et al. 2015). Exenatide is the 
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synthetic form of exendin-4 and was approved by US Food and 
Drug Administration (FDA) in 2005 for the treatment of T2DM 
(Vishal Gupta 2013, Seungah Lee & Dong Yun Lee, 2017).  
1.5.7 Liraglutide 
Liraglutide is a GLP-1 analogue that has a high sequence 
homology (approx. 97%) to native GLP-1 (Jacobsen et al. 
2016). The half-life of Liraglutide is about 13 hrs due to C-16 
fatty acid derivation, and hence it is suitable for once-daily 
subcutaneous administration in humans (Chaudhury et al. 2017, 
Lorenz et al. 2017, Meece 2017). In 2009, Liraglutide was 
approved by European Medicines Agency for T2DM treatment, 
and then it was also approved by US Food and Drug 
Administration in early 2010 (Peterson & Pollom 2010). Several 
clinical studies of Liraglutide have been carried out and it was 
demonstrated that once-daily subcutaneous administration of 
Liraglutide at a dose of 0.6-1.8 mg was well tolerated (Rigato & 
Fadini 2014, Zang et al. 2016). Liraglutide can also be used as 
single drug or in combination with other drugs such as 
metformin and/or a sulphonylurea, in poorly controlled T2DM 
patients (Pfeiffer et al. 2014, Marin-Penalvar et al. 2016). 
Moreover, recently Liraglutide has been approved for the 
treatment of obesity at an elevated dose of 3.0 mg (Nuffer & 
Trujillo 2014, Scheen 2016). 
 
1.6 XENIN  
1.6.1 Synthesis, secretion, signaling and pancreatic action of 
xenin 
Xenin is a 25-amino acid peptide which is secreted by intestinal 
K-cells in response to the food intake (Wice et al. 2012, Martin 
et al 2016). Xenin is synthesised from its precursor proxenin 
through post translational enzymatic action of Cathepsin-E 
(Hamscher et al.1996; Feurle, 1998).  Xenin was first isolated 
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from human gastric mucosa (Feurle et al 1992). Importantly, 
xenin is known to potentiate the biological actions of GIP which 
are known to be compromised in T2DM (Taylor et al. 2010, 
Wice et al. 2010, Martin et al. 2012 and Gault et al. 2015).   
Xenin is structurally similar to neurotensin because it contains 
identical C-terminal amino acid sequence which is highly 
conserved through evolution (Hamscher et al. 1996). The major 
metabolic actions of xenin include effects on gut motility, 
promoting satiety and reducing food intake (Sterl et al. 2016). 
However, it has also been reported that xenin plays important 
role in glucose homeostasis and insulin secretion (Taylor et al. 
2010, Hussain et al. 2016). The possible mechanism of GIP 
mediated insulin release could be through activation of non-
ganglionic cholinergic neurons (Wice et al. 2010), but effects of 
cAMP as well as beta-cell membrane potential and intracellular 
calcium levels are not believed to be important (Taylor et al. 
2010). The therapeutic potential of xenin is restricted because it 
is rapidly degraded by aspartic proteases at lysine and argine 
residues (Martin et al. 2012). The C-terminal octapeptide 
fragment of xenin (xenin-8, but also termed xenin(18-25) was 
found in circulating in plasma highlighting its potential 
physiological importance (Martin et al. 2014). Xenin-8 retains 
biological activity and exhibits insulin secretory properties and 
potentiates GIP mediated insulin release (Martin et al. 2014). 
Interestingly, when xenin-25 and xenin-8 were administered 
along with (DAla2GIP) this led to improved insulinotropic and 
glycaemic actions in mice (Martin et al. 2014).  This GIP 
potentiating effect of xenin is quite remarkable, because this will 
help to overcome GIP resistance which is normally seen in 
T2DM patients (Hasib et al. 2017, Kaji et al. 2017).  
Recently, a study conducted in our laboratory has demonstrated 
that the amino acid substitution of Lys and Arg residues in 
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xenin-25 and xenin-8 with Gln, to impede enzymatic 
degradation, induces superior metabolic effects mice 
(Parthsarathy et al. 2016). In this regard, xenin or related 
fragments could have therapeutic potential in the treatment of 
T2DM (Martin et al. 2016). Xenin also plays an important role 
in secretion of various hormones such as pancreatic polypeptide, 
vasoactive intestinal peptide, insulin and glucagon (Feurle et al. 
1997), which merits further study. 
1.6.2 Extrapancreatic actions 
Extrapancreatic effects of xenin revolve mainly around 
regulation of intestinal motility and food intake suppression 
(Clemens et al. 1997; Nustede et al. 1999; Kim and Mizuno, 
2010a). No specific receptor for xenin has been reported to date, 
but neurotensin receptors have been suggested as possible 
targets for xenin (Bhavya et al. 2017). Xenin mediated 
suppression of food intake have been reported previously in 
different animal models, as well as humans (Alexiou et al. 1998; 
Cline et al. 2007, Chowdhury et al. 2014).  
 
1.7 EFFECTS OF TYPE 2 DIABTES ON BONE 
METABOLISM  
There is considerable amount of evidence which suggests type 2 
diabetes is associated with increased bone fracture risk even 
though bone mineral density (BMD) is seen to be unaltered or 
even increased (Vianna et al. 2017, Wallander et al. 2017). 
There are different factors which increase fracture risk in 
diabetes such as inadequate glycaemic control, greater risk of 
falling as a consequence of hypoglycaemia, osteopaenia and 
impairment of bone quality (Sanches et al. 2017). Lack of 
scientific in-depth knowledge makes it difficult to develop a 
strategy to treat bone fractures in diabetes. Even though type-2 
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diabetes and osteoporosis are not directly related, they share 
many common features including genetic predispositions, 
molecular mechanisms and pathophysiological mechanisms 
(Billings et al. 2012).  
According to World Health Organisation, osteoporosis is 
defined as disease characterised by low bone mass and 
microarchitectural deterioration of bone tissue leading to 
enhanced bone fragility and consequent increase in fracture risk. 
Osteoporosis reduces BMD and affects around 200 million 
women and accounts for 8.9 million fractures annually in 
women who are above the age of 50 (International osteoporosis 
foundation-The global burden of osteoporosis factsheet). The 
commonly used tools to estimate fracture risk are BMD and a 
fracture risk assessment tool called FRAX, to help predict 10-
year probability of bone fracture risk (Hiller et al. 2011, Rubin 
et al. 2013). However, BMD is considered as gold standard by 
world health organisation (Garg & Kharb 2013). BMD is 
expressed as a T-score, which is the number of the number of 
standard deviations that the individual is above or below the 
average age of a healthy adult (Schwartz et al. 2017).  On the 
other hand, FRAX is used to calculate femoral neck BMD T-
score (Gadam et al. 2013). The FRAX algorithm takes into 
account several other factors like age, sex, alcohol consumption, 
arthritis, history of fracture, basal metabolic index and 
glucocorticoid intake (Cavalli et al. 2016). Unfortunately, 
FRAX does not include Diabetes as a risk factor and hence, the 
algorithm is not considered to be accurate for this disease 
(Leslie et al. 2012, Oie et al. 2015).  
In response to food ingestion, incretin hormones are released 
into blood circulation which enhances glucose-mediated insulin 
secretion from pancreatic β cells (Irwin et al. 2015). There is an 
intimate relationship between glucose homeostasis and bone 
metabolism, controlled by many factors including advanced 
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glycation end products (AGEs), insulin, insulin-like growth 
factor-1 (IGF-1), peroxisome proliferator-activated receptor 
gamma (PPARγ), glucose-dependent insulinotropic peptide 
(GIP), glucagon-like peptide 1 and 2 (GLP-1 and GLP-2), 
osteocalcin and sclerostin (Sanches et al. 2017, Vianna et al. 
2017).  
1.7.1 Advanced glycation end products (AGEs) 
Hyperglycaemia contributes to the bone loss as it affects cellular 
and extracellular bone matrix (Jiao et al. 2015). Glucose causes 
formation of intermediate highly reactive dicarbonyls, through a 
non-enzymatic glycation process (Napoli et al 2014), and 
ultimately leads to production of AGEs (Singh et al. 2001). 
AGE formation causes impairment of bone matrix (Ahmed et al. 
2005, Hernandez et al. 2005) and increases fracture risk 
(Epstein et al. 2016). Briefly, the mechanism involves binding 
of AGEs to it receptor known as receptor for AGEs (RAGE) 
that leads to production of reactive oxygen species, 
inflammation and macrophage and platelet activation (Figure 
1.8). Therefore, bones become more brittle with reduced bone 
strength. Formation of AGEs causes osteoblast deterioration and 
enhances osteoclast activation, ultimately decreasing bone 










Figure 1.8 Relationship between accumulations of AGEs in 
the bone 
 
(Taken from Sanguineti et al. 2008) 
1.7.2 Insulin and Insulin-like growth factor-1 (IGF-1)  
Insulin has two receptors, namely insulin receptor 1 and insulin 
receptor 2, and both the receptors are present on bone 
(Gallagher et al. 2013). Insulin receptors stimulate osteoblast 
proliferation, bone formation and collagen synthesis (Lee et al. 
2017). Similar to insulin, insulin-like growth factor-1 (IGF-1) 
promotes osteoblast proliferation and enhances bone matrix 
deposition by reducing collagen degradation (Yin et al. 2017). 
Previously, it has been widely reported that there is a positive 
correlation between IGF-1 and BMD (McCarthy et al. 2004, 
Sanguineti et al. 2008).   
1.7.3 Peroxisome proliferator-activated receptor gamma 
(PPARγ) 
PPARγ has two isoforms namely- PPARγ1 and PPARγ2 (Wang 
et al. 2017). PPARγ1 is expressed in osteoclasts and helps in 
differentiation of osteoclasts as well as bone resorption (Chong 
et al. 2007). PPARγ2 regulates mesenchymal stem cell 
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differentiation (Camp et al. 2017). PPARγ induces adipogenesis 
and suppresses osteoblastogenesis, by inhibiting Runx2 function 
(Figure 1.9), causing in a reduction of osteoblasts in the bone 
marrow (Fan et al. 2017).  
Figure 1.9 Peroxisome proliferator ‑ activated receptor 
gamma (PPARγ) 
 
(Taken from Kawai et al. 2010) 
C/EBPs - enhancer binding proteins, CCAAT-
enhancer binding proteins, Osx/ Runx2- runt related 
transcription factor 2 
 
1.7.4 Vitamin D 
Hyperglycaemia causes impairment of renal calcium absorption 
(Chaiban et al. 2015).  Further, hyperglycaemia results into 
reduced number of 1, 25(OH)2D3 (1,25-dihydroxy vitamin D) 
receptors on osteoblasts (Garcia-Gil et al. 2017). Therefore, it 
becomes difficult for osteoblasts to produce osteocalcein in 
response to 1, 25(OH)2D3. However, there are some reports that 
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contest involvement of vitamin D in type-2 diabetes to increase 
fracture risk (Manigrasso et al. 2013). 
1.7.5 Osteocalcein  
Type-2 diabetes does have an impact on serum bone turnover 
markers (BTM) particularly, osteocalcein (OC) and amino-
terminal propeptide of procollagen type 1 (PINP), as there levels 
are decreased in type-2 diabetic patients (Rosen et al. 1997, 
Rubin et al. 2015). It has been reported that postmenopausal 
women with T2DM have lower OC and PINP levels (Shu et al. 
2012, Yamamoto et al. 2012, Raska Junior et al. 2017). The 
bone resorption marker CTX (serum C-terminal telopeptide 
from type 1 collagen), is found to be reduced in type-2 diabetic 
patients (Oz et al. 2006, Rubin et al. 2015), while some reports 
indicate that there is no difference in CTX (Achemlal et al. 
2005). Of all bone turnover markers, osteocalcein is considered 
as important when it comes to understand pathophysiology of 
T2DM, mainly because osteocalcein stimulates insulin secretion 
and enhances insulin sensitivity (Pittas et al. 2009, Booth et al. 
2013, Zanatta et al. 2014, Ippei Kanazawa 2015, Eibhlís 
M.O'Connor & Edel Durack 2017).   
1.7.6 Sclerostin  
Sclerostin is expressed by osteocytes (Weivoda et al. 2017). 
Sclerostin inhibits Wnt/ß-catenin pathway and negatively 
regales bone formation by binding to low-density lipoprotein 
receptor related protein (LPR) 5 or 6. The Wnt/ß-catenin 
pathway enhances osteoblast proliferation and bone formation 
(Kim et al. 2017). Wnt/ß-catenin signalling suppresses 
osteoclasts by inducing osteoprotegerin (Figure 1.10). Wnt/ß-
catenin signalling also reduces bone resorption by acting 
directly on osteoclast precursors. Thus, Wnt has dual effecst on 
osteoblasts and osteoclasts results in increased bone mass. As 
such, after binding of sclerostin to Wnt receptors, osteoclasts are 
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inhibited and osteoblasts promote bone formation (Canalis et al. 
2013). Type-2 diabetes patients have higher levels of sclerostin 
which are related with increased fracture risk (Garcia-Martin 
et.al. 2012, Rubin et al. 2015).  
 
Figure 1.10 Canonical Wnt signaling and bone remodelling 
 
(Taken from Canalis et al. 2013)  
Canonical Wnt signaling and bone remodelling, Lrp- 
lipoprotein receptor-related protein  
 
1.7.7 Incretin hormones and bone  
Bone formation and bone breakdown are closely related to food 
ingestion, and upon food intake, biomarkers for bone resorption 
are reduced (Bonjour et al. 2011, Motil et al. 2014, Graff et al. 
2016). GIP and GLP-1 are secreted in response to nutrient intake 
(Pais et al. 20116, Hansen et al. 2017, Hutchinson et al. 2017) 
and therefore it is suspected that incretins may play a role in 
bone turnover. GIP does have direct action on bone as GIPR 
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mRNA and protein are present in normal bone cells (osteoblast 
and osteoclast) and progenitor bone cells (Zhong et al. 2007, 
Ding et al. 2008, Tokarev et al. 2014).   
 1.7.7.1 GIP  
Binding of GIP to GIPR on osteoblasts increases cAMP and 
Ca2+ concentrations and subsequently elevates expression of 
bone formation biomarkers, collagen type 1 and alkaline 
phosphatase activity (Bollag et al. 2000, Bart Clarke, 2008, 
Yutaka Seno &Daisuke Yabe, 2013), indicating a positive action 
of GIP on bone formation. GIP plays an important role in 
proliferation of osteoblasts as it was observed that GIP has 
stimulatory effects on the release of transforming growth factor-
β (TGF-β) (Patil et al. 2011). Investigation of potential 
osteoprotective effects of GIP using primary mouse osteoblasts 
and osteoblastic-like SAOS-2 cells found that pre-treatment 
with GIP significantly reduced the percentage of apoptotic cells 
(Tsukiyama et al. 2006). Furthermore, there is a possible role of 
GIP in the early process of osteogenesis by promoting 
osteoblastic differentiation of bone marrow stromal cells 
(Meiczkowska et al. 2015, Kainuma et al. 2016, Fujita et al. 
2017). With regards to action of GIP on bone-resorbing 
osteoclast cells, there is limited information. However, it has 
been reported that GIP inhibits osteoclast activity and 
differentiation in vitro (Zhong et al. 2007), suggesting a role of 
GIP in reducing bone resorption (Berlier et al. 2015, Mabilleau 
et al. 2016). This has later been confirmed in studies showing 
that GIP can reduce osteoclast differentiation and resorption 
(Mabilleau et al. 2016), as well as improving osteoclast function 
following serum deprivation-induced apoptosis (Berlier et al. 
2015). 
Rodent studies in GIPR knockout mice have revealed reduced 
bone size and lower bone mass as well as a decrease in bone 
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formation biomarkers compared with the wild type mice (Xie et 
al. 2005, Shapses & Sukumar 2012, Gilbert & Pratley 2015). 
Bone histomorphometrical analyses of GIPR-deficient mice 
demonstrated that the reduction in bone mass was due to 
increased multinucleated osteoclasts, which are responsible for 
active bone resorption (Tsukiyama et al. 2006). In GIP over 
expressing transgenic mice, it was found that bone mass, bone 
size and biomarkers for bone formation were increased while 
bone resorption biomarkers were decreased (Xie et al. 2007, Yu 
et al. 2016, Tsung-Rong Kuo & Chih-Hwa Chen, 2017). These 
observations are in agreement with in vitro data that reported a 
stimulatory effect of GIP on osteoblasts and inhibitory effect on 
osteoclasts (Hansen et al. 2017). A bone assessment study 
performed using highly sophisticated imaging techniques found 
that the bones of GIPR KO have altered microstructure and 
decreased strength, highlighting the beneficial effects of GIP on 
bone (Mieczkowska et al. 2013). It has been demonstrated 
earlier that administration of GIP prevented bone loss in 
ovariectomised rats (Ma et al 2014, Wee & Baldock, 2014). In 
another recent study, it was found that rats injected with a stable 
GIP analogue appeared to have increased tissue material 
properties at the cortical bone level (Mabilleau et al. 2014, 
Meiczkowska et al. 2015, Mabilleau 2017).  A number of 
additional studies have demonstrated that GIP receptor deficient 
mice have shown altered bone microarchitecture (Hansen et al. 
2017, Christensen et al. 2017, Palmero et al. 2017). A recent 
study carried out in 2017 by Mantelmacher and colleagues has 
shown that GIP receptor deficiency results in impaired bone 
marrow haematopoiesis. The study highlighted that GIP receptor 
deficient mice affected GIP signaling and showed reduced levels 
of bone marrow as well as immune cells (Mantelmacher et al. 





1.7.7.2 GLP-1  
There is conflicting evidence regarding the expression of GLP-
1Rs on bone cells (Ceccarelli et al. 2013, Mabilleau et al. 2013, 
Yusta et al. 2015, Adil et al. 2017, Napoli et al. 2017). 
However, the inconsistencies may result from the use of 
different bone cell lines. GLP-1 appears to affect bone turnover 
in a beneficial manner, as GLP-1R-deficient mice have reduced 
bone mass and bone mineral density, while bone resorption 
biomarkers appeared to be significantly increased (Yamada et 
al. 2008). In addition, GLP-1R knock-out mice also have 
reduced cortical bone strength, due to alterations of cortical 
thickness and bone material properties (Mabilleau et al. 2013). 
Other studies demonstrated that bone formation biomarkers 
were elevated after 3-day subcutaneous administration of GLP-1 
or exendin-4 in streptozotocin-induced diabetic rats (Nuche-
Berenguer et al. 2009, Nuche-Berenguer et al. 2010a). These 
findings do highlight that GLP-1 does have positive effects on 
the bone. Exenatide, a GLP-1 analogue, has proven to be quiet 
effective when it comes to bone physiology. As such, a clinical 
study carried out by Wanq and colleagues in 2017 has revealed 
that 30 obese patients treated with exenatide for 18 weeks 
present with reduced bone morphogenic protein-4 (BMP-4) 
levels. As BMP-4 regulates white adipogenesis and plays 
important role in fat distribution, the study highlighted the fact 
that exenatide might have potential when it comes to 
augmenting bone quality (Wanq et al. 2017).  
GLP-1 receptor agonists, DPP-4inhibitors and SGLT2 inhibitors 
are widely used as anti diabetic drugs. It has already been 
reported that thiazolidinediones have detrimental effects on 
bone metabolism and fracture risk (Ruppert et al. 2017).  A 
recent report published by Eggar and colleagues in 2016, 
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suggest that SGLT2 causes alteration in calcium and phosphate 
homeostasis. This alteration is mainly because of secondary 
hyperparathyroidism induced by increased phosphate 
reabsorption. These results highlight potential negative effects 
of SGLT2 inhibitors on skeletal integrity, but not on bone 
metabolism directly (Egger et al. 2016). The role of liraglutide, 
a GLP-1 analogue, which is widely used in the treatment of 
type-2 diabetes and obesity in bone formation, was unclear until 
recently, when it was demonstrated that liraglutide reduces 
osteoblastic differentiation of MC3T3-E1 cells via modulation 
of AMPK/mTOR signalling (Hu et al. 2016). The study 
demonstrated that liraglutide upregulated phosphorylated 
adenosine monophosphate-activated protein kinase (p-AMPK) 
and downregulated phosphorylated mammalian target of 
rapamycin (p-mTOR) and TGF‑β protein expression levels.  
The effect of liraglutide to reduce osteoblastic differentiation 
was eradicated by AMPK‑specific inhibitor, Compound C and 
mTOR activator, MHY1485 (Hu et al. 2016). Recently, it has 
been reported that GLP-1 receptors affect fat-bone axis by 
enhancing osteogenic differentiation and inhibiting adipogenic 
differentiation of bone mesenchymal precursor cells (BMSCs) 
(Palmero et al. 2017). A similar study published by Meng and 
colleagues in 2016, demonstrated that activation of GLP-1 
receptors promoted osteogenic differentiation of bone marrow 
stromal cells through the β-catenin pathway (Meng et al. 2016). 
There are some studies that reveal conflicting data when it 
comes to liraglutide and exendin-4 effects on bone. For 
example, Pereira and colleagues carried out study in 
overactomised mice where liraglutide (0.3 mg/kg/day) and 
exenatide (10 μg/kg/day) were injected for four weeks. Both, 
liraglutide and exenatide increased trabecular bone mass with no 
effect on cortical bone. But in case of exenatide, the osteoclasts 
number was increased.  In addition, liraglutide and exenatide 
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stimulated osteoblastic differentiation (Pereira et al. 2015).  
Another study carried out by Lu and colleagues in 
overactomised female Wistar rats, but without diabetes, assessed 
the impact of liraglutide on bone mass and bone quality. 
Liraglutide increased trabecular volume, trabecular thickness, 
number of trabecular as well as bone mineral density (Hansen et 
al. 2017). Together, these studies highlight the protective 
positive effects of liraglutide on bone quality.  
 
1.7.8 Diabetes and bone 
Diabetes negatively affects bone health by disturbing several 
underlying pathophysiological pathways which regulate bone 
physiology (Karpinski et al. 2017). Several pathways pertaining 
to bone formation, bone resorption, collagen formation, 
inflammatory cytokine, bone marrow adiposity and calcium 
metabolism are affected in diabetic, patients eventually 
increasing fracture risk. In type-1 diabetic patients, there is six-
fold increase in hip fracture risk and two-fold increase in 
vertebral fracture risk as compared to that of non-diabetic 
individuals (Russo et al. 2016). In type-2 diabetic patients there 
is about two- to three-fold increase in hip fracture risk as 
compared to that of normal individuals (Palmero et al. 2017). 
Interesting, a study carried out in 2017 by Westberg-Rasmussen 
and colleagues, aimed to clarify whether oral or intravenous 
administration of glucose affects bone turnover differently. An 
oral glucose tolerance test was performed, followed by 
isoglysemic intravenous glucose infusion. Blood samples were 
analysed for different bone turnover serum markers such as, C-
terminal telopeptide of type-1 collagen (s-CTX) and procollagen 
type IN propeptide (s-P1NP), insulin and gastrointestinal 
hormones such as GIP, GLP-1 and GLP-2. Oral glucose caused 
a 50% reduction in s-CTX marker while only 30% reduction 
43 
 
was observed in case of isoglycemic intravenous glucose 
infusion (Westberg-Rasmussen et al. 2017).  
Further investigation is needed to realise the untapped potential 
of incretin hormones and their positive effects on bone. Future 
clinical trials will be necessary to investigate the relationship 
between incretin hormones and fracture risk in diabetic patients. 
1.8 OLIGOPEPTIDE TAGGING  
Targeted drug delivery to the bone can be achieved (Stapleton et 
al. 2017), due to the the physical nature of bone. As such, the 
majority of the bone is comprised of inorganic compound called 
hydroxyapatite (HAP) (Florencio-Silvia et al. 2015). Evidence 
shows that targeted drug delivery to HAP can be achieved 
(Takahashi-Nishioka et al. 2008, Newman & Benoit 2016 and 
Haider et al. 2017). In this respect, acidic oligopeptides can 
serve as novel drug delivery method to increase site-specific 
drug delivery to the bone (Low et al. 2014, Dang et al. 2016, 
Shaikh & Sawarkar 2016, Ulbrich et al. 2016). For example, 
non-collagenous proteins in the bone namely, osteopontin and 
sialoprotein, have repetitive sequence of acidic amino-acids (L-
Asp and L-Glu) that bind to hydroxyapatite (Takahashi et al. 
2008, Zurick et al. 2016, Jiang et al. 2017), making introduction 
of acidic oligopeptides a promising candidate as a bone 
targeting carrier.  
With this idea in mind, the peptides used in the present bone 
studies were designed in such a way that they were targeted 
towards by adding six repetitive aspartic amino acid and 
glutamic amino acid residues to the C-terminal. Along with 
appropriate parent peptides, the bone-targetting peptides used in 
these studies were (D-Ala2)GIP-Asp, (D-Ala2)GIP-Glu, (D-
Ala2)GLP-1-Asp, (D-Ala2)GLP-1-Glu, Xenin-25[Lys13PAL]-






1.9 AIMS OF THE THESIS 
The primary aim of this thesis was to investigate the impact of 
diabetes on bone and to characterise the effects of long-acting 
antidiabetic peptide analogues, with potential bone targeting 
moieties, on metabolic control as well as bone strength and 
quality in diabetes. 
 
The specific objectives of this thesis were: 
 
1. Designing bone targeting peptides by adding six 
repetitive amino aspartic amino acid and glutamic 
amino acid residues to the C-terminal.   
2. Assess in vitro effects of the peptides on beta-cell 
insulin release and human osteoblast cell function. 
3. Understand the mechanism of peptide signaling 
pathways in bone by assessing alkaline phosphatase 
activity, TGF-beta release, IGF-1 release and cAMP 
generation. 
4. Perform long term animal studies in normal and high 
fat fed mice with assessment of metabolic parameters 
such as glucose tolerance, insulin sensitivity, food 
intake, body weight, body composition as well as 
bone mineral density and content. 
5. Perform assessment of bone-specific parameters in 
these mice using techniques such as 3-point bending, 





































2.1 PEPTIDES  
2.1.1 Synthesis of peptides  
All peptides were purchased from EZ Biolabs Ltd. (Carmel, IN, 
USA). The peptides used in these studies were divided into four 
distinct groups, namely GIP based peptides, xenin based 
peptides, GIP/xenin hybrid based peptides and GLP-1 based 
peptides. Specifically, the peptides used were (D-Ala2)GIP, (D-
Ala2)GIP-Asp, (D-Ala2)GIP-Glu, (D-Ala2)GLP-1, (D-Ala2)GLP-
1-Asp, (D-Ala2)GLP-1-Glu, Xenin-25[Lys13PAL], Xenin-
25[Lys13PAL]-Asp, GIP/Xenin, GIP/Xenin-Asp, GIP/Xenin-Glu 
(Table 2.1). 
Table 2.1 Peptides employed within this thesis   
Group 
 



























































































2.1.2 Peptide purification, identification and 
characterisation 
All peptides were purified using reverse phase high performance 
liquid chromatography (RP-HPLC). Briefly, peptides were 
dissolved in distilled water at a concentration of 1 mg/ml. A 
peptide solution (100 µl of 1 mg/ml peptide) was then made up 
to 1 ml using 0.1% (v/v) TFA/water. Next the solution was 
injected into Kinetex C-18 analytical column (150 x 4.60 mm, 
Phenomenex, Cheshire, UK) equilibrated with 0.1% (v/v) 
TFA/water at a flow rate of 1 ml/min. Acetonitrile (70%) was 
used as the eluting solvent. The concentration of eluting solvent 
was increased using linear gradients from 0 - 36% acetonitrile 
over 5 mins followed by 36 - 40% over 15 mins and 40 - 70% 
over 5 mins and absorbance measured at 214 nm. 
The peptides were identified by mass spectroscopy. The 
molecular mass of all the peptides was confirmed using a 
Voyager-DE Biospectrometry Workstation (PerSeptive 
Biosystems, Farmingham, MA, USA). Bone is mainly composed 
of fibrious protein collagen, water and hydroxyapaptite. 
Addition of six aspartic acid and glutamic acid residues towards 
C-terminal increased affinity of peptides to bind to 
hydroxyapaptite. Parent xenin peptides were carboxylated, but 
with addition of six aspartic acid and glutamic acid residues all 
oligopeptides were amidated, as this has proven to main 
bioactivity of tagged peptodes (Takahashi-Nishioka et al. 2008).  
2.1.3 DPP-4 degradation profile 
DPP-4 degradation profile of the peptides was performed as 
described by Gault et al., (2011). In short, 30 µl of peptide (1 
mg/ml) was incubated with 5 µl of porcine DPP-IV (5 mU, 
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purchased from Sigma Aldrich, UK) in 50 mM Triethanolamine 
hydrochloride (TEA-HCl) (pH 7.8; final volume 440 µl) at 37oC 
for 0, 2, 8, 12 and 24 hrs. The enzymatic reaction was then 
stopped using 50 µl TFA/H2O (10% v/v).  Degradation profiles 
were followed using HPLC (as described in Section 2.1.2) and 
degradation products were analyzed using mass spectroscopy as 
detailed in Section 2.1.2. 
Table 2.2 Identification and characterisation of peptides by 
mass spectroscopy 




















































































































































2.2 CELL CULTURE   
2.2.1 BRIN-BD11 cells 
BRIN-BD11 cells are immortalised pancreatic beta-cells derived 
from the electro fusion of rat pancreatic islet cells and tumoral 
rat insulinoma RINm5F cells (McClenaghan et al. 1996). BRIN-
BD11 cells were cultured in RPMI-1640 growth medium  
supplemented with 10% (v/v) foetal bovine serum (FBS) and 
1% (v/v) antibiotics – penicillin (100 U/ml), streptomycin (0.1 
mg/l)  in 75 cm2 sterile tissue culture flasks (Greiner bio one, 
UK) and  maintained at 37°C and 5% CO2, in a LTEC incubator 
(Laboratory technical engineering, Nottingham, UK). Then the 
culture media was removed from the flasks and cells were 
washed with 10 ml Hanks buffer saline solution (HBSS). Then 
the cells were harvested from the surface of the tissue culture 
flask by using 3 ml trypsin/ EDTA. Then, 7 ml fresh culture 
media was added to the detached cells and it was pipetted in and 
out so as to form a single suspension. The cell suspension was 
centrifuged at 900 rpm for 5 mins and the pellet was re-
suspended in 10 ml of pre-warmed culture medium. The 
counting of cells was performed using Neubauer 
haemocytometer (Scientific Supplies Co., UK).  100 cell 
suspension was stained with 100 µl of trypan blue. Viable cells 
(unstained and bright) were counted in all the four WBC squares 
and average was calculated to obtain the total number of cells in 
the suspension.  
 The acute test was carried out as described by Gault et al. 
(2002). In order to perform acute test, the BRIN-BD11 cells 
were seeded at 150,000 cells/well seeding density in 24-well 
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plates. Then the cells were allowed to attach (24 hrs) overnight 
at 37oC. The pre-incubation step was carried out using Krebs–
Ringer bicarbonate buffer (KRBB) (115 mmol/l NaCl, 4.7 
mmol/l KCl, 1.2 mmol/l MgSO4, 1.28 mmol/l CaCl2, 1.2 mmol/l 
KH2PO4, 25 mmol/l HEPES and 8.4% NaHCO3, containing  
0.5% (w/v) BSA , pH 7.4) which is supplemented with 1.1mM 
glucose. Then the test incubations (n=8) were performed in the 
presence of glucose (5.6mM and 16.7mM) with a range of 
concentrations varying from 10-12 to 10-6 M of respective 
peptides for 20 mins at 37oC. After incubation, 200 µl aliquots 
of assay buffer were collected from each well and stored at -
20oC for measurement of insulin by radioimmunoassay (RIA) 
method.  
Iodinated bovine insulin  
Iodogen solution was prepared by dissolving 100 µg/ml of 1, 3, 
4, 6-tetrachloro-3α,6α-diphenylglycoluril in dichloromethane, 
followed by dispense of the solvent (100 µl) into Eppendorf 
tubes. Then the tubes were left in a fume hood to allow 
evaporation of the solvent and leaving a uniform layer of 
iodogen at the bottom of the tubes. Bovine insulin solution (125 
µg/ml) was prepared by diluting 1 mg/ml solution of bovine 
insulin in 10 mM HCl with 500 mM phosphate buffer. 20 µl of 
the bovine insulin solution and 5 µl of Na125I (100 mCi/ml 
stock) was added to the iodogen-coated eppendorf tubes and left 
on ice with gentle agitation for 15 mins. The iodogen reaction 
was stopped by removing the reaction mixture into a fresh 
Eppendorf tube with an addition of 500 µl of 50 mM sodium 
phosphate buffer. The solution was kept on ice before carrying 
out HPLC separation.  
HPLC separation was carried out using a Vydac C-8 analytical 
column (4.6 x 250 mm). The mobile phases used were 0.12% 
(v/w) TFA (in purified H2O) and 0.1% TFA (in 70% 
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acetonitrile-30% purified H2O). The separation programme was 
set for 67 mins and 1 ml fractions were collected by fraction 
collector (Frac-110, LKB). Then 5 µl from each fraction was 
aliquoted into LP3 tubes. Radioactivity counts were assessed 
using a gamma counter (Perkin Elmer Wallac Wizard 1470 
Automatic Gamma Counter). The fractions with highest counts 
were kept to perform antibody-binding tests and further pooled 
together to be used as the 125I-labelled tracer in the insulin 
radioimmunoassay.   
2.2.2 Radioimmunoassay (RIA) 
Radioimmunoassay stock buffer was prepared by adding 
disodium hydrogen with orthophosphate, base (17.035 g in 3 
litres of distilled water, i.e. 40 mM solution) and sodium 
hydrogen orthophosphate, acid (6.240 g in 1 litre of distilled 
water, i.e. 40 mM solution).  Then 0.6 g of thimerosal and 9 g of 
NaCl were added to the base. The pH of acidic solution was 
adjusted to 7.4 and both the solutions were stored at 4⁰C until 
further use. On the experimental day, working RIA buffer was 
prepared by dissolving bovine serum albumin (BSA, Sigma) 
0.5% (w/v) in stock RIA buffer i.e. 0.5 g in 100 ml, in 40 mM 
sodium phosphate buffer (pH 7.4). Insulin standards were 
prepared by serial dilution (0.039 to 20 ng/ml concentration) 
from frozen rat insulin stock (40 ng/ml) in working RIA buffer. 
To determine insulin concentration in experimental samples, 180 
µl of working RIA buffer was added to 20 µl of unknown 
sample to give a total volume of 200 µl per LP3 test tube. 
Guinea pig anti-porcine antibody was prepared by diluting 
frozen stock (100 µl) to 30 ml with working RIA buffer (i.e. 
1/30,000 final concentration). Prepared antibody (100 µl) was 
then added to unknown and standard samples (triplicate) 
followed by addition of 100 µl 125I-labelled insulin (10,000 
cpm/100 µl in working RIA buffer) into all samples. Then the 
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tubes were stored at 4⁰C for 48 hrs in order to allow sufficient 
time for competitive binding to take place.  
Dextran T 70 (5 g) was dissolved in sodium phosphate buffer 
(5%, without BSA) and 50 g charcoal was added with 
continuous mixing, making the final volume up to 1l with assay 
buffer. Stock dextran coated charcoal (DCC) solution was 
prepared at least 24 hrs prior to use. Working dextran coated 
charcoal solution was then prepared using a 1:5 dilution of stock 
DCC with stock RIA buffer. The separation of free from bound 
125I-label was achieved by adding 1 ml of working DCC to all 
the tubes except the total tubes of the standard. All the tubes 
were then vortexed and incubated for 20 mins at 4⁰C in cooled 
centrifuge (Beckmann Coulter) and then further centrifuged for 
20 mins at 2500 rpm. The supernatant was discarded and the 
unbound (free) 125I-labelled tracer was absorbed to black 
charcoal pellet at the bottom of the tube. Radioactivity was 
measured using Perkin Elmer Wallac Wizard Gamma Counter. 
The insulin concentration in the unknown sample was 
determined from rat insulin standard curve, as shown in Figure 























Standard curve of rat insulin for radioimmunoassay 
2.2.3 Sarcoma osteogenic SAOS-2 cells   
The Sarcoma osteogenic SAOS-2 cell line was procured from 
ATCC. These cells are derived from primary osteosarcoma of 
11 year old Caucasian girl in 1973 by Fogh et al. The cells from 
the stock vial were transferred to small flask very gently. After 
that, fresh 10 ml of alpha-MEM media was added into the flask. 
Then after 24 hrs, again the media was changed.  SAOS-2 cells 
were cultured in Minimum Essential Media (MEM) alpha 
medium, without phenol red (GIBCO, Invitrogen, UK). The 
MEM alpha medium was supplemented with 10% of foetal 
bovine serum (FBS) obtained from Lonza (Levallois-Perret, 
France) and 1% of penicillin/streptomycin (5000 U/ml, 5000 


























flasks in a controlled atmosphere at 37⁰C, 5% CO2. As the cells 
were 80 % confluent, they were washed and trypsinised. The 
trypsin was removed by centrifugation at 900 rpm for five mins 
and re-suspended in pre-warmed culture medium. 
2.2.4 Measurement of alkaline phosphatase activity 
SAOS-2 cells were seeded at a density of 1 x 105 cells/well in 6-
well plates and cultured for 72 hrs in growth media. 24 hrs 
before adding peptide, media was replaced with 2% FBS-
containing media. Cells were then incubated with varying 
concentrations of respective peptides (10-6 - 10-12 M) in media 
which was supplemented with 2% FBS, 1% 
penicillin/streptomycin. After the desired incubation period (24, 
48 and 72 hrs), cells were washed 3 times with PBS (Oxford, 
England). Then 250 µl of 0.2% Nonidet-40 (NP-40) (Sigma) 
was added into each well and plates were left on an orbital 
shaker for 10 mins. Using cell scraper (Costar) cells were then 
scraped and cellular material was homogenised by 3 cycles of 
freeze (-70oC)-thawing (37oC). The mixture of cells/0.2% NP-40 
was collected in 500 μl eppendorf tubes and those tubes were 
snap-frozen in liquid nitrogen. The tubes were then placed on a 
shaker for 16 hrs at 4oC. Finally, the contents of the tube 
sonicated using Soniprep 150 Plus ultrasonic disintegrator for 15 
seconds. The sonicated samples were then centrifugated for 15 
mins at 13000g at 4oC and supernatant was collected for 
determination of alkaline phosphatase activity and total protein 
contents. 
2.2.5 Alkaline phosphatase determination 
Samples (50 µl) were added to 96-well plates in duplicate and 
alkaline phosphatase activity was indirectly measured using 4-
methyl umbelliferyl phosphate (Sigma) as the substrate. After 
incubation for 30 mins at 37oC, the reaction was stopped by 
addition of 100 µl of 0.6 M Na2CO3 (Sigma-Aldrich). The basic 
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principle is that alkaline phosphatase cleaves the phosphate 
group of the non-fluorescent 4-methylumbelliferyl phosphate 
(MUP) and this leads to generation of highly fluorescent and 
stable 4-methyl umbelliferone (MU). Using FlexStation 3 
(Molecular Devices) fluorescence was measured at excitation 
wavelength of 360 nm and an emission wavelength of 450 nm. 
The cut off was kept at 435 nm. Alkaline phosphatase activity 
was calculated from a standard curve (0-1000 pmol) of 4-methyl 
umbelliferone.  
2.2.6 Total protein determination 
Total protein content in samples (whose alkaline phosphatase 
activity was measured) was determined using the bicinchoninic 
acid (BCA) protein assay kit (Pierce).  Sample (25 μl) and 
standard were added to a 96-well plate in duplicate.  Reagent 
AB (200 μl of 50:1) supplied in the kit was added. The plates 
were then incubated at 37oC for 30 mins. After desired 
incubation the plates were then left for 5 mins at room 
temperature. The plates were read at 562 nm using a microplate 
reader (Molecular Devices). Total protein content was then 
calculated according to a bovine serum albumin standard curve 
(0-1500 µg/ml).  Alkaline phosphatase activity was normalised 
against total protein content per well and was expressed as pmol 
4-MU/µg protein. 
2.2.7 Measurement of TGF-β   
SAOS-2 cells were seeded in 6 well plates at a density of 2 x 105 
cells/well. The cells were incubated in media which was 
supplemented with 10% FBS and maintained until they were 
confluent. 24 hrs before adding peptide, media was changed 
with fresh 0.1% FBS-containing media. On the day of 
experimentation, media was removed and 1 ml of respective 
peptides (10-12 - 10-6 M) was added to each well. Plates were 
then incubated for 8 hrs. After 8 hrs, media was collected and 
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TGF-β released in the supernatant was measured using a TGF-β 
Immunoassay kit (Quantikine, R&D Systems). The 
concentration of TGF-β was calculated from a standard curve of 
recombinant human TGF-β ranging from 0 to 2000 pg/ml.     
2.2.8 Measurement of IGF-1 
SAOS-2 cells were seeded in 6 well plates at a density of 2 x105 
cells/well and were maintained until they were confluent in 10% 
FBS-containing media. Media was changed with fresh media 
which was supplemented with 0.1% FBS 24 hrs prior to addition 
of respective peptides. Then the media was removed, followed 
by an addition of 1 ml of respective peptides (10-12 - 10-6 M). 
Plates were then incubated at 37oC for 8 hrs. After desired 
incubation, media was collected and IGF-1 released in the 
supernatant was measured using IGF-1 Immunoassay kit 
(Quantikine, R&D Systems). The concentrations of IGF-1 in the 
samples was determined from a standard curve of recombinant 
human IGF-1 in the range of 0 - 60 ng/ml.   
2.2.9 Measurement of cyclic AMP  
SAOS-2 cells were seeded at a density of 5 x 104 cells in 96-well 
plates. The cells were cultured in α-MEM 1X media 
(Invitrogen) which was supplemented with 10% FBS (Lonza),  
penicillin and streptomycin for 24 hrs so that they  attach to the 
plate. Prior to experimentation, cells were washed with HBSS 
(Invitrogen). Cells were then incubated with various 
concentrations (10-12-10-6 M) of respective peptides
 supplemented with 200 µM of 3-isobutyl-1-methylxanthine 
(IBMX). The plate was left for 40 mins at 37oC and after 
that, cells were washed 3 times with 150 µl of PBS. Cell lysis 
buffer (R&D Systems) was then used to lyse the cells and a 
freeze (-20oC) -thaw (37oC) cycle was carried out. The contents 
were then collected into 500 µl Eppendorf tubes and 
centrifugated at 600 g for 10 mins at 4oC. Supernatants
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 were then collected and cAMP was measured using a cAMP 
assay kit (R&D Systems). The concentration of cAMP was 
calculated from a standard curve of cAMP ranging from 0 to 240 
pmol/ml. 
 2.3 ANIMALS     
NIH Swiss mice (male, 8 weeks, Envigo Ltd., Blackthorn U.K.) 
were housed individually in air conditioned room at 22 ± 20 C 
with 12 hour light and 12 hour dark cycle. All animals had free 
access to standard rodent maintenance or high fat (45% fat, 20% 
protein, 35% carbohydrate) diets, as appropriate and drinking 
water. In all experiments calcein (300 µl) was injected 11th, 7th 
and 4th day before culling, to help determine mineralisation rate. 
All the animal experiments were performed according to the 
guidelines given by UK Animals Scientific Procedure Act 1986.   
2.3.1 Collection of blood samples 
Blood was collected from the tail vein of mice and stored in 
fluoride coated microvette blood tubes (Sarstedt, Germany). The 
samples were centrifuged immediately using microcentrifugate 
(Beckman Instruments, Galway, Ireland) for 5 mins at 13000 g. 
Plasma was then aliquoted into 500 µl Eppendorf tubes and 
stored at -200C prior to further use. 
2.3.2 Intraperitoneal glucose tolerance test  
Mice were fasted for 18 hrs before intraperitoneal injection of 
glucose (18 mmol/kg bw). Blood was collected immediately 
before (0 mins) giving glucose injection. Blood was then 
collected at 15, 30, 60 and 105 mins post injection as described 
in Section 2.3.1, and subsequently processed for measurement of 
plasma insulin concentrations. Blood glucose was measured 
immediately using a hand-held glucose monitor (Ascenscia 
glucose meter, (Bayer Contour).   
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  2.3.3 Intraperitoneal insulin sensitivity test  
Bovine insulin (25 U/kg bw in 0.9% saline) was injected 
intraperitoneally in mice and blood glucose was measured using 
a hand held glucose monitor at 15, 30, 60 and 105 mins as 
described in Section 2.3.2. 
2.3.4 Plasma insulin determination  
Plasma insulin concentration was determined by using modified 
dextran-coated charcoal radioimmunoassay (RIA) as described 
in Section 2.2.2. 
 
2.4 MEASUREMENT OF BODY COMPOSITION, BONE 
MINERAL DENSITY AND BONE MINERAL 
CONTENT BY DEXA SCANNING 
The mice were placed in a glass bell jar; in which the cotton 
mops were placed at the bottom of the jar. These cotton mops 
were dipped into isopropanol solution. After placing the mice in 
the jar, the mice became unconscious. Then the unconscious 
mice were placed on a specimen tray of the dual energy X-ray 
absorptiometry (DEXA) scanner and the whole body was 
scanned. The parameters measured using DEXA scanner (Inside 
Outside Sales, Wisconsin, USA) were bone mineral density 
(BMD), bone mineral content (BMC), lean mass, fat mass and 
percentage of total fat. The mice were exposed to X-rays and a 
high resolution picture was captured. The whole body was 
scanned along with regions of interests (femur, tibia and lumbar 
spine), as shown in Figure 2.2. The calibration of the machine 
was performed as per the manufacturer’s guidelines using a 










Figure 2.2A shows total region, whole body (in green) 
excluding the head (in red) 
Figure 2.2B shows femoral region 
Figure 2.2C shows lumbar or lower spine region  












2.5 ASSESSMENT OF BONE STRENGTH AND BONE 
QUALITY  
Tibias and femurs were dissected from the mice and cleaned. 
The excised tibias and femurs were kept in 70% ethanol, and 
stored at 4⁰C until further use.  Four techniques that were then 
employed to assess direct bone properties including; 
nanoindentation, quantitative back scattered electron imaging, 
X-ray microcomputed tomography (microCT) and three-point 
bending. These techniques were performed in bone research lab 
under the supervision of Dr. Guillaume Mabilleau at University 
of Angers, France  
2.5.1 Nanoindentation  
Nanoindentation determines hardness and elastic modulus of the 
bone. The biggest advantage of nanoindentation is that it can 
measure mechanical properties of the material on smaller scales 
(below microns) and therefore provide higher accuracy to 
investigate material properties of the bone matrix. The main 
purpose of using nanoindentation is to determine mechanical 
properties of bone matrix (Mabilleau et al. 2013). In order to 
carry out nanoindentation, blocks of embedded bone were 
polished with a DiaPro Nap-B diamond particle using Struers 
Tegramin-30 machine (Struers, Denmark) one day before the 
assessment and then left in saline solution (NaCl 0.9% (w/v)) 
overnight. The polished block of the bone was then placed on 
the Table Top Nanoindentation Tester (TTX-NHT, Figure 2.3) 
machine platform (CSM instrument, Peseux, Switzerland). An 
indentation area of 3 mm below growth plate in cortical section 
of the bone was selected. After selecting the region of 
indentation the block was passed under the indenter. Up to 12 
indentations were positioned in cortical bone using NHT-TTX, 
which was equipped with a Berkowitch pyramidal diamond 
probe as an indenter. A force of 40 mN/minute was applied to 
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the bone and indentations were produced of 900 nm in depth. 
The load was maintained for total duration of 15 seconds. 
Maximum force, indentation modulus, hardness and dissipated 
energy were estimated using nanoindentation as described 










H max  
Where: 
Fmax is the maximum force 

























Figure 2.3A shows the position of PMMA block on a 
stable platform and under the indenter.  
Figure 2.3B shows the pyramidal indentation as an 


































Indentation modulus is the initial slope of the unloading 



































Ei = Elastic modulus of the indenter (1141 GPa) 
Er = Reduced modulus of the indentation contact 
vi = Poisson’s ratio of the indenter (0.07) 
vs = Poisson’s ratio of the sample  
 
2.5.2 Quantitative back scattered electron imaging (QBEI) 
QBEI was used to determine bone mineral density distribution 
(BMDD). Polymethylmethacrylate (PMMA) blocks were 
polished with DiaPro Nap-B diamond particles (Struers, 
Denmark and then coated with carbon. The blocks were 
observed under scanning electron microscope (EVO LS10, Carl 
Zeiss Ltd., Nanterre, France) (Figure 2.4A). The scanning 
electron microscope was equipped with a five quadrant semi-
conductor backscattered electron detector. For every specimen, 
at least four images were taken from the cortical bone area. The 
electron microscope was operated at 20 keV with a 250 pA 
probe current at working distance of 15 mm. The backscattered 
electron signal was calibrated using pure carbon (Z = 6, mean 
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grey level = 25), pure aluminium (Z = 13, mean grey level = 
225) and pure silicon (Z = 14, mean grey level = 253) as 
standards (Micro-analysis Consultants Ltd., St. Ives, UK). 
Samples were scanned using a focused beam of electrons. This 
beam of electrons comes in contact with the atoms present in the 
sample. Based on the composition and topography of sample 
these electrons produce an image. The signal generated is 
closely related to atomic number (Z) of the sample. High atomic 
number atoms will have stronger interaction with the electrons 
and will appear brighter in the gray level image of microscope.  
The advantage of scanning electron microscope is that it 
provides 200x magnification of region of interest. Images are 
generated by MATLAB software (Angers University, France), 
where atomic number (Z) corresponds to y-axis and 
Backscattered electron (BSE) gray level to x-axis. The BSE gray 
level histogram was converted to weight percentage of calcium 
using hydroxyapatite, Ca10(PO4)6(OH)2 (Z = 14.06). Bone 
mineral density distribution (BMDD) was determined from 3 
parameters; Capeak, Camean and Cawidth.   Capeak represents the most 
frequent calcium content of the bone area, Camean corresponds to 
mean calcium content of the bone area obtained from area under 
the curve and Cawidth is the heterogeneity of mineralisation 













Figure 2.4 Scanning electron microscope (A), PMMA blocks 







Figure 2.4A shows scanning electron microscope system 
that was used in quantitative backscattered electron 
imaging technique 
Figure 2.4B shows proximal longitudinal section of 
embedded bone in PMMA blocks 
Figure 2.4C shows microarchitectural image of 













2.5.3 Micro Computed Tomography (Micro CT)  
Micro CT is mainly employed to study bone mass and 
microstructural morphology of tibia. A high-resolution Skyscan 
1172 microtomograph (Bruker-Skyscan, Kontich, Belgium), 
which was equipped with an X-ray tube working at 50 kV/100 
µA, was used to assess the tibia (Figure 2.5). Bones were placed 
inside an Eppendorf tubes that contained water in order to keep 
the bones hydrated. A sponge was placed in the tube in order to 
keep the position of tibia stationary. The Eppendorf tube was 
kept inside the central scanner along the axis on a carbon bed in 
the sample’s chamber before subjecting the bone to X-rays. The 
bone is moved 180⁰ step by step, at rotations of 0.3⁰.  Bones 
were scanned cross-sectionally and distally to produce a series 
of 2D projection images followed by 3D reconstruction of bones 
from the stack of images after removing noise background and 
interactive thresholding using NRecon software (Bruker 
microCT, Belgium).  
 
Different trabecular variables were measured using CTAn 
software (release 1.11.4.2, Bruker). These include; BV/TV 
(bone volume / trabecular volume, %), Tb.Th (trabecular bone 
thickness, mm), Tb.N (numbers of trabecular bone, 1/mm) and 
Tb.Sp (trabecular separation, mm). The measurements were in 
accordance with the guidelines on bone microstructure proposed 
by the American Society for Bone and Mineral Research 
(Bouxsein et al. 2010).  
 
Along-with trabecular variables, cortical bone thickness (Ct.Th, 
in µm) and cross-sectional moment of inertia (CSMI, in mm4) 
were assessed by measuring the diameter of cortical bone 
(B.Dm, in mm) and bone marrow (Ma.Dm, in mm) at 3-4 mm 
below the growth plate using ImageJ software (imajej.nih.gov). 
The measurements were conducted according to guidelines on 
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bone histomorphometry proposed by the American Society for 




























B.Dm = the diameter of bone 



















   
 
Figure 2.5A shows the microtomography system which 
consists of sample and x-ray chambers.  
Figure 2.5B shows how tubes containing bones aligned 
on a carbon bed in sample chamber 






































2.5.4 Three- point bending  
Three- point bending determines, as assessed using an Instron-
5942 3-point bending machine (Instron, U.S.A.), determines the 
mechanical properties of femoral bones. Before the experiment 
the bones were kept in saline solution for 24 hrs at room 
temperature. Femurs were positioned in such a way that their 
anterior side was facing upward, on top of a pair of rounded 
grips (10 mm apart) as supports (Figure 2.6). Then using a 
control panel, a vertically-moving crosshead was slowly brought 
down to the midshaft of the specimen and a pressing force was 
applied to the femur until the bone was broken. A loading speed 
of 2 mm min-1 was employed and the load and time taken until 
bone failure was recorded by the captor. The load-time curve 
was converted to a force-displacement curve (Figure 2.6), 
measured by Bluehill 3 software (Instron, France). The variables 
which were assessed from the curve were ultimate load, ultimate 
displacement, stiffness and work to failure as published 
previously (Turner 2006). 
 
2.5.5 Fourier –transformed infrared microscopy (FTIRM) 
Femurs were subjected to FTIRM analysis after three-point 
bending. In order to carry out FTIRM, femurs were cut at the 
mid-shaft with the help of diamond saw (Accutom, Struers, 
Champigny sur Marne, France). Further, femurs were embedded 
in polymethymethacrylate at 4⁰C. Cross-sections (4 µm 
thickness) of femur were cut on a microtome equipped with a 
tungsten carbide blade (Leica Polycut S). Spectral analysis of 
femurs was obtained on a Bruker Vertex 70 spectrometer 
interfaced with a Bruken Hyperion 3000 infrared microscope 
(Bruker Optics Ettlingen, Germany).  For every femur, 12 
spectra were acquired between the double calcein labelling 
areas, and analysed with Opus Software (release 6.5, Bruker). 
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Further, individual spectra were subjected to curve-fitting using 
G/AI 8.0, Thermofisher scientific commercially available 
software. Collagen maturity index, collagen glycation index and 































Figure 2.6A shows three-point bending instrument 
connected to a computer with Bluehill 3 software that is 
responsible for measuring mechanical properties of bone. 
Figure 2.6B shows the position of femur on 10 mm-
apart grips and a moving crosshead. 
Figure 2.6C shows control panel of the three-point 
bending instrument that allows vertical movement of 










Figure 2.7 Representative of force-displacement curve for 





This graph represents mechanical properties determined 
by three point bending; total absorbed energy (area under 
curve), stiffness, maximum displacement (displacement 
at maximum force); yield (a transition point, above 
which force begins to cause permanent damage to bone) 
and the post-yield energy (area under the curve after 
yield point). 
 
2.6 STATISTICAL ANALYSIS  
The statistical analysis was carried out using GraphPad Prism-5 
software. All results were expressed as mean ± SEM. For the 
comparative analysis of values student’s unpaired t-test, one 
way ANOVA and Student Newman Kewl’s post hoc test were 




































Effects of GIP, GLP-1, Xenin and Hybrid 













Incretin hormones such as glucose dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) 
augment insulin secretion following food ingestion. The 
bioactivity of GIP and GLP-1 is limited because they are rapidly 
degraded by dipeptidyl peptidase 4 (DPP-4).  In order to prolong 
their bioactivity several long-acting GIP and GLP-1 analogues 
have developed which can overcome DPP-4 degradation. It is 
well known that GIP receptors (GIPR) are present in pancreas, 
brain, heart, lung, adrenal cortex, and adipose tissue and 
recently it has been revealed that GIPR are present in the bone 
as well. With the help of acidic oligopeptide tagging bone-
specific GIP, GLP-1, xenin and GIP/Xenin hybrid analogues 
were designed as they have high affinity towards 
hydroxyapattite which is a major component of the bone. This 
study mainly focuses on the effects of bone-specific analogues 
on bone formation biomarkers- alkaline phosphatase activity, 
cyclic adenosine monophosphate (cAMP) generation in human 
osteoblastic SAOS-2 cells as well as role of cytokine factors 
such as transforming growth factor- beta (TGF-β) and insulin-
like growth factor-1 (IGF-1) in bone formation. Bone-specific 
analogues (D-Ala2)GIP-Asp and (D-Ala2)GIP-Glu demonstrated 
significant (p<0.01) insulin secretion  as that of (D-Ala2)GIP. 
Similar results were obtained regarding xenin-25[Lys13PAL], 
xenin-25[Lys13PAL]-Asp and GIP/Xenin hybrid analogues. (D-
Ala2)GIP, (D-Ala2)GIP-Asp were found to have increased 
(p<0.01) alkaline phosphatase activity during 24 and 48 hour 
incubation at concentrations of 10-10 M and above. Alkaline 
phosphatase activity was enhanced during 72 hour incubation 
with positive effects observed at 10-11 M and above. A similar 
pattern was observed regarding (D-Ala2)GLP, (D-Ala2)GLP-1-
Asp and (D-Ala2)GIP-1-Glu. No activity was observed regarding 
xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp. GIP/Xenin 
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and GIP/Xenin-Asp enhanced (p<0.5 to p<0.01) alkaline 
phosphatase activity during 24 h incubation period while 
GIP/Xenin-Glu did not show any effect on alkaline phosphatase 
activity.  Bone specific analogues (D-Ala2]GIP and (D-
Ala2)GIP-Asp significantly (p<0.05 to p<0.001) stimulated 
cAMP production in SAOS-2 cells . Regarding (D-Ala2)GLP-1, 
(D-Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu similar pattern of 
cAMP production was observed. No cAMP generation was seen 
regarding xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp. 
Regardin GIP/Xenin hybrid peptides, GIP/Xenin enhanced 
cAMP production at 10-8 M and above, GIP/Xenin-Asp and 
GIP/Xenin-Glu increased cAMP production only at 10-6 M. For 
(D-Ala2)GIP-Asp and (D-Ala2)GIP-Glu significant (p<0.05 to 
p<0.01) augmentation of TGF-β levels were observed at 10-8M 
and above. Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp 
did not induce any effect in terms of TGF- β release. GIP/Xenin 
significantly (p<0.01 to p<0.001) increased TGF-β levels at 10-
10 M and above. IGF-1 release profile was similar to that of 











3.2 INTRODUCTION  
Enteroendocrine cells produce different peptides including the 
incretin hormones glucose dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1) as well as xenin, 
cholecystokinin (CCK) amongst many others (Drucker 2007). In 
the 1960s a series of experiments were conducted which 
demonstrated the role of intestinal hormones in post-prandial 
insulin release (Daniel & Zietek 2015). This effect was 
described as the ‘incretin effect’ by Perley& Kipnis in 1967, and 
relates to the augmentation of insulin release following an oral 
glucose load mediated exclusively by GIP and GLP-1 (Lindgren 
et al. 2015). GIP is 42 amino acid hormone secreted from 
enteroendocrine K-cells postprandially (Fujita et al. 2016). GIP 
receptors are present in many tissues including pancreas, lung, 
testis, kidney, brain and adrenal cortex (Wang et al. 2017). 
Recent evidence has also reported that GIP receptors are present 
in bone (Holst et al. 2016).     
Following secretion, GIP is rapidly degraded by ubiquitous 
enzyme dipeptidyl peptidase-4 (DPP-4) resulting in a very short 
biological half-life. In humans, it has been reported that the half-
life of GIP is around 5-7 mins (Deacon et al. 2000, Hanna et al. 
2014). In rodents, the half- life is GIP is thought to be less than 
2 mins (Kieffer et al. 1995, Gilor et al. 2016). The unique 
speciality of DPP-4 is that it cleaves GIP at the N-terminal 
position 2 alanine residue, and converts GIP(1-42) into GIP (3-
42), which does not have any biological activity (Irwin et al. 
2015). In order to overcome this shortcoming several 
structurally modified DPP-4 resistant GIP analogues have been 
developed (Irwin et al. 2005a). 
GLP-1 is secreted from intestinal L-cells in response to food 
intake (Kim et al. 2017). GLP-1 is principally known to 
stimulate insulin release from pancreatic β cells in a glucose 
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dependent manner (Pais et al. 2016). However, GLP-1 also has 
positive effects when it comes to weight loss, as it delays gastric 
emptying and inhibits appetite (Lee & Lee 2017). Like GIP, 
GLP-1 is also rapidly degraded by ubiquitous enzyme DPP-4, 
but enzymatically stable forms are also readily available 
(Mabilleau et al. 2017). In terms of effects on bone, GLP-1 
administration promotes bone formation and helps normalize the 
impaired trabecular architecture (Nuche-Berenguer et al. 2015).  
In firm agreement, the GLP-1R agonist, liraglutide, had anabolic 
bone effects in overiectomized rats (Nan Lu et al. 2015). 
Xenin is a 25 amino acid peptide hormone and is co-secreted 
with GIP from the intestinal K-cells in response to food intake 
(Anlauf et al. 2000). The major metabolic actions of xenin 
include effects on gut motility, stimulating insulin secretion, 
reducing food intake and promoting satiety (Taylor et al. 2010). 
Unlike GIP and GLP-1, xenin is not degraded by DPP-4 but it 
rapidly broken down by serine proteases in blood (Taylor et al. 
2010). Importantly, xenin is known to enhance the biological 
actions of GIP (Taylor et al. 2010). Therefore, xenin may have 
positive effects on bone that could either be independent or 
linked to beneficial effects of GIP on bone. Interestingly, the 
specific receptor that xenin binds to still remains elusive, 
however interaction with neurotensin receptors has been 
proposed (Mazella et al. 2012).   
Several reports highlight the importance of GIP and GLP-1 
action on bone. Studies conducted by Gaudin-Audrain and 
colleagues showed that GIPR knockout (KO) mice exhibited 
higher trabecular bone volume, but there was a decrease in 
osteoclasts and increase in osteoblast activity, resulting in 
increased bone fracture risk (Gaudin-Audrain et al. 2013). In 
addition, collaborative studies at Ulster and Angers have shown 
that the GLP-1R is essential for maintenance of bone strength 
and quality (Mabilleau et al. 2013).  In agreement with these 
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observations in GIP and GLP-1 receptor KO mice, double-
incretin knockout (DIRKO) mice show reduced cortical bone 
mass and cortical bone strength and exhibit a combination of 
detrimental effects on bone as seen in GIPR and GLP-1R KO 
mice (Mieczkowska et al. 2015).  
Taken together, it is apparent that GIP, GLP-1 and also possibly 
xenin, could possess beneficial effect on bone. This is especially 
true for diabetic patients, where fragility bone fractures are a key 
concern (Mabilleau et al. 2017, Hansen et al. 2017). However, 
native GIP, GLP-1 and xenin are rapidly broken down in the 
circulation immediately upon secretion, making them 
therapeutically unattractive. To circumvent this problem, 
numerous well characterised, enzymatically stable, long-acting 
GIP/GLP-1/xenin analogues have been developed (Irwin & Flatt 
2015). However, despite their enhanced pharmacokinetic 
profile, these analogues show no specificity towards bone. Thus, 
in 2008, Takahashi-Nishioka et al. demonstrated the use of acid 
olionucleotides tagging (Glu and Asp) which can help deliver 
peptides to bones, due to preferential peptide deposition in 
hydroxyapatite (Wang et al. 2015). Based in this knowledge, the 
present study has utilised well established stable GIP, GLP-1, 
xenin and related hybrid peptides that incorporate oliopeptide 
tagging to make them more bone specific. Essentially this body 
of work has investigated the effects of four different families of 
peptides on metabolic and bone related parameters. The peptide 
families include GIP, comprising of (D-Ala2)GIP, (D-Ala2)GIP-
Asp and (D-Ala2)GIP-Glu; GLP-1 that consists of (D-Ala2)GLP-
1, (D-Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu; a xenin family 
including Xenin-25[Lys13PAL], Xenin-25[Lys13PAL]-Asp and 
finally a GIP/xenin family of peptides that incorporates 
GIP/Xenin, GIP/Xenin-Asp, GIP/Xenin-Glu. As such, following 
peptide characterisation, the potential beneficial effects of these 
peptides on the release of TGF-β and IGF-1, cAMP production 
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and alkaline phosphatase activity in human osteoblastic-derived 
SaOS-2 cells was examined. In addition, in a screening exercise 
to confirm bioactivity, relating to the insulinotropic action of all 
peptides was conducted in pancreatic clonal BRIN BD11 beta-
cells.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Peptides 
All the peptides namely, (D-Ala2)GIP, (D-Ala2)GIP-Asp, (D-
Ala2)GIP-Glu, (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp, (D-
Ala2)GLP-1-Glu, Xenin-25[Lys13PAL], Xenin-25[Lys13PAL]-
Asp, GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu were 
purchased from EZ Biolabs Ltd. (Carmel, United States of 
America) and were characterised by mass spectrometry as 
described in section 2.1.1. 
3.3.2 Maintenance of BRIN-BD11 cells   
BRIN-BD11cells were maintained as described in Section 2.2.1. 
Culture medium was changed every 3 days and the cells were 
utilised at 80% confluency.  
3.3.3 Maintenance of SAOS-2 cells 
SAOS-2 cells were maintained as described in Section 2.2.3. 
Culture medium was changed every 3 days and the cells were 
utilised at 80% confluency. MEM alpha medium supplemented 
with 10% of foetal bovine serum (FBS) and 1% of 
penicillin/streptomycin was used to culture the cells. The cells 





3.3.4 Measurement of plasma insulin  
An insulin RIA was carried out as described in Section 2.2.2 to 
determine plasma insulin concentrations. 
3.3.5 Measurement of TGF-β   
TGF-β was measured using a TGF-β Immunoassay kit 
(Quantikine, R&D Systems) as described in Section 2.2.7. 
Briefly, SAOS-2 cells were incubated in media which was 
supplemented with 10% FBS and maintained until the cells were 
confluent. Before adding the peptides the media was changed 
with 0.1% FBS-containing media. 1 ml of respective peptides 
(10-12 - 10-6 M) was added to each well and plates were then 
incubated for 8 hrs. After 8 hrs, TGF-β released in the 
supernatant was measured using a TGF-β Immunoassay kit 
(Quantikine, R&D Systems).  
3.3.6 Measurement of IGF-1  
IGF-1 was measured using IGF-1 Immunoassay kit (Quantikine, 
R&D Systems) as described in Section 2.2.8. In order to carry 
out IGF-1 assay, SAOS-2 cells were seeded at a density of 2 
x105 cells/well and cells were maintained until they were 
confluent in 10% FBS-containing media. Afterwards, media was 
changed with fresh media (supplemented with 0.1% FBS) 24 hrs 
prior to addition of respective peptides. Then the media was 
removed and 1 ml of respective peptides (10-12 - 10-6 M) was 
added. Plates were then incubated for 8 hrs. After desired 
incubation, IGF-1 released in the supernatant was measured 
using IGF-1 Immunoassay kit (Quantikine, R&D Systems).  
3.3.7 Measurement of cyclic AMP 
cAMP was measured using a cAMP assay kit (R&D Systems) as 
described in Section 2.2.9. For cAMP assay, SAOS-2 cells were 
cultured in α-MEM 1X media which was supplemented with 
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10% FBS, penicillin and streptomycin for 24 hrs so that the cells 
could attach to the plate. Cells were then incubated with various 
concentrations (10-12-10-6 M) of respective peptides
 supplemented with 200 µM of 3-isobutyl-1-methylxanthine 
(IBMX). The plate was left for 40 mins at 37oC. Following this, 
the cells were washed 3 times with 150 µl of PBS. Cell lysis 
buffer (R&D Systems) was then used to lyse the cells and a 
freeze (-20oC) -thaw (37⁰C) cycle was carried out. The contents 
were then collected into 500 µl Eppendorf tubes and 
centrifugated at 600 g for 10 mins at 4⁰C. Supernatant was 
collected and cAMP was measured using a cAMP assay kit 
(R&D Systems).  
3.3.8 Measurement of alkaline phosphatase activity 
Alkaline phosphatase activity was determined as described in 
Section 2.2.4. Samples (50 µl) were added to 96-well plates in 
duplicate and alkaline phosphatase activity was indirectly 
measured using 4-methyl umbelliferyl phosphate (Sigma) as the 
substrate. The reaction was stopped after 30 mins incubation at 
37oC, addition of 100 µl of 0.6 M Na2CO3 (Sigma-Aldrich). 
FlexStation 3 (Molecular Devices) was used to measure the 
fluorescence at excitation wavelength of 360 nm and an 
emission wavelength of 450 nm. The cut off was kept at 435 nm. 
Alkaline phosphatase activity was calculated from a standard 
curve (0-1000 pmol) of 4-methyl umbelliferone.  
3.3.9 Statistical analysis   
Data were analyzed using one-way and two-way ANOVA with 
Newman-Keuls post hoc tests and two-tailed t-tests using PRISM 
5.0. Data are expressed as mean ± S.E.M and a P value < 0.05 






3.4.1 Reverse-phase HPLC purification HPLC Traces of pure 
peptides 
The reverse-phase HPLC of the synthetic peptides, performed 
using a C-18 analytical column, showed homogenous well 
resolved peaks indicating a high degree of purity (Figure 1, A; 
Figure 2, A; Figure 3 A; Figure 4, A;  Figure 5, A;  Figure 6, A; 
Figure 7, A; Figure 8, A; Figure 9, A; Figure 10, A and Figure 11, 
A). Furthermore, this in-house HPLC analysis confirmed the 
peptide purity information supplied by the manufacturer.  
3.4.2 Mass spectrometry analysis  
The molecular mass of each peptide was determined using mass 
spectrometry (Figure 1, B; Figure 2, B; Figure 3 B; Figure 4, B;  
Figure 5, B;  Figure 6, B; Figure 7, B; Figure 8, B; Figure 9, B; 
Figure 10, B and Figure 11, B). Mass spectrometry data 
confirmed the peptides were synthesised successfully, as all m/z 
ratios corresponded well to theoretical masses (Table 1). 
3.4.3 Dose dependent effects of GIP, GLP-1, Xenin and 
Hybrid peptides on in-vitro insulin secretion from BRIN-
BD11 cells  
Figure 12 (A) demonstrates the effect of a range of concentrations 
(10-12 to 10-6 M) of (D-Ala2)GIP, (D-Ala2)GIP-Asp and (D-
Ala2)GIP-Glu on insulin secretion from the clonal pancreatic beta 
cell line, BRIN-BD11 at 5.6 and 16.7 mM glucose. As expected, 
(D-Ala2)GIP demonstrated significant (p<0.001) dose-dependent 
increases in insulin secretion at both glucose concentrations 
(Figure 12A,B). (D-Ala2)GIP-Asp and (D-Ala2)GIP-Glu also 
evoked similar significant (p<0.01) increases of insulin secretion, 
but were marginally less effective than (D-Ala2)GIP at 10-12 M 
when incubated at 16.7 mM glucose (Figure 12A,B). For (D-
Ala2)GLP-1, (D-Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu there 
was a comparable augmentation (p<0.001) of insulin secretion at 
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both 5.6 and 16.7 mM glucose, with (D-Ala2)GLP-1-Glu being 
somewhat less efficacious at lower concentrations (Figure 
13A,B). The significant (p<0.001) insulinoptropic actions of 
xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp were also 
comparable, with xenin-25[Lys13PAL]-Asp being less effective at 
10-11 and 10-12 M when incubated with 5.6 and 16.7 mM glucose, 
respectively (Figure 14A,B). In case of the hybrid peptides, 
namely GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu, again 
there was a cleat dose-dependent increase (p<0.001) of insulin 
secretion at both 5.6 and 16.7 mM glucose (Figure 15A, B). 
Similar to the other peptide families, at lower concentrations (10-
12 and 10-11 M) there was a marginal reduction in efficacy with 
both GIP/Xenin-Asp and GIP/Xenin-Glu (Figure 15A,B). Taken 
together, these data confirm that C-terminal extension of stable 
GIP, GLP-1, xenin or GIP/xenin hybrid peptides did not 
dramatically impede biological activity. 
3.4.4 Dose- and time-dependent effects of GIP, GLP-1, xenin 
and hybrid peptides on alkaline phosphatase activity   
(D-Ala2)GIP, (D-Ala2)GIP-Asp and (D-Ala2)GIP-Glu enhanced 
(p<0.05 to p<0.001) alkaline phosphatise activity during 24, 48 
and 72 hour incubation periods (Figure 16A,B & 17). During 24 
and 48 hour incubations, (D-Ala2)GIP, (D-Ala2)GIP-Asp were 
found to have increased (p<0.01) alkaline phosphatase activity at 
concentrations of 10-10 M and above (Figure 16A,B), with 
positive effects observed at 10-11 M and above during 72 hour 
incubations (Figure 17). Interestingly, (D-Ala2)GIP-Asp appeared 
to be more effective than (D-Ala2)GIP-Glu (Figure 16A,B & 17). 
A similar pattern was observed for (D-Ala2)GLP-1, (D-Ala2)GLP-
1-Asp and (D-Ala2)GIP-Glu (Figure 18 A,B & 19). As such, 
alkaline phosphatase activity increased as the incubation time was 
increased from 24 to 72 hrs in a dose-dependent manner for each 
peptide (Figure 18 A,B & 19). (D-Ala2)GLP-1 possessed 
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significant activity at concentrations 10-9 M (p< ) and above 
during 24 hour incubations (Figure 18A) and 10-10 M (p<0.001) 
and above during 48 and 72 hrs time periods (Figure 18B & 19). 
As with the GIP family of peptides, the (D-Ala2)GLP-1-Asp 
analogue seemed to be more effective than the (D-Ala2)GIP-Glu 
peptide (Figure 18 A,B & 19). In terms of alkaline phosphatase an 
activity of xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp, 
no activity was observed at any of the time points or doses 
employed (Figure 20A, B & 21). In terms of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu, during 24 hour incubations 
only GIP/Xenin and GIP/Xenin-Asp caused elevations (p<0.5 to 
p<0.01) in alkaline phosphatase activity, with GIP/Xenin-Glu 
being ineffective (Figure 22A). However, all three GIP/Xenin 
peptides evoked increases (p<0.05 to p<0.001) in alkaline 
phosphatase activity during 48 and 72 hour incubation periods 
(Figure 22B & 23). Similar to observations with the GIP and 
GLP-1 families of peptides, GIP/Xenin-Asp was more effective 
than GIP/Xenin-Glu (Figure 22A,B & 23) 
3.4.5 Dose-dependent effects of GIP, GLP-1, Xenin and 
hybrid peptides on cAMP production in SAOS-2 cells  
As shown in Figure 24, (D-Ala2]GIP and (D-Ala2)GIP-Asp 
significantly (p<0.05 to p<0.001) stimulated cAMP production in 
SAOS-2 cells compared to controls at 10-10 M and above (Figure 
24A). The only effective (p<0.05) concentration of (D-Ala2)GIP-
Glu was 10-6 M (Figure 24A). A fairly similar pattern of cAMP 
production was observed for (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp 
and (D-Ala2)GLP-1-Glu (Figure 24B), with (D-Ala2)GLP-1 and 
(D-Ala2)GLP-1-Asp being effective (p<0.01) at 10-8 M and (D-
Ala2)GLP-1-Glu (p<0.01) only at 10-6 M (Figure 24B).  No 
cAMP generation was observed with xenin-25[Lys13PAL] and 
xenin-25[Lys13PAL]-Asp (Figure 25A). In terms of the GIP/xenin 
hybrid peptides, there was enhanced (p<0.05 to p<0.01) cAMP 
85 
 
production for GIP/Xenin at 10-8 M and above, but only at 10-6 M 
for GIP/Xenin-Asp and GIP/Xenin-Glu (Figure 25B). 
3.4.6 Dose-dependent effects of GIP, GLP-1, xenin and hybrid 
peptides on TGF-β and IGF-1 release from SAOS-2 cells  
After exposure of SAOS-2 cells for 8 hrs, TGF-β levels were 
increased significantly (p<0.01 to p<0.001) by (D-Ala2)GIP at all 
concentrations employed (Figure 26A). Significant (p<0.05 to 
p<0.01) augmentation of TGF-β levels were recorded for (D-
Ala2)GIP-Asp and (D-Ala2)GIP-Glu at 10-8 M and above (Figure 
26A). Furthermore, (D-Ala2)GLP-1 significantly (p<-0.01 to 
p<0.001) increased TGF–β levels in SAOS-2 cells at 10-10 M and 
above (Figure 26B). For (D-Ala2)GLP-1-Asp, increased (p<0.01 
to p<0.001) levels were observed at 10-6 and 10-8 M, whereas (D-
Ala2)GLP-1-Glu was only effective (p<0.01) at the highest dose, 
10-6 M, employed (Figure 26B). No effect of xenin-25[Lys13PAL] 
and xenin 25[Lys13PAL]-Asp was seen in terms of TGF-β release 
(Figure 27A). However, GIP/Xenin produced significant (p<0.01 
to p<0.001) increases TGF-β concentrations at 10-10 M and above 
(Figure 27B). GIP/Xenin-Asp generated significant (p<0.01 to 
p<0.001) levels of TGF-β at both 10-6 to 10-8 M, whilst this was 
only observed at 10-6 M for GIP/Xenin-Glu (Figure 27B). The 
impact of the peptides of IGF-1 release was remarkably similar to 
that observed with TGF-B release (Figures 28&29). As such, all 
GIP-related (Figure 28A), GLP-1-related (Figure 28B) and 
GIP/xenin-related (Figure 29B) peptides evoked significant 
increases of IGF-1 release from SAOS-2 cells, whereas the xenin 
family of peptides were ineffective in this regard (Figure 29A). 
  
3.5 DISCUSSION 
Bone is highly complex dynamic organ and is constantly 
remodeled throughout life by the sequential activity of osteoblasts 
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and osteoclasts (Murugananda & Sinal 2014). This activity is 
controlled by various autocrine and paracrine factors (Matsuo & 
Ire 2008). Gastrointestinal hormones such as GIP and GLP-1 are 
known to play important role in remodelling of bone (Henrikson 
et al. 2003). GIP, secreted by intestinal K-cells, has specific 
receptors present on bone cells (Bollag et al.2000, Zhong et al 
2007). Thus, GIP has direct positive beneficial effects on the 
bones (Gilbert & Pratley 2015, Palmero et al. 2016). Interestingly, 
xenin is a hormone co-released with GIP from K-cells (Hasib et 
al. 2017). To date there is no real knowledge in relation to the 
potential effects of xenin on bone, but since xenin is known to 
augment the biological actions of GIP (Martin et al. 2016); an 
effect on bone would not be unsurprising. Intriguingly, there has 
been a recent report of a GIP/xenin hybrid molecule that 
combines the activity of GIP and xenin into a single compound 
(Hasib et al. 2017). Given the aforementioned actions, it would be 
interesting to examine the effects of this hybrid peptide on bone. 
Another important gastrointestinal hormone is GLP-1, secreted by 
ileal L-cells (Grneier & Backhed 2016). There are numerous 
reports which suggest that GLP-1 can be considered as a potential 
option for treatment of bone fractures (Lepsen et al. 2015, 
Wolverton & Blair 2017). In addition, there are numerous GLP-1 
receptor knock out studies in mice that suggest that GLP-1R is 
essential for maintenance of bone strength and quality (Lu et al. 
2015, Mabilleau et al. 2015, Mieczkowska et al. 2015, Meng et 
al. 2016).  
There are many obstacles in considering the use GIP, GLP-1, 
xenin or related peptides as a therapeutic option against bone 
fractures. Firstly, the native peptides are not enzymatically stable, 
and have an extremely short half-life (Gilor et al. 2016, Hanna et 
al. 2014). Fortunately however, numerous well characterised 
stable long-acting forms of GIP, GLP-1 and xenin analogues have 
been described (Uccellatore et al. 2015, Minamnres & Perez 
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2017). The second main obstacle revolves around specificity of 
these peptide analogues for bone. Bone is composed of mainly 
three main components, fibrous protein collagen, calcium 
phosphate hydroxyapatite and water (Ferreira et al. 2012). Thus, 
through oligopeptide tagging, involving addition of six C-terminal 
acidic L-Asp or L-Glu amino acid residues to encourage binding 
to hydroxyapatite (Takahashi-Nishioka et al. 2008), we can 
increase specificity of these peptides towards bone.  Initially, all 
peptides were characterised by HPLC and mass spectrometry 
before progressing to investigating effects within each 
experimental system.  
In order to confirm bioactivity of the novel C-terminally extended 
peptides, effects on insulin secretion from clonal BRIN BD11 
cells was examined. Notably, (D-Ala2)GIP, (D-Ala2)GLP-1, 
xenin-25[Lys13PAL] and the GIP/xenin hybrid peptide have all 
been shown to stimulate insulin secretion from this cell line 
(Parthsarthy et al. 2016, Martin et al. 2016, Hasib et al. 2017). In 
addition, since the GIP receptor on pancreatic beta-cells is 
identical to that found on bone (Faienza et al. 2015, Holst et al. 
2016, Hansen et al. 2017), we can be confident that effects can be 
translated to bone. Interestingly, all peptides dose-dependently 
stimulated insulin secretion, suggesting retention of bioactivity. It 
did appear the C-terminal extensions (Takahashi-Nishioka et al. 
2008) slightly impaired bioactivity, and that the L-Asp extension 
was less detrimental than the L-Glu extension in this regard. 
Further studies would be required to examine why this difference 
occurred. Nonetheless, given the potential for increased 
deposition within bone of the novel peptides, bioactivity data 
generated here was still very encouraging. This paved the way for 
investigating the effects of all peptides on bone cells. 
There are various osteoblastic cell lines available, namely SAOS-
2 and MG-63 which have shown the presence of GIP receptors 
(Mabilleau et al. 2016). With this in mind, the SAOS-2 cell line 
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was chosen for this study. TGF-β is a product of osteoblasts and it 
is abundantly found in bone matrix (Florencio-Silva et al. 2015). 
The main function of TGF-β is stimulating proliferation and 
differentiation of osteoblasts (Robey et al. 1987, Lee at al. 2002, 
Janssens et al. 2005, Tang et al. 2009). In the current study, TGF-
β concentrations were significantly increased in presence of (D-
Ala2)GIP and related C-terminally extended analogues, which 
was expected (Budi et al. 2015). In harmony with this, (D-
Ala2)GLP-1 analogues also evoked increased concentrations of 
TGF-β, suggesting a direct effect of GLP-1 on these osteoblast 
cells. However, the xenin family of peptides was unable to 
modulate TGF-β concentrations. This would suggest that xenin 
has no direct effect on osteoblast cells. Although, since the exact 
xenin receptor has not yet been characterised (Irwin & Flatt 
2015), it is difficult to relate this effect to a specific receptor. In 
case of the GIP/Xenin hybrid peptide, this peptide enhanced 
concentrations of TGF-β, suggesting that the acute effects of this 
peptide are mediated largely by the GIP component, as observed 
perviosuly (Hasib et al. 2017). IGF-1 is considered as important 
growth factor because of its dual action in both proliferation and 
differentiation of bone cells, and through positive effects on bone 
mineralization (Zhang et al. 2002, Xian et al. 2012). Interestingly, 
effects of the peptides on IGF-1 release almost mirrored actions 
on TGF-β release. This could suggest similar effects of gut-
derived peptides on the secretion of both IGF-1 and TGF-β from 
osteoblasts. However, further investigation of the cell signalling 
pathways involved in these actions would be required to confirm 
this. 
Alkaline phosphatase is considered as an important biomarker for 
bone formation (Kuo & Chen 2017). In the current study, as 
would be anticipated alkaline phosphatase activity increased as 
incubation time was increased from 24 to 72 h, confirming 
suitability of the experimental system. As expected (Lee et al. 
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2016, Pujari-Palmer et al. 2016) all GIP peptide forms augmented 
alkaline phosphatase activity, again confirming a direct effect on 
osteoblasts. Similar observations were made for all GLP-1 and 
GIP/xenin hybrid peptides. In addition, no activity was seen with 
the xenin group of peptides. These effects are virtually identical to 
those observed with IGF-1 and TGF-β release. This is interesting 
and again suggests similar effects of gut-derived hormones on 
bone. Moreover, activation of the GIP and GLP-1 receptors is 
known to modulate very similar pathways within various cell 
types (Campbell & Drucker 2013, Lee & Jun 2014, Athauda & 
Foltynie 2016), so the current observations may not be completely 
unexpected. Further research into lack of direct effects of xenin 
on SAOS-2 cells is required, although it may be that indirect 
effects are key, as has been observed with xenin actions on 
pancreatic beta cells. Nonetheless, alkaline phosphatase is a 
protein involved in bone mineralisation, with the main principle 
that it reduces extracellular inorganic pyrophosphate which is 
considered as a suppressor of hydroxyapatite crystals (Orimo 
2010, Penido & Alon 2012). Therefore, the GIP, GLP-1 and 
GIP/Xenin peptides examined within the current study could play 
an important role in bone mineralisation.  
In terms of cell signalling effects of peptides within SAOS-2 
cells, effects on intracellular cAMP levels were assessed (Baggio 
& Drucker 2007). It was found that in presence of the GIP and 
GLP-1 peptides, cAMP generation was enhanced. Xenin had no 
impact on cAMP levels, but this has also been observed in 
pancreatic beta-cells (Taylor et al. 2010).  In terms of the 
GIP/Xenin hybrid, enhanced cAMP production was also seen, 
likely related to activation of GIP receptors (Hasib et al. 2016).  
The results from cAMP assay further highlight the direct effect of 
GIP and GLP-1 on osteoblast cells.  
In conclusion, the present work has confirmed that biologically 
active, C-terminally extended, versions of stable gut-derived 
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peptides were generated. These novel peptides exhibited good 
bioactivity both in pancreatic beta-cells and bone derived 
osteoblast cells. It is clear that L-Asp extensions were superior to 
L-Glu extensions in terms of retention of biological activity. 
Given that these novel peptides are likely to accumulate in 
hydroxylapatite within bone, they may have potential as 
therapeutic options for bone fractures. In addition, since GIP, 
GLP-1 and xenin already have established benefits in the 
treatment of diabetes (Irwin & Flatt 2015, Pais et al. 2016, Hasib 
et al. 2017) it would seem most logical to assess the impact of 


















Table 1 Mass spectroscopy analysis of the peptides 
Name Amino acid sequence Theoretical 

































4329.67  4326.20  3.47 
Xenin-25[Lys13PAL] MLTKFETKSARVK(gamm
a glutamyl  
PAL)GLSFHPKRPWIL-
OH  






4219.54  4216.29  3.25 
GIP/Xenin H-Y-(d-Ala)-EGTFISDYS-
IAMHPQQPWIL-OH  









3531.65  3528.49  3.16 








Figure 3.1 (A) RP-HPLC of (D-Ala2)GIP and (B) Mass Spec of 
(DAla2)GIP  
  
































499.0 1799.4 3099.8 4400.2 5700.6 7001.0 
3534.02 
mAU 
Retention time (minutes) 
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Figure 3.2 (A) RP-HPLC of (D-Ala2)GIP-Asp and (B) Mass 
Spec of (D-Ala2)GIP-Asp 

































2400.0 3299.4 4900.8 5000.2 5700.6 7001.0 




Figure 3.3 (A) RP-HPLC of (D-Ala2)GIP-Glu and (B) Mass 

































499.0 1799.4 3099.8 4600.2 5700.6 7001.0 
4507.16 
Retention time (minutes) 
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Figure 3.4 (A) RP-HPLC of (D-Ala2)GLP-1 and (B) Mass Spec 
















RP-HPLC and Mass Spec trace of (D-Ala2)GLP-1 
 




















Figure 3.5 (A) RP-HPLC of (D-Ala2)GLP-1-Asp and (B) 
Mass Spec of (DAla2)GLP-1-Asp 
































3400.2 4000.8 4900.3 5700.6 7001.0 
4244.49 
Retention time (minutes) 
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Figure 3.6 (A) RP-HPLC of (D-Ala2)GLP-1-Glu and (B) Mass 





    




























499.0 1799.4 3099.8 4400.2 5700.6 7001.0 
Retention time (minutes) 
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Figure 3.7 (A) RP-HPLC of Xenin-25[Lys13PAL] and (B) 
Mass Spec of Xenin 25[Lys13PAL] 






























499.0 1599.4 2699.8 3800.2 4900.6 6001.0 
3331.17 




Figure 3.8 (A) RP-HPLC of Xenin-25[Lys13PAL]-Asp and (B) 
Mass Spec of Xenin-25[Lys13PAL]-Asp  
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Retention time (minutes) 






Figure 3.9 (A) RP-HPLC of GIP/Xenin and (B) Mass 
Spec of GIP/Xenin 















RP-HPLC and Mass Spec trace of GIP/Xenin 
















500.0 1510.4 2000.8 2899.2 4900.6 6001.0 
Mass (m/z) 






Figure 3.10 (A) RP-HPLC of GIP/Xenin-Asp and (B) Mass 
Spec of GIP/Xenin-Asp 
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1500.0 3010.4 3800.8 4000.2 4900.6 
Retention time (minutes) 
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Figure 3.11 (A) RP-HPLC of GIP/Xenin-Glu and (B) 
Mass Spec of GIP/Xenin-Glu 













    
 















499.0 1599.4 2699.8 3800.2 4900.6 





Figure 3.12 Dose dependent effects of (D-Ala2)GIP,(D-
Ala2)GIP-Asp and (D-Ala2)GIP-Glu  on insulin secretion from 
BRINBD-11 cells.  
 





































































































Insulinotropic responses of (D-Ala2)GIP,(D-Ala2)GIP-Asp and 
(D-Ala2)GIP-Glu at A) 5.6mM, B) 16.7mM glucose from 
BRIN BD11 cells. Values are mean ± SEM with n=8 for 
insulin release. *p<0.05, **p<0.01, ***p<0.001 compared 






Figure 3.13 Dose dependent effects of (D-Ala2)GLP-1,(D-
Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu  on insulin 





















Insulinotropic responses of (D-Ala2)GLP-1,(D-Ala2)GLP-1-Asp 
and (D-Ala2)GLP-1-Glu at A) 5.6mM, B) 16.7mM glucose from 
BRIN BD11 cells. Values are mean ± SEM with n=8 for insulin 
release. *<0.05, **p<0.01, ***p<0.001 compared with 




















































































































Figure 3.14 Dose dependents effect of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp on insulin 























Insulinotropic responses of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp at at A) 5.6mM glucose and B) 16.7mM 
glucose  from BRIN BD11 cells. Values are mean ± SEM 
with n=8 for insulin release. *p<0.05, **p<0.01, ***p<0.001 
compared with respective control.    
A 
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Figure 3.15 Dose dependent effects of GIP/Xenin, GIP/Xenin-
Asp and GIP/Xenin-Glu on insulin secretion from BRIN 
BD11 cells. 





















Insulinotropic responses of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu at A) 5.6mM, B) 16.7mM glucose from BRIN 
BD11 cells. Values are mean ± SEM with n=8 for insulin release. 
*p<0.05, **p<0.01, ***<0.001 compared with respective control.    
 


































































































Figure 3.16 Dose dependent effects of (D-Ala2)GIP, (D-
Ala2)GIP-Asp and (D-Ala2)GIP-Glu  on alkaline phosphatase 
activity after (A) 24 hrs and (B) 48 hrs in human osteoblast 
SAOS-2 cells. 
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SAOS-2 cells were grown in 6-well plates and stimulated with 
indicated concentrations of peptides. After (A) 24 h and (B) 48 h, 
the reaction was stopped and AlkP production was indirectly 
measured using 4-methyl umbelliferyl phosphate as substrate. The 
values were normalised against total amount of protein/well using 
BCA protein kit. Values are mean ± SEM of n=6. *p<0.05, 
**<0.01, ***p<0.001 vs control.  
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 Figure 3.17 Dose dependent effects of (D-Ala2)GIP, (D-
Ala2)GIP-Asp and (D-Ala2)GIP-Glu  on alkaline 
phosphatase activity after 72 hrs  in human osteoblast 
SAOS-2 cells. 
 
    




















































SAOS-2 cells were grown in 6-well plates and stimulated 
with indicated concentrations of peptides. After 72 h, the 
reaction was stopped and AlkP production was indirectly 
measured using 4-methyl umbelliferyl phosphate as substrate. 
The values were normalised against total amount of 
protein/well using BCA protein kit. Values are mean ± SEM 











Figure 3.18 Dose dependent effects of (D-Ala2)GLP-1, (D-
Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu on alkaline 
phosphatase activity after (A) 24 hrs and (B) 48 hrs  in 
human osteoblast SAOS-2 cells. 
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SAOS-2 cells were grown in 6-well plates and stimulated with 
indicated concentrations of peptides. After (A) 24 h and (B) 48 
h the reaction was stopped and AlkP production was indirectly 
measured using 4-methyl umbelliferyl phosphate as substrate. 
The values were normalised against total amount of 
protein/well using BCA protein kit. Values are mean ± SEM of 
n=6. *p<0.05, **p<0.01, ***p<0.001 vs control. 
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Figure 3.19 Dose dependent effects of (D-Ala2)GLP-1,(D-
Ala2)GLP-1-Asp and (D-Ala2)GLP-1-Glu on alkaline 
phosphatase activity after 72 hrs in human osteoblast SAOS-
2 cells. 
 










































SAOS-2 cells were grown in 6-well plates and stimulated with 
indicated concentrations of peptides. After 72 h, the reaction 
was stopped and AlkP production was indirectly measured using 
4-methyl umbelliferyl phosphate as substrate. The values were 
normalised against total amount of protein/well using BCA 
protein kit. Values are mean ± SEM of n=6. *p<0.05, **p<0.01, 












Figure 3.20 Dose dependent effects of Xenin-
25[Lys13PAL] and Xenin25[Lys13PAL]-Asp on alkaline 
phosphatase activity after (A) 24 hrs and (B) 48 hrs in 
human osteoblast SAOS-2 cells. 
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SAOS-2 cells were grown in 6-well plates and stimulated 
with indicated concentrations of peptides. After (A) 24 hrs 
and (B) 48 hrs the reaction was stopped and AlkP 
production was indirectly measured using 4-methyl 
umbelliferyl phosphate as substrate. The values were 
normalised against total amount of protein/well using 
BCA protein kit. Values are mean ± SEM of n=6.  
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Figure 3.21 Dose dependent effects of Xenin-25[Lys13PAL] 
and Xenin25[Lys13PAL] Asp on alkaline phosphatase 
activity after 72 hrs in human osteoblast SAOS-2 cells. 
 



































SAOS-2 cells were grown in 6-well plates and stimulated with 
indicated concentrations of peptides. After 72 h, the reaction was 
stopped and AlkP production was indirectly measured using 4-
methyl umbelliferyl phosphate as substrate. The values were 
normalised against total amount of protein/well using BCA 














Figure 3.22 Dose dependent effects of GIP/Xenin, GIP/Xenin-
Asp andGIP/Xenin-Glu on alkaline phosphatase activity after 
(A) 24 hrs and (B) 48 hrs in human osteoblast SAOS-2 cells.  
            A 
 




SAOS-2 cells were grown in 6-well plates and stimulated with 
indicated concentrations of peptides. After (A) 24 h and (B) 48 
h, the reaction was stopped and AlkP production was indirectly 
measured using 4-methyl umbelliferyl phosphate as substrate. 
The values were normalised against total amount of protein/well 
using BCA protein kit. Values are mean ± SEM of n=6. 
*p<0.05, **p<0.01, ***p<0.001 vs control.   
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Figure 3.23 Dose dependent effects of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin Glu on alkaline phosphatase 




SAOS-2 cells were grown in 6-well plates and stimulated 
with indicated concentrations of peptides. After 24 h, the 
reaction was stopped and AlkP production was indirectly 
measured using 4-methyl umbelliferyl phosphate as substrate. 
The values were normalised against total amount of 
protein/well using BCA protein kit. Values are mean ± SEM 













Figure 3.24 Effects of (A) (D-Ala2)GIP, (D-Ala2)GIP-Asp, (D-
Ala2)GIP-Glu and (B) (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp 
and (D-Ala2)GLP-1-Glu on cAMP generation in human 






















Human osteoblast SAOS-2 cells were exposed to different 
concentrations (10-12 – 10-6 M) of test peptides for 60 mins. cAMP 
release was then measured using a commercially available cAMP 
assay kit. Values are mean ± SEM for n=4-5. *p<0.05, **p<0.01, 
***p<0.0001 vs. control.     















































































Figure 3.25 Effects of (A) Xenin-25[Lys13PAL], Xenin-
25[Lys13PAL]-Asp and (B) GIP/Xenin, GIP/Xenin-Asp and 





























Human osteoblast SAOS-2 cells were exposed to different 
concentrations of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu 
for 60 mins. cAMP release was then measured using a 
commercially available cAMP assay kit. Values are mean ± SEM 
for n=4-5. *p<0.05, **p<0.01 vs control.  
 
 


































































Figure 3.26 Effects of (A) (D-Ala2)GIP, (D-Ala2)GIP-Asp, (D-
Ala2)GIP-Glu and (B) (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp 
and (D-Ala2)GLP-1-Glu on TGF-β re1ease from human 
osteoblast SAOS-2 cells.   
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Human osteoblast SAOS-2 cells were exposed to different 
concentrations of (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp and (D-
Ala2)GLP-1-Glu for 8 h and TGF-β levels were measured using 
recombinant human TGF-β Immunoassay kit. Values are mean 





Figure 3.27 Effects of (A) Xenin-25[Lys13PAL], Xenin-
25[Lys13PAL]-Asp and (B) GIP/Xenin, GIP/Xenin-Asp and 
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Human osteoblast SAOS-2 cells were exposed to different 
concentrations of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu for 8 
h and TGF-β levels were measured using recombinant human TGF-β 
Immunoassay kit. Values are mean ± SEM for n=4. **p< 0.01, ***p< 





Figure 3.28 Effects of (A) (D-Ala2)GIP, (D-Ala2)GIP-Asp, (D-
Ala2)GIP-Glu and (B) (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp 
and  (D-Ala2) GLP-1-Glu on IGF-1 release from human 






























Human osteoblast SAOS-2 cells were exposed to different 
concentrations of (D-Ala2)GLP-1, (D-Ala2)GLP-1-Asp and (D-
Ala2)GLP-1-Glu for 8 h and IGF-1 levels were measured using 
recombinant human IGF-1 Immunoassay kit. Values are mean ± 







Figure 3.29 Effects of (A) Xenin-25[Lys13PAL], Xenin-
25[Lys13PAL]-Asp and (B) GIP/Xenin, GIP/Xenin-Asp and 






























Human osteoblast SAOS-2 cells were exposed to different 
concentrations of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu for 8 h and IGF-1 levels were measured using recombinant 
human IGF-1 Immunoassay kit. Values are mean ± SEM for 














Chapter 4  
Impact of bone-specific GIP peptides on 
metabolic control as well as bone quality 




4.1 SUMMARY  
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-
amino acid gastrointestinal hormone that regulates blood 
glucose levels by stimulating insulin secretion following food 
intake. GIP receptors (GIPRs) are found in pancreas, brain, and 
liver. However recently, the presence of functional GIPRs has 
been reported on bone cells, and been shown to have direct 
positive effects on bone strength and quality. GIP is rapidly 
degraded by dipeptidyl peptidase 4 (DPP-4). In order to 
circumvent DPP-4 activity, stable GIP peptides have been 
developed. The bone-specific action of GIP could be further 
exploited by generating bone-targeting GIP forms, through 
oligopeptide tagging by addition of six C-terminal acidic L-Asp 
amino acid residues that encourage binding to hydroxyapatite, 
the major component of the bone. The present study has 
investigated the effects of once-daily administration of (D-
Ala2)GIP and  (D-Ala2)GIP-Asp  (25 nmol/kg bw) for 42 days 
on bone mineral density (BMD) and content (BMC), bone 
geomertry and bone tissue specific properties, as well as 
metabolic control in high-fat fed mice. Once daily injection of 
the peptides had no effect on body weight and food intake, but 
circulating glucose was significantly (p<0.001) decreased by 
day 42.  Glucose tolerance was enhanced by (D-Ala2)GIP, but 
not by (D-Ala2)GIP-Asp. DEXA analysis revealed that there was 
no difference in overall, femoral and lumbar BMD and BMC 
between groups of mice. However, tibial BMC was enhanced, 
revealing marked (p<0.01) benefits of [D-Ala2]GIP-Asp. Total 
trabecular area was enhanced (p<0.01) in the mice treated with 
(D-Ala2)GIP-Asp. In (D-Ala2)GIP treated mice cortical thickness 
was reduced (p<0.01) but not in (D-Ala2)GIP-Asp mice. Infrared 
spectroscopy analysis revealed enhancement of collagen cross-
linking by (D-Ala2)GIP and (D-Ala2)GIP-Asp. In conclusion, 
this study has shown that biologically active, bone-targeting, 
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forms of stable GIP analogues can be produced which requires 
further investigation for the treatment of bone-related diseases.  
 
 4.2 INTRODUCTION  
Glucose-dependent insulinotropic polypeptide (GIP) is released 
in response to food ingestion (Christensen MB 2016). The 
primary effect of GIP is to enhance the secretion of insulin in a 
glucose-dependent manner and therefore, control postprandial 
glucose concentrations (Seino et al. 2016). However, previously 
it has been reported that functional GIP receptors are present on 
bone (Bollag et al. 2000, Zhong et al.2007), indicating a direct 
action of GIP on bone. GIP has only short half-life of around 2 
to 4 mins in rodents and humans (Kieffer et al. 1995, Deacon et 
al. 2000). GIP is rapidly degraded by dipeptidyl peptidase 4 
(DPP-4) upon secretion into the bloodstream (Godinho et al. 
2015). To overcome this, DPP-4-resistant GIP molecules with 
prolonged bioactivity have been developed (Irwin et al. 2005a).  
The insulin secretory activity of GIP is well documented, but 
less attention has been given to the fact that GIP has positive 
effect on bone.  
Bone remodeling is a complex and continuous process which 
occurs via communication between osteoblasts and osteoclasts, 
where old bone is constantly removed by osteoclasts, and is 
replaced by new bone formed by osteoblasts (Matsuo & Irie 
2008). Bone is mainly comprised of collagen, hydroxyapaptite 
and water (Bolesky 2013). Through oligopeptide tagging, by 
addition of six C-terminal acidic L-Asp amino acid residues to 
GIP, binding of peptides to hydroxyapaptite can be increased 
(Takahashi-Nishioka et al. 2008) making these types of GIP 
analogues potential treatment option for fragility bone fractures. 
Thus, (D-Ala2)GIP-Asp represents one such analogue (Chapter 
3), that will be further characterised in this chapter. 
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Different types of mice models have been developed to 
investigate detrimental effects of type 2 diabetes on bone 
quality. Some of these models include obese Zucker (fa/fa) rats, 
obese diabetic (ob/ob) mice and diabetic (db/db) mice (Fajardo 
et al. 2014). In 2004, studies carried out by Hamrick and co-
workers reported that homozygous mutation of the leptin gene 
in ob/ob mice or defective leptin receptor in db/db mice, 
severely and detrimentally affected bone microarchitecture and 
strength (Hamrick et al. 2004). Similar findings were reported 
by Matsunuma et al., as they also found there were severe 
alterations in bone microarchitecture (Matsunuma et al. 2004). 
Regarding ob/ob mice, histomorphometry analysis revealed 
reduced bone mass, shorter femoral length and reduced cortical 
thickness (Stephen et al. 2000).  In db/db mice, it has been 
reported that bone mineral content (BMC) and bone mineral 
density (BMD); are both significantly reduced leading to 
alterations on bone biomechanical properties (Ealey et al. 2006). 
Another important model which allows studying the effects of 
type 2 diabetes on bone skeleton is high-fat fed mice model. The 
high-fat diet is more or less similar to the Westernised diet that 
can lead to obesity, insulin resistance and type 2 diabetes 
(Zhang et al. 2009). Several studies have been carried on high-
fat fed mouse models, and report detrimental effects on bone 
mass and bone volume (Patsch et al. 2011), as well as reduction 
in bone biomechanical strength and alterations in bone 
microstructure (Halade et al. 2010). This suggests that the high-
fat diet has adverse effects on bone. The present study was 
therefore undertaken to assess the effects of (D-Ala2)GIP, and 
(D-Ala2)GIP-Asp on metabolic control, BMD, BMC and 






 4.3 MATERIALS AND METHODS   
 4.3.1 Synthesis of peptides 
The (D-Ala2)GIP, (D-Ala2)GIP-Asp peptides used in this study 
were purchased from EZ Biolabs Ltd. (Carmel, IN, USA). The 
peptides were characterised by mass spectrometry as described 
in Section 2.1.2. Identity of the peptides was confirmed by 
comparing values for experimental mass obtained from mass 
spectroscopy and theoretical masses. 
4.3.2 Animals and study design 
Young male NIH Swiss mice (n=5, 8 weeks old) were 
maintained on high-fat diet for three months. All the mice were 
housed separately in air conditioned room with 12 hour light and 
12 hour dark cycle. Mice were grouped (n=5) according to body 
weight and blood glucose. Initially mice were injected with 
saline solution (0.9% NaCl) for 3 days so that they could get 
accustomed to the injection regimen. Group 1 received high-fat 
diet and saline injection (0.9% NaCl). Group 2 mice received 
high fat diet and (D-Ala2)GIP injection (25 nmol/kg bw) once a 
day.  Group 3 received high-fat diet and (D-Ala2)GIP-Asp (25 
nmol/kg bw) injection once a day. The injecton schedule was 
followed for 42 days. Body weight, food consumption, non-
fasting and blood glucose concentrations were measured at 
regular intervals. Intraperitoneal glucose tolerance test (18 
mmol/kg bw, 18 hour fast) and non-fasting insulin sensitivity 
(25 U/kg bw) tests were performed at the end of the study as 
described in Sections 2.3.2 and 2.3.3, respectively. All 
experiments were carried out according to UK Home Office 
Regulations (UK Animals Scientific Procedures Act 1986).  
4.3.3 Measurement of plasma insulin 
An insulin RIA was carried out as described in Section 2.4.2 to 
determine plasma insulin concentrations.   
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4.3.4 Measurement of body composition, bone density and 
mineral content by DEXA scanning 
Mice were anaesthetised with isoflurane and then they were 
placed on a specimen tray of DEXA scanner and the whole body 
was scanned. BMD, BMC, lean mass and fat mass were 
determined as explained in Section 2.4. 
4.3.5. X-ray microcomputed tomography (µCT) 
Microcomputed tomography was carried out to assess trabecular 
bone mass, trabecular bone thickness, number of trabeculae, 
cortical bone diameter, cortical thickness, diameter of bone 
marrow and cross-sectional moment of inertia as described in 
Section 2.5.3.   
4.3.6 Fourier transformed infrared (FT-IR) imaging and 
micro spectroscopy 
FT-IR was performed as per described in section 2.5.5. In short, 
polymethylacrylate sections (4 µm) of bones were prepared 
using micrtome equipped with tungsten carbide knife. Further, 
spectral analysis was carried out using a Bruker Vertex 70 
spectrometer interfaced with Bruker Hyperion 3000 infrared 
microscope equipped with mercury cadmium telluride detector. 
The spectra were recorded in the same location (region of 
interest on the bone). On an average 32 spectra were recorded.    
4.3.7 Statistical analysis 
Data were analysed using repeated measures one-way or two-
way ANOVA with Tukey post hoc tests or two-tailed t-tests 
using PRISM 5.0. Data are expressed as mean ± S.E.M and a P 






4.4.1 Effects of (D-Ala2)GIP and (D-Ala2)GIP-Asp on body 
weight, food intake,  blood glucose and plasma insulin in 
high-fat fed mice  
Daily administration of (D-Ala2)GIP and (D-Ala2)GIP-Asp did 
not cause any significant changes in terms of body weight, fat 
mass, lean mass (Figure 4.1A-C) or food intake (Figure 4.2).  
Circualting blood glucose was decreased by both treatment 
interventions, with both (D-Ala2)GIP and (D-Ala2)GIP-Asp 
treated mice having significantly (p<0.05 to p<0.001) reduced 
glucose concentrations compared to saline controls on day 42 
(Figure 4.3 A). Insulin levels were reduced in the mice treated 
with (D-Ala2)GIP-Asp (Figure 4.3 B) 
4.4.2 Effects of (D-Ala2)GIP and (D-Ala2)GIP-Asp on glucose 
tolerance and insulin sensitivity in high-fat fed mice 
Glucose tolerance tests were carried out on day 42 and blood 
glucose and plasma insulin measured at 0, 15, 30, 60 and 105 
mins post glucose challenge. Blood glucose levels were reduced 
(p<0.01) in both treatment groups at 105 min (Figure 4.4A), but 
AUC values were not different from saline controls (Figure 
4.4B). Corresponding insulin levels were reduced by the 
treatments, and signficaintly (p<0.05 to p<0,001) so by (D-
Ala2)GIP-Asp (Figure 4.4C), but again AUC values were similar 
in all groups (Figure 4.4D). Accordignly, insulin sensitivity was 
imporved by (D-Ala2)GIP and (D-Ala2)GIP-Asp comapared to 
controls, but only significantly by (D-Ala2)GIP-Asp (Figure 
5A,B). 
4.4.3 DEXA analysis of femur, tibia and lumbar spine in 
high-fat fed mice 
DEXA analysis revealed that there was no difference in wholw 
body (Figure 4.6), femoral (Figure 4.7) and lumbar (Figure 4.8) 
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BMD and BMC between groups of mice. However, tibial BMC 
was increased (p<0.01) by (D-Ala2)GIP-Asp (Figure 4.9), 
indicating the potential benefits of (D-Ala2)GIP-Asp.  
4.4.4 Effects of (D-Ala2)GIP and (D-Ala2)GIP-Asp on 
trabecular bone morphology and cortical bone geometry in 
high-fat fed mice  
Microcomputed tomography (MicroCT) was performed on 
bones to analyse parameters such as trabecular bone volume, 
cortical thickness, trabecular separation and number of 
trabeculae (Figure 4.10). Interestingly, total trabecular area was 
augmented (p<0.01) in the mice treated with (D-Ala2)GIP-Asp, 
but not by (D-Ala2)GIP (Figure 4.11A).  Cortical area, bone 
mineralisation and moment of inertia were unaffected after 
treatment with (D-Ala2)GIP and (D-Ala2)GIP-Asp (Figure 
4.11B-D). Cortical thickness was reduced (p<0.01) in the mice 
treated with (D-Ala2)GIP, but not in (D-Ala2)GIP-Asp mice 
(Figure 4.10E). Cross-sectional moment of inertia was similar in 
all groups (Figure 4.10F).    
4.4.5 Effects of (D-Ala2)GIP and (D-Ala2)GIP-Asp on bone 
tissue level parameters in high-fat fed mice  
Five different parameters were analysed using infrared 
spectroscopy. These parameters included collagen cross-linking, 
crystallinity of hydroxyapaptite, degree of mineralisation, 
degree of carbonate substitution and content of acid phosphate 
(Figure 4.11A-O). From these measurements, the only 
treatment-indcued changes were an enhancement of collagen 
cross-linking by both by (D-Ala2)GIP, and especially (D-






4.5 DISCUSSION  
Bone turnover is controlled by sequential activity of osteoblasts 
and osteoclasts which is controlled by various autocrine and 
paracrine factors (Matsuo & Ire 2008).  After food ingestion 
bone resorption biomarkers undergo rapid change (Henrikson et 
al. 2003), suggesting that gastrointestinal hormones do play a 
role in bone remodelling. GIP is released by entero-endocrine K 
cells and it has been reported that GIP receptors are present on 
bone cells (Bollag et al.2000, Zhong et al 2007).  Less attention 
has been given to the fact that there are direct positive beneficial 
effects of GIP on bone. A small number of studies have been 
carried out to suggest use GIP as a therapeutic option for 
treatment of fragility fractures. For example, in 2013, Gaudin-
Audrain and colleagues reported that GIPR KO mice exhibited 
higher trabecular bone volume, but had decreased osteoclasts 
and increased osteoblast activity, resulting in increased bone 
formation (Gaudin-Audrain et al. 2013). In a similar study 
carried out study in double incretin receptor knockout mice 
(DIRKO), it was found that cortical bone mass and cortical bone 
strength was reduced and exhibited detrimental effects on bone 
(Mieczkowska et al. in 2015). However, most importantly, 
administration of a long acting GIPR agonist had positive effects 
on bone in normal and diabetic rodents (Mabilleau et al. 2015). 
The present study assessed the effects of once-daily 
administration of (D-Ala2)GIP and (D-Ala2)GIP-Asp for 42 days 
on bone parameters in high-fat fed mice. (D-Ala2)GIP is a well 
characterised long-acting GIP agonist (Tatarkiewicz et al. 2014) 
whereas (D-Ala2)GIP-Asp is a bone-targetting stable GIP form 
charatersied within Chapter 3 of this thesis. The findings of this 
study revealed that there was no effect on body weight and food 
intake, but that circulating non-fasting glucose levels were 
reduced by both treatments. These observations are consistent 
with other studies employing stable GIP agonists in diabetic 
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mouse models (Shimazu-Kuwahara et al. 2017). Interestingly, 
(D-Ala2)GIP-Asp enhanced glucose tolerance and insulin 
sensitivity to an equal, or even superior degree than (D-
Ala2)GIP. This is interesting and merits further study, and might 
suggest that (D-Ala2)GIP-Asp has potential important 
antidiabetic actions. DEXA analysis revealed that there was no 
difference in overall, femoral and lumbar BMD and BMC. 
However, BMC assessment of tibia revelaed clear benefits of 
(D-Ala2)GIP-Asp over (D-Ala2), highlighting the benefit 
afforded by directing the peptide towards bone by acidic 
oligopeptide tagging (Wang et al. 2016, Zhu et al. 2017). 
Microcomputed tomography was performed to assess cortical 
area, bone mineralisation, cortical thickness, moment of inertia 
and total area.  MicorCT analysis revealed that cortical area, 
bone mineralisation and moment of inertia remain unaffected in 
the mice treated with (D-Ala2)GIP and (D-Ala2)GIP-Asp.  
Cortical thickness was increased in the mice treated with (D-
Ala2)GIP-Asp. These findings are in harmony with the previous 
studies suggesting positive effects of GIP on bone (Mansur et al. 
2015, Mabilleau 2017). Similarly, total area was also increased 
in the mice treated with (D-Ala2)GIP-Asp. This again suggests 
key bone-specific benefits of the additional six aspartic acid 
residues added to the molecule (Carbone et al. 2017, Smith & 
Samadfam 2017). The abnormalities in cortical bone geometry 
in the high fat fed mice are due to overt hyperglycaemia, as 
hyperglycaemia leads to alterations and modifications in bone 
collagen which further causes alterations in bone matrix 
eventually leading to bone fragility (Palmero et al. 2017).  
The analysis of bone at the tissue level was performed by 
infrared spectroscopy. Collagen cross-linking, crystallinity of 
hydroxyapaptite, degree of mineralisation, degree of carbonate 
substitution and content of acid phosphate were determined with 
the help of infrared spectroscopy. Collagen cross-linking was 
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augmented significantly in the mice treated with (D-Ala2)GIP 
and (D-Ala2)GIP-Asp. Indeeed, as observed before this bone 
effect was enhanced by acidic oligopeptide tagging (Castro et al. 
2017, Schimdt et al. 2017). An increase in collagen cross-
linking demonstrates enhanced collagen maturity and integrity 
(Kimura-Suda & Ito 2017). These findins can be backed up by 
previous studies where hybrid peptides, that contained a 
significant GIP component, have shown to improve bone 
strength at organ and tissule levels (Mansur et al. 2016). The 
degree of mineralisation, degree of carcarbonate substitution, 
crystallinity of hydroxyapaptite and acid phosphate content 
remain unaffected by the treatment interventions.  The 
contradictory findings with increased collagen cross linking on 
the one hand, but no effects on rest of the parameters, point out 
the fact that dynamics of bone biology are dependent on many 
factors including bone integrity, mineralisation, morphology, 
bone mass and microstructure. Further analysis by three-point 
bending and nanoindentation would therefore be required to 
assess biomechanical properties of cortical bone, and confirm 
this viewpoint (Peacock et al. 2017, Arnold et al. 2018).    
Based on the findings from this chapter, it is clear that 
generation of biologically active, bone-targeting, forms of stable 
GIP analogues is possible. Further investigation still needs to be 











Figure 4.1 Effects of once daily administration of (D-
Ala2)GIP and (DAla2)GIP-Asp for 42 days on (A) body 
weight (B) % fat mass and (C) total lean mass in high fat fed 
mice 
 






















           








(A) Body weight was measured for 3 days before and 42 days 
during (indicated by blackhorizontal bar) once daily treatment 
with saline vehicle (0.9% w/v NaCl), (D-Ala2)GIP and (D-
Ala2)GIP-Asp (each peptide at 25 nmol/kg bw). Values 
represent means ± SEM for 5 mice.  (B) % fat mass and (C) lean 
mass as measured by DEXA scanning in high fat fed mice 
following 42 days treatment with (D-Ala2)GIP and (D-Ala2)GIP-













































Figure 4.2 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on cumulative 






































Cumulative energy intake was measured for 3 days before and 
42 days during (indicated by black horizontal bar) once daily 
treatment with saline vehicle (0.9% w/v NaCl), (D-Ala2)GIP and 
(D-Ala2)GIP-Asp (each peptide at 25 nmol/kg bw). Values 














Figure 4.3 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on non fasting 
(A) blood glucose and (B) plasma insulin in high fat fed 
mice.  
 
















































 (A) Non fasting blood glucose and (B) plasma insulin levels 
were measured for 3 days before and 42 days during 
(indicated by black horizontal bar) once daily treatment with 
saline vehicle (0.9% w/v NaCl), (D-Ala2)GIP and (D-
Ala2)GIP-Asp (each peptide at 25 nmol/kg bw). (B) Mice 
were injected once daily with saline vehicle (0.9%, w/v, 
NaCl), (D-Ala2)GIP and (D-Ala2)GIP-Asp (each at 25 
nmol/kg b.w) for 42 days. Blood was collected 3 days before 
and 42 days and every 4 days thereafter. Values are expressed 
as mean ± S.E.M for 5 mice. *p<0.05, **p<0.01, ***p<0.001 
compared with high-fat fed control.   
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B 
































Figure 4.4 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on (A) glucose 










































Tests were conducted after once daily treatment with saline, (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days. (A) Blood glucose 
before and after i.p injection of glucose (18 mmol/kg bw) alone 
in 18 hrs fasted mice. (B) AUC values for blood glucose for 0-
105 min are shown in insets. (C) Glucose alone (18 mmol/kg 
b.w) was administered at time 0 in 18 hrs fasted mice and 
plasma insulin concentrations prior to, and 15, 30 and 60 min 
after glucose administration were recorded. (D) Plasma insulin 
AUC values are also shown. Values are mean ± S.E.M for 5 
mice per group. *p<0.05, **p<0.01 compared with high-fat fed 
control.  
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Figure 4.5 Effects of once daily administration of (D-Ala2)GIP and 
(D-Ala2)GIP-Asp for 42 days on insulin sensitivity in high fat fed 
mice   
 









Following 42 days treatment with saline, (D-Ala2)GIP and (D-
Ala2)GIP-Asp (each peptide at 25 nmol/kg bw), insulin (25 U/kg 
bw) was injected intraperitoneally (at t=0) in non-fasted mice to 
assess insulin sensitivity. Blood glucose and blood glucose AAC 
values for 0-105 min are shown in inset. Values represent means 
± SEM for 5 mice. *p< 0.05, **p < 0.01 and ***p< 0.001 











































































Figure 4.6 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on whole body 
(A) BMD and (B) BMC in high fat fed  mice 
     
 
                                                                           
 






(A)Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) as measured by DEXA scanning in high fat fed mice 
following 42 days treatment with (D-Ala2)GIP and (D-Ala2)GIP-
















































Figure 4.7 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp  for 42 days on femur (A) 
BMD and (B) BMC in high fat fed mice  
 
                                                                                      
 








 (A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) as measured by DEXA scanning in high fat fed mice 
following 42 days treatment with (D-Ala2)GIP and (D-Ala2)GIP-















































Figure 4.8 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on lumbar spine 
(A) BMD and (B) BMC in high fat fed mice  
  
 
                               
                                                          
 
                                                                       
 
  
                                                                                          
 
 (A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) as measured by DEXA scanning in high fat fed mice 


















































Figure 4.9 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp for 42 days on tibia (A) 
BMD and (B) BMC in high fat fed mice  
  
                              
                                                          
 
                                                                       
 
 
                 
 
 
 (A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) mass as measured by DEXA scanning in high fat fed 
mice following 42 days treatment with (D-Ala2)GIP and (D-
Ala2)GIP-Asp. Values represent means ± SEM for 5 mice. 































































Figure 4.10 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp on cortical bone geometry in 
high fat fed mice 
 























Images of cortical bone were obtained from a microtomography 
scan of tibia following 42 days once daily administration of 
saline (0.9%, w/v, NaCl), (D-Ala2)GIP or (D-Ala2)GIP-Asp 
(each at 25 nmol/kg b.w). Cortical bone was located 3 mm 
below growth plate and total area (A), cortical area (B), bone 
marrow diameter (C) cortical thickness (D), bone mineralisation 
(E) and moment of inertia (F) were measured. Values are mean 
± S.E.M for 5 mice. *p < 0.05, **p < 0.01 compared to high-fat 


















































































































































Figure 4.11 Effects of once daily administration of (D-
Ala2)GIP and (D-Ala2)GIP-Asp on bone tissue parameters in 








































































































































































































































































































































































































































































(A) Collagen maturity-mean, (B) collagen maturity width, 
(C) collagen maturity-peak, (D) crystallinity-mean, (E) 
crystallinity-width, (F) crystallinity-peak, (G) 
phosphate/amide-mean, (H) phosphate/amide-width, (I) 
phosphate/amide peak, (J) carbonate/phosphate-mean, (K) 
carbonate/phosphate-width, (L) carbonate/phosphate-peak, 
(M) acid/phosphate-mean, (N) acid/phosphate-width, and (O) 
acid/phosphate-peak were measured by infrared spectroscopy 
following 42 days once daily administration of saline (0.9%, 
w/v, NaCl), (D-Ala2)GIP and (D-Ala2)GIP-Asp (each at 25 
nmol/kg b.w). Values are mean ± S.E.M for 5 mice.  



























































































Impact of bone-specific, 
enzymatically stable xenin peptides 
on metabolic control as well as bone 
quality and strength in lean control 




5.1 SUMMARY  
Peptide based therapies are often restricted by number of 
factors, including rapid enzymatic degradation and renal 
clearance. Hence, in the current chapter, the effects of modified, 
long-acting and enzyme-resistant bone-specific peptides on 
metabolism, bone quality and bone strength was examined in 
lean and high fat fed mice. Once daily administration of xenin-
25[Lys13PAL] did not cause any significant changes in any of 
the body weight, food intake or any of metabolic parameters 
assessed in lean mice. However, Xenin-25[Lys13PAL] increased 
(p<0.05) lumbar BMD and tibial BMC in lean mice. 
Interestingly, three-point bending analysis revealed a reduction 
(p<0.01) in ultimate load bearing capacity of femoral cortical 
bone following 42 days treatment with Xenin-25[Lys13PAL] in 
lean mice. Xenin-25[Lys13PAL] treated lean mice also had 
reduced (p<0.05) trabecular bone volume and number. In 
addition, Xenin-25[Lys13PAL] induced significant (p<0.05 to 
p<0.01) increases in hardness, indentation modulus and force, 
with no change in dissipated energy, of cortical bone matrix in 
lean mice. However, collagen maturity, carbonate phosphate 
ratio and carbonate substitution were reduced (p<0.01) 
following once daily treatment of Xenin-25[Lys13PAL] in lean 
mice. In high-fat fed mice, Xenin-25[Lys13PAL], and its related 
bone-targeting form Xenin-25[Lys13PAL]-Asp, did not cause 
any significant changes in body weight, fat mass, lean mass or 
food intake. Xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp 
reduced (p<0.05) circulating blood glucose but there was no 
change in plasma insulin concentrations in high-fat fed mice. 
Both Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp 
improved glucose tolerance, despite decreased glucose-
stimulated insulin concentrations in high fat fed mice. This 
suggested improved insulin sensitivity, which was corroborated 
by injection of exogenous insulin into these high fat fed mice. 
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DEXA analysis revealed that both peptides increased (p<0.05 to 
p<0.001) lumbar spine BMC, with Xenin-25[Lys13PAL] also 
increasing (p<0.05) whole body as well as tibial BMC in high 
fat mice. No changes were observed on nanomechanical 
properties of cortical bone matrix or cortical bone mineral 
density distribution in Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp treated high fat mice. However, Xenin-
25[Lys13PAL] increased (p<0.05 to p<0.01) crystallinity, 
phosphate/amide ratio, acid/phosphate ratio and carbon content 
of bone in high fat fed mice. No effect of Xenin-25[Lys13PAL] 
and Xenin-25[Lys13PAL]-Asp was seen on trabecular thickness. 
However, numbers of trabeculae were reduced in mice treated 
with Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp. 
Cortical microarchitecture parameters of the bone such as total 
area, cortical area, bone marrow diameter, cortical thickness, 
bone mineralization and moment of inertia remain unaffected in 
the mice treated with Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp. In conclusion, activation of xenin pathways 
appeared to improve overall metabolic control in lean and high 
fat fed mice, but had variable effects on the specific bone 
parameters assessed.  
 
5.2 INTRODUCTION  
Bone is highly complex, living mineralized material and 
undergoes constant remodeling (Elnenaei et al. 2010). Bone 
remodelling is under complex regulation from various autocrine 
and paracrine factors. In this regard, recent evidence suggests a 
role for gastrointestinal (GIT) hormones in bone remodelling 
(Guadin-Adrian et al. 2012). In addition, altered secretion and 
action of these GIT hormones has been implicated in the 
pathogenesis of diabetes (Adamska et al. 2014, Choudhury et al. 
2016). Thus, there has been growing interest to understand the 
mechanisms involved in diabetic related bone loss, and to 
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develop new therapies to tackle bone fragility fractures in 
diabetes, where GIT hormones could be key (Moseley 2012). A 
variable increase in fracture risk has been reported in diabetes of 
around 20%, but this appears to be highly dependent on skeletal 
site and diabetes duration (Moayeri et al. 2017, Russo et al. 
2016). Indeed, the detrimental effects of chronically elevated 
glucose levels on bone should be added to the more well-known 
complications of diabetes (Oie el al. 2015). As such, the longer 
the disease duration, presence of diabetic complications, 
inadequate glycemic control, insulin use and increased risk of 
falls are all reported to increase fracture risk in diabetes 
(Moayeri et al 2017).   
Xenin, a 25 amino acid peptide hormone co-secreted with GIP 
from the intestinal K-cells in response to food intake (Anlauf et 
al., 2000), is known to enhance the insulin secretory action of 
GIP (Taylor et al. 2010, Wice et al 2010, Chowdhury et al. 
2014). This has resulted in a recent upsurge in interest in the 
therapeutic capacity of xenin for type 2 diabetes (Hasib et al. 
2017), since reduced biological activity of GIP is known to be 
an important characteristic of type 2 diabetic patients (McIntosh 
2017, Wang et al. 2017). However, native xenin is rapidly 
broken by serine proteases in blood (Taylor et al., 2010), but 
like other gut-derived peptide hormones, stable xenin 
derivatives have been generated (Gault et al. 2015, Parthsarthy 
et al. 2016, Hasib et al. 2017). In addition, there is no specific 
receptor reported for xenin to date, but there is some evidence to 
suggest that the actions of xenin could be linked to modulation 
of neurotensin receptors (Clemens et al. 1997; Nustede et al. 
1999; Kim and Mizuno, 2010a).  It has been also reported that 
xenin potentiates GIP-mediated insulin secretion by activating 
non-ganglionic cholinergic neurons (Wice et al. 2010). Given 
the GIP potentiating effect of xenin, and the notable action of 
GIP on bone (Holst et al. 2016, Hansen et al. 2017) the 
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possibility that xenin might have positive direct or indirect 
effects on the bone requires further investigation.   
 Bone is unique tissue because it is mostly composed of the 
inorganic compound hydroxyapatite (Florencio-Silva et al. 
2015, Wu et al. 2017). Therefore, targeting a drug to 
hydroxyapatetite would appear to be the most promising 
approach for selective drug delivery to bone (Takahashi-
Nishioka et al. 2008). There has been increased interest in use of 
amino acid oligopeptide tagging (Glu and Asp) that can help 
deliver the peptides to bones, due to preferential peptide 
deposition in hydroxyapatite (Takahashi-Nishioka et al. 2008). 
Acidic oligopeptides tagging is a new approach where repetitive 
L-Asp and L-Glu acidic amino acid sequences will rapidly bind 
to hydroxyapaptite in bone (Lips 2001 and Teitelbaum & Ross 
2003). With this idea in mind, in the present study, the well 
characterised stable xenin analogue, xenin-25[Lys13PAL] 
(Martin et al. 2014, Gault et al. 2015, Hasib et al. 2017), and its 
oligopeptide tagged counterpart, namely xenin-25[Lys13PAL]-
Asp with six C-terminal aspartic acid amino acid residues 
extensions, were synthesised and characterised.  
 These peptides were then taken forward to experiments in lean 
control and high fat fed mice, using a once daily injection 
regimen. Thus, xenin-25[Lys13PAL] has previously been shown 
to exert prominent antidiabetic effects following once daily 
dosing in mice (Irwin & Flatt 2015, Gault et al. 2015, Hasib et 
al. 2017). The aim was to investigate the effects of xenin-
25[Lys13PAL] on metabolic control and bone related parameters 
under normal physiological conditions, and similarly under the 
pathophysiology of diet-induced diabetes whilst also employing 
oligopeptide tagging of the test peptide. Highly advanced 
imaging techniques were used to assess bone quality and 
strength following 42 days administration of the respective 
peptides in each mouse model. These techniques included bone 
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three-point bending, nanoindentation, quantitative backscattered 
electron imaging (QBEI) and fourier transformed infrared 
microscopy (FTIR) imaging. The findings of this study reveal 
that xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp 
possesses positive effects on diabetes control and bone health in 
high fat fed mice. 
 
5.3 MATERIALS AND METHODS 
5.3.1 Synthesis of peptides  
Xenin-25[Lys13PAL] and xenin-25[Lys13PAL]-Asp were 
purchased from EZ Biolabs Ltd. (Carmel, IN, USA). The 
peptides were characterised in-house by mass spectrometry as 
described in Section 2.1.2.  
5.3.2 Animal study design 
Two separate in-vivo studies were carried out as part of these 
studies. In the first study, high fat fed mice were used, and in the 
second study the effects of test peptides lean mice was 
examined. All studies used male NIH Swiss male mice (12-14 
week old), and for high fat studies mice (8 week old) were 
maintained on high-fat diet for three months. All mice were 
housed separately in air conditioned room with 12 hour light and 
12 hour dark cycle. All mice were grouped (n=5-6) according 
body weight and blood glucose. Prior to commencing the 
experiment, all mice were injected with saline vehicle (0.9% 
NaCl) for 3 days to acclimatise to the injection regimen. Lean 
control mice received saline injection (0.9%NaCl) and Xenin-
25[Lys13PAL]. Groups of high fat fed mice then received saline 
injection (0.9% NaCl), xenin-25[Lys13PAL] or xenin-
25[Lys13PAL]-Asp (each at 25 nmol/kg bw) once daily for 42 
days. Body weight, food intake, non-fasting glucose and insulin 
concentrations were measured at regular intervals. 
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Intraperitoneal glucose tolerance (18 mmol/kg bw, 18 hour fast) 
and non-fasting insulin sensitivity test (25 U/kg bw) tests were 
performed at the end of the study as described in Section 2.3.2 
and 2.3.3 respectively. Bones were then collected and processed 
to assess bone mass and bone quality. All experiments were 
carried out according to UK Home Office Regulations (UK 
Animals Scientific Procedures Act 1986). 
5.3.3 Measurement of plasma insulin 
An insulin RIA was carried out as described in Section 2.4.2 to 
determine plasma insulin concentrations. 
5.3.4 Measurement of body composition, bone density and 
mineral content by DEXA scanning 
Mice were anesthetised using isoflurane before being placed on 
a specimen tray of the DEXA scanner. Bone mineral density 
(BMD), bone mineral content (BMC), lean mass, fat and lean 
masses were determined as explained in Section 2.4. 
5.3.5 Three-point bending test 
Mechanical properties of the femur were measured using three-
point bending. The properties determined were ultimate load, 
ultimate displacement, stiffness and work to failure ratio. Before 
carrying out studies, femurs were kept in vials containing saline 
(NaCl, 0.9%) so that they remained hydrated. Three-point 
bending was carried out as described in Section 2.5.4. 
5.3.6 X-ray microcomputed tomography (µCT) 
Microcomputed tomography was used to process the tibias of all 
the mice. Tibias were further scanned to assess trabecular bone 
mass, trabecular bone thickness, number of trabeculae, cortical 
bone diameter, cortical thickness, diameter of bone marrow and 




Nanoindentation was performed on all the bones as described in 
the Section 2.5.1 and following parameters were assessed: 
maximum force, hardness, indentation modulus and dissipated 
energy. Briefly, polymethylacrylate blocks of bone were 
polished three times with diamond particles to obtain a smooth 
surface. Afterwards, blocks were left in saline (NaCl, 0.9%) 
solution overnight and processed next morning.  
5.3.8 Quantitative backscattered electron imaging (qBEI) 
Polymethylmethacrylate blocks were again polished three times 
with diamond particles, and were then subjected to carbon 
coating for 4 hrs. After carbon coating, the polymethylacrylate 
blocks were observed under a scanning electron microscope as 
described in Section 2.5.2 to assess bone mineral density 
distribution.  
5.3.9 Fourier transformed infrared (FT-IR) imaging and 
micro spectroscopy 
FT-IR was carried out as per described in section 2.5.5. Briefly, 
polymethylacrylate sections (4 µm) of bones were prepared 
using micrtome equipped with tungsten carbide knife. Spectral 
analysis was conducted using a Bruker Vertex 70 spectrometer 
interfaced with Bruker Hyperion 3000 infrared microscope 
equipped with mercury cadmium telluride detector. Infrared 
spectra were recorded with an average of 32 scans in 
transmission mode in the same locations (region of interest on 






5.3.10 Statistical analysis 
Data were analysed using one-way or two-way ANOVA with 
two-tailed t-tests using PRISM 5.0. Data are expressed as mean 





5.4.1 Effects of Xenin-25[Lys13PAL] on body weight, fat 
mass, total lean mass and food intake in lean mice 
Once daily administration of Xenin-25[Lys13PAL] did not cause 
any significant changes in body weight (Figure 5.1A), fat mass 
(Figure 5.1B), lean mass (Figure 5.1C) or food intake (Figure 
5.2) in lean mice.     
5.4.2 Effects of Xenin-25[Lys13PAL] on circulating blood 
glucose and plasma insulin in lean mice   
There was no significant difference between groups of lean mice 
in terms of circulating blood glucose (Figure 5.3A) or plasma 
insulin (Figure 5.3B) concentrations.  
5.4.3 Effects of Xenin-25[Lys13PAL] on glucose tolerance 
and insulin sensitivity in lean mice 
After injecting glucose intraperitoneally (18 mmol/kg bw) on 
day 42, blood glucose levels were not affected by Xenin-
25[Lys13PAL] treatment (Figure 5.4A, B). Similarly, glucose-
induced insulin concentrations were not significantly different 
between control and treated mice (Figure 5.4C, D). In addition, 
no change in the action of peripherally injected insulin was 




5.4.4 DEXA analysis of whole body, femur, tibia and lumbar 
spine in lean mice  
DEXA analysis revealed that there was no significant difference 
in femoral BMD and BMC but the whole body BMC was 
increased (p<0.05) in Xenin-25[Lys13PAL] treated lean mice 
(Figure 5.6A-D). No differences were observed in lumbar BMC 
(Figure 5.7B) however, xenin-25[Lys13PAL] decreased (p<0.05) 
lumbar BMD compared to saline controls (Figure 5.7A). In 
addition, tibial BMD was no different between groups (Figure 
5.8A), but tibial BMC was increased (p<0.05) by xenin-
25[Lys13PAL] treatment in lean mice (Figure 5.8B).   
5.4.5 Effects of Xenin-25[Lys13PAL] on trabecular bone 
morphology and cortical bone geometry in lean mice  
Microcomputed tomography (MicroCT) was carried out to 
analyse different parameters of the bone including trabecular 
bone volume, thickness, separation and number of trabeculae. 
Xenin-25[Lys13PAL] treated lean mice showed a reduction 
(p<0.05) in both bone volume and number of trabeculae (Figure 
5.9A, C). In addition, Xenin-25[Lys13PAL] did not affect 
trabecular thickness (Figure 5.9D), but increased (p<0.05) 
trabecular separation (Figure 5.9D). Cortical bone geometry 
parameters including total area, cortical area, bone marrow 
diameter, cortical thickness, bone mineralisation and moment of 
inertia were not affected by Xenin-25[Lys13PAL]  treatment for 
42 days in lean mice (Figure 5.10A-F).  
5.4.6 Effects of Xenin-25[Lys13PAL] on whole-bone 
mechanical properties in lean mice    
Three-point bending analysis revealed a reduction (p<0.05) in 
ultimate load bearing capacity of femoral cortical bone 
following 42 days treatment with Xenin-25[Lys13PAL] (Figure 
5.11A). However, no significant changes in ultimate 
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displacement were observed (Figure 5.11.B). Xenin-
25[Lys13PAL] treated mice also had reduced (p<0.01) femoral 
cortical bone stiffness (Figure 5.11C). Work-to-failure ratio was 
similar between the two groups of lean mice (Figure 5.11D).  
5.4.7 Effects of Xenin-25[Lys13PAL] on nanomechanical 
properties of cortical bone matrix in lean mice  
Xenin-25[Lys13PAL] induced significant (p<0.05 to p<0.01) 
increases in hardness (Figure 5.12A), indentation modulus 
(Figure 5.12B), and force (Figure 5.12C), with no change in 
dissipated energy (Figure 5.12D), of cortical bone matrix in lean 
mice.  
5.4.8 Effects of Xenin-25[Lys13PAL] on bone mineral density 
distribution in lean mice  
All the three variables analysed relating to bone mineral density 
distribution includi ng Capeak, Camean and Cawidth at cortical 
parts of the tibial bone were similar in both groups of lean mice 
(Figure 5.13A-C). 
5.4.9 Effects of Xenin-25[Lys13PAL] on bone at tissue level in 
lean mice 
Different parameters relating directly to the bone tissue were 
analysed using infrared spectroscopy. These parameters 
included collagen maturity, crystallinity, acid phosphate ratio, 
mineral to matrix ratio, carbonate phosphate ratio and carbonate 
substitution (Figure 5.14A-G).  Among these, collagen maturity, 
carbonate phosphate ratio and carbonate substitution were 
reduced (p<0.05 to p<0.01) following once daily treatment with 




5.4.10 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on body weight, fat mass, total lean mass 
and food intake in high-fat fed mice 
Once daily administration of Xenin-25[Lys13PAL] or Xenin-
25[Lys13PAL]-Asp did not cause any significant changes in 
body weight (Figure 5.15A), fat mass (Figure 5.15B), lean mass 
(Figure5.15C) or food intake (Figure 5.16) in high fat fed mice.     
5.4.11 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on circulating blood glucose and plasma 
insulin in high-fat fed mice   
In terms of blood glucose, Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp reduced (p<0.05) blood glucose by day 42 
(Figure 5.17A), but there was no significant difference in plasma 
insulin concentrations between groups (Figure 5.17B).  
5.4.12 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on glucose tolerance and insulin 
sensitivity in high-fat fed mice 
After injecting glucose intraperitoneally (18 mmol/kg bw) on 
day 42, blood glucose was significantly (p<0.05 to p<0.01) 
reduced in all treatment groups when compared to saline 
controls at 30 and 60 mins post-injection (Figure 5.18 A). This 
corresponded to significantly (p<0.001) decreased AUC values 
in these mice when compared to saline controls (Figure 5.18B). 
No significant effect of the treatments was seen on individual 
plasma insulin concentrations at the time points examined 
(Figure 5.18C), however both Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp treated mice had significantly reduced 
(p<0.05 and p<0.01, respectively) overall insulin secretory 
response (Figure 5.18D). This effect was accompanied by 
significantly (p<0.05 to p<0.01) reduced individual and overall 
blood glucose values following injection of exogenous insulin in 
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both peptide treated groups when compared to high fat controls 
(Figure 5.19A).  
5.4.13 DEXA analysis of whole body, femur, tibia and 
lumbar spine in high-fat fed mice  
DEXA analysis revealed that there was no significant overall 
difference in whole body or femoral BMD between all groups of 
high fat fed mice (Figure 5.20A, C). However, whole body 
BMC was increased (p<0.05) by Xenin-25[Lys13PAL] treatment 
(Figure 5.20B). In addition, no difference was observed in 
lumbar BMD (Figure 5.21A), but both treatment groups had 
elevated (p<0.05 to p<0.01) lumbar BMC compared to saline 
controls (Figure 5.21B). Similarly, tibial BMD was consistent 
among all groups of high fat mice (Figure 5.22.A), however 
tibial BMC was increased by Xenin-25[Lys13PAL] treatment for 
42 days (Figure 5.22.B).   
5.4.14 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on trabecular bone morphology and 
cortical bone geometry in high-fat fed mice 
Microcomputed tomography (MicroCT) was performed to 
analyse various parameters of the bone such as trabecular bone 
volume, thickness, trabecular separation and number of 
trabeculae. Xenin-25[Lys13PAL] treated high fat fed mice 
showed reduction in bone volume (p<0.01) as well as number of 
trabeculae. Xenin-25[Lys13PAL]-Asp treated high fat fed mice 
showed almost the same results as both bone volume (p<0.05) 
and number of trabeculae (p<0.01) were reduced (Figure 5.23A, 
C). Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp did not 
affect trabecular thickness (Figure 5.23B), but increased 
(p<0.01) trabecular separation (Figure 5.23D). Cortical bone 
geometry parameters such as total area, cortical area, bone 
marrow diameter, cortical thickness, bone mineralisation and 
moment of inertia remain unchanged by Xenin-25[Lys13PAL] 
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and Xenin-25[Lys13PAL]-Asp treatment for 42 days in high fat 
fed mice (Figure 5.24A-F).  
5.4.15 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on whole-bone mechanical properties in 
high-fat fed mice    
Three-point bending analysis was carried out to analyse ultimate 
load, stiffness, ultimate displacement and work-to-failure ratio. 
However, no significant changes were observed in any of these 
parameters (Figure 5.25A-D).  
5.4.16 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on nanomechanical properties of cortical 
bone matrix in high-fat fed mice  
No changes were detected in terms of hardness, indentation 
modulus, force and dissipated energy of cortical bone matrix in 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp treated high 
fat fed mice (Figure 5.26A-D).  
5.4.17 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on bone mineral density distribution in 
high-fat fed mice   
All the three variables analysed relating to cortical bone mineral 
density distribution including Capeak, Camean and Cawidth in high-
fat fed mice were unaffected in both treatment groups when 
compared to saline controls (Figure 5.27A-C). 
5.4.18 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on bone at tissue level in high-fat fed mice  
Infrared spectroscopy was used to analyse different parameters 
related directly to the bone tissue. These parameters included 
collagen maturity, crystallinity, phosphate amide ratio and acid 
phosphate ratio (Figure 5.28A-J). Crystallinity, phosphate/amide 
ratio, acid/phosphate ratio, carbon content and acid phosphate 
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were increased (p<0.05 to p<0.01) in the mice treated with 
Xenin-25[Lys13PAL] (Figure5.28D, F, G, I). Interestingly, 
Xenin-25[Lys13PAL]-Asp decreased (p<0.05) collagen maturity 
(Figure 5.28B), but had no effect on any of the other variables 
assessed. 
 
5.5 DISCUSSION  
Xenin is a hormone co-secreted with GIP from a subset of 
enteroendocrine K cells (Althage et al. 2008, Hasib et al. 2017), 
and enhances the biological activity of GIP (Martin et al. 2016). 
As such, numerous previous studies confirm the GIP-
potentiating effects of xenin in normal and type 2 diabetes 
conditions (Taylor et al. 2010, Wice et al. 2010, Martin et al. 
2014 and Choudhary et al. 2016). There is also evidence to 
suggest that xenin acts as an independent satiety hormone in 
animals (Cline et al. 2007, Cooke et al. 2009, Taylor et al. 2010 
and Kim et al. 2016) and humans (Schiavo-Cadozo et al. 2013). 
Given this, it is plausible that xenin could affect bone 
metabolism in its own right, or as a consequence of its GIP 
enhancing actions. To date, there has been absolutely no 
investigation into the effects of xenin on bone. 
It is already reported that, with the help of amino acid acidic 
oligopeptide tagging, peptides can be preferentially delivered to 
the bone because of the affinity of the acidic oligopeptides 
towards hydroxyapetite (Lips 2001, Teitelbaum & Ross 2003, 
Takahashi-Nishioka et al. 2008).  With this idea, the present 
study was undertaken to assess the impact of enzymatically 
stable xenin peptide, Xenin-25[Lys13PAL], on metabolic control 
as well as bone quality and strength in lean mice. In addition, 
acidic oligopeptide tagging of Xenin-25[Lys13PAL] was 
employed and the impact of this on high fat fed mice examined. 
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The xenin peptides had no impact on body weight or food intake 
in lean and high fat fed mice following 42 days daily 
administration of 25 nmol/kg body weight. Thus, xenin has been 
shown to induce appetite suppression, but only at much higher 
doses than those employed for this study (Kaji et al. 2017). 
Interestingly, Xenin-25[Lys13PAL] had no effect on glucose or 
insulin levels in lean mice, but significantly reduced circulating 
glucose in high fat fed mice. As such, the suggestion that xenin 
does not possess important biological actions in type 2 diabetes, 
appears to be unfounded. Furthermore, glucose tolerance and 
insulin sensitivity were substantially improved by Xenin-
25[Lys13PAL] in high fat fed mice, in full agreement with 
previous observations (Gault et al. 2015, Martin et al. 2016 and 
Hasib et al. 2017). Xenin-25[Lys13PAL] had no real impact on 
metabolic control in lean mice, likely because no pathologies are 
apparent here. 
DEXA analysis of lean mice on day 42 revealed no difference in 
whole body and femoral BMC and BMD. However, lumbar 
BMD was decreased and tibial BMC were increased by Xenin-
25[Lys13PAL]. These inconsistencies in terms of BMC indicate 
the need for further detailed study, or the possibility that xenin 
differentially affects bone regions. In terms of high fat fed mice, 
DEXA analyses revealed that no significant difference in whole 
body and femoral BMD; however, whole body BMC was 
increased by Xenin-25[Lys13PAL], but not by Xenin-
25[Lys13PAL]-Asp. However, lumbar BMC was augmented by 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp, whereas 
Tibial BMC was increased only by Xenin-25[Lys13PAL] 
treatment. In type-2 diabetic patients, BMD is believed to be 
higher than the normal (Janghorbani et al. 2007, Vestergaard, 
2007) and fracture risk is often misjudged in this population, 
which could also be true for the high-fat fed mice used in this 
study. Thus, the observed effects on BMD, and especially BMC, 
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need to be considered in this context. As such, bone quality does 
not depend only on BMD and BMC as there are many other 
factors such as microarchitecture, bone matrix composition, 
biomechanical strength that play an important role in overall 
bone quality and integrity (Hernandez & Keaveny 2006, Seeman 
& Delmas 2006, Mieczkowska et al. 2013). This may also help 
explain the differences observed between treatment with Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp in high fat fed 
mice.  In order to gain a deeper insight of bone quality at tissue 
level, more detailed bone-specific investigations were 
undertaken.  
MicroCT was performed to assess trabecular bone volume, 
thickness, separation and number of trabeculae in the bone. 
Interestingly, in normal lean mice it was found that the number 
of trabeculae and trabecular bone volume were reduced by 
Xenin-25[Lys13PAL], and trabecular separation increased. This 
might suggest a negative impact of xenin signalling on bone 
under normal physiological conditions. In high fat fed mice, 
micocomputed tomography results revealed reduction in bone 
volume and number of trabeculae. However, trabecular 
separation was increased in the mice after treatment with Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp. Cortical bone 
parameters were assessed to further understand the possible 
differential actions of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on bone in diabetes (Pickle et al. 2016, 
Shanbhogue et al. 2016, Samelson et al. 2017). None of the 
cortical bone parameters showed any changes after treatment 
with both Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp. 
However, treatment of high-fat fed mice with Xenin-
25[Lys13PAL] or Xenin-25[Lys13PAL]-Asp had no effect on the 
nanomechanical properties of cortical bone and bone mineral 
density distribution. On the other hand, Xenin-25[Lys13PAL] 
induced significant benefits on the nanomechanical properties of 
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cortical bone including increase in hardness, indentation 
modulus and force. Interestingly, this mirrors with similar 
observations in GIP receptor KO mice (Meiczkowska et al. 
2013, Gaudin-Audrain et al. 2013), and rodents treated with 
stable GIP receptor mimetics (Mansur et al. 2016, Ramsey et al. 
2017, Hansen et al. 2017).  Thus, in contrast to effects on 
trabecular bone, this would suggest benefits of xenin signalling 
in bone. Again, the idea that xenin may have differential effects 
on bone is strongly suggested here, and requires further detailed 
study. Indeed, the impact of xenin in combination with GIP 
merits investigation, given their biological interplay (Parthsarthy 
et al. 2016).  
 
Infrared spectroscopy was performed in to analyse collagen 
maturity, crystallinity, phosphate amide ratio, acid phosphate 
ratio and carbon content (Schimdt et al. 2017). This analysis 
revealed contrasting effects of Xenin-25[Lys13PAL] in lean 
control and high fat fed mice. Thus, in lean mice there were 
reductions in crystallinity, carbonate/phosphate ratio and 
carbonate substitutions, all of which imply reduced bone quality 
(Gourion-Arsiquaud et al. 2012, Wang et al. 2016). Whereas in 
high fat fed mice, Xenin-25[Lys13PAL] actually increased 
crystallinity of the bone tissue, phosphate/amide ratio and 
carbon content. Thus, as noted previously, and although not 
fully consistent with all data collected here, there is a suggestion 
that xenin has altered biological effects under diabetic 
conditions (Khan et al. 2017, Sterl et al. 2016). This could be 
one reasonable explanation for the very contrasting data on bone 
tissue properties in lean control and high fat fed mice. Further to 
this, Xenin-25[Lys13PAL]-Asp was generated in an effort to 
enhance xenin-induced actions on bone. In contrast, Xenin-
25[Lys13PAL]-Asp lacked any positive effects on bone tissue 
properties and actually decreased collagen maturity in high fat 
fed mice. This is extremely hard to comprehend, and 
163 
 
sophisticated imaging studies would be required to establish the 
fate of Xenin-25[Lys13PAL]-Asp after injection. Indeed, fatty 
acid derivation may in some way impede the actions of acidic 
oligopeptide tagging to deposit the peptide in bone, likely 
through stearic hindrance (Narayana et al. 2015).  
 
In conclusion, Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-
Asp possessed beneficial metabolic effects in high fat fed mice. 
Xenin-25[Lys13PAL] appeared to have a positive impact on 
bone health in diabetes, but inconsistent effects on bone under 
normal physiological conditions. Engineering of a bone-specific 
xenin analogue, namely Xenin-25[Lys13PAL]-Asp, did not 
appear to further enhance the benefits of xenin on diabetic bone. 
Further detailed studies are needed to fully assess whether the 
current peptides, Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp, can be used as potential therapeutic 




















Figure 5.1 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on (A) body weight (B) % fat and 





















(A) Body weight was measured for 3 days before and 42 days 
during (indicated by black horizontal bar) once daily 
treatment with saline vehicle (0.9%w/v NaCl) or Xenin-
25[Lys13PAL] (peptide at 25 nmol/kg bw). (B) %Fat mass 
and (C) lean mass as measured by DEXA scanning in lean 
mice on day 42 Values represent means ± SEM for 6 mice.    
 






































































































Figure 5.2 Effects of once daily administration of Xenin-


















Cumulative energy intake was measured for 3 days before and 
42 days during once daily treatment with saline vehicle (0.9% 
w/v NaCl) or Xenin-25[Lys13PAL] (peptide at 25 nmol/kg bw). 

















































Figure 5.3 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on non-fasting (A) glucose and (B) 









                                                                                     
 
 
   
 
 
(A) Blood glucose and (B) plasma insulin were measured for 3  
days before and 42 days during once daily treatment with saline 
vehicle (0.9%w/v NaCl) or Xenin-25[Lys13PAL] (peptide at 25 
nmol/kg bw). Values represent means ± SEM for 7 mice.    
 
 




































































Figure 5.4 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on (A) glucose tolerance and (B) 



















Tests were conducted after once daily treatment with saline or 
Xenin-25[Lys13PAL] for 42 days. (A) Blood glucose before and 
after i.p injection of glucose (18 mmol/kg bw) alone in 18 hrs 
fasted mice. (B) AUC values for blood glucose for 0-120 min 
are shown. (C) Glucose alone (18 mmol/kg b.w) was 
administered at time 0 in 18 hrs fasted mice and plasma insulin 
concentrations prior to, and 15, 30, 60 and 120 min after glucose 
administration were recorded. (D) Plasma insulin AUC values 
are also shown. Values are mean ± S.E.M for 6 mice.  
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Figure 5.5 Effects of once daily administration of Xenin-









                                                                                            
 
 
(A) Insulin (25 U/kg bw) was injected intraperitoneally (at t=0) 
in non-fasted mice following 42 days treatment with saline or 
Xenin-25[Lys13PAL] (peptide at 25 nmol/kg bw). (B)  Blood 
glucose AUC values for 0-120 min are shown. Values represent 






































































Figure 5.6 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on (A) whole body bone mineral 
density (BMD), (B) whole body bone mineral content 
(BMC), femur (A) bone mineral density (BMD) and (B) 
bone mineral content (BMC) in lean mice  
 
                                 
















(A) Whole body bone mineral density (BMD) and (B) whole 
body bone mineral content (BMC) as measured by DEXA 
scanning in lean mice following 42 days treatment with Xenin-
25[Lys13PAL]. (C) Femur BMD and (D) femur BMC as 
measured by DEXA scanning in lean mice following 42 days 
treatment with Xenin-25[Lys13PAL] (peptide at 25 nmol/kg bw). 
Values represent means ± SEM for 6 mice. *p < 0.05 compared 



































































Figure 5.7 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on lumbar spine (A) bone mineral 
density (BMD) and (B) bone mineral content (BMC) in lean 
mice 
 









(A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) of lumbar spine as measured by DEXA scanning in high 
fat fed mice following 42 days treatment with Xenin-
25[Lys13PAL]. Values represent means ± SEM for 6 mice. *p < 














































Figure 5.8 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on tibia (A) bone mineral density 
(BMD) and (B) bone mineral content (BMC) in lean mice 
 
                                                                                                                                                                                     








(A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) mass of tibia as measured by DEXA scanning in lean 
mice following 42 days treatment with Xenin-25[Lys13PAL]. 
Values represent means ± SEM for 6 mice.  *p < 0.05 compared 


















































Figure 5.9 Effects of once daily administration of Xenin-
25[Lys13PAL] on trabecular bone mass and 





















Parameters were obtained from a microtomography scan of tibia 
following 42 days once daily administration of saline (0.9%, 
w/v, NaCl), Xenin-25[Lys13PAL] (peptide at 25 nmol/kg bw). 
Values are means ± SEM for 6 mice. *p<0.05 compared with 
















































































Figure 5.10 Effects of once daily administration of Xenin-






















Images of cortical bone were obtained from a microtomography 
scan of tibia following 42 days once daily administration of 
saline (0.9%, w/v, NaCl) or Xenin-25[Lys13PAL] (each at 25 
nmol/kg b.w). Cortical bone was located 3 mm below growth 
plate and total area (A), cortical area (B), bone marrow diameter 








































































































of inertia (F) were measured. Values are mean ± S.E.M for 6 
mice.  
Figure 5.11 Effects of once daily administration of Xenin-
25[Lys13PAL] for 42 days on whole-bone mechanical 




















Parameters were obtained following 3-point bending tests after 
42 days once daily administration of Xenin-25[Lys13PAL] (25 
nmol/kg b.w) in high fat fed mice. Values are mean ± S.E.M for 






































































































Figure 5.12 Effects of once daily administration of Xenin-
25[Lys13PAL] on nanomechanical properties of cortical bone 





















Parameters were measured by nanoindentation following 42 
days once daily administration of saline (0.9%, w/v, NaCl) or 
Xenin-25[Lys13PAL] (each at 25 nmol/kg b.w). Values are mean 
± S.E.M for 6 mice.  *p < 0.05, **p < 0.01 compared to lean 
























































































Figure 5.13 Effects of once daily administration of Xenin-
25[Lys13PAL] on cortical bone mineral density distribution 





















Bone mineralisation at cortical bone was measured by 
quantitative backscattered electron imaging following 42 days 
once daily administration of saline (0.9%, w/v, NaCl) or Xenin-
25[Lys13PAL] (each at 25 nmol/kg b.w). Values are mean ± 










































































































Figure 5.14 Effects of once daily administration of Xenin-





















(A)Collagen maturity, (B) mineral crystallinity, (C) acid 
phosphate, (D) mineral-to-matrix, (E) carbonate/phosphate ratio, 
(F) type-A carbonate substitution and (G) type-B carbonate 
substitution were measured by infrared spectroscopy following 
42 days once daily administration of saline (0.9%, w/v, NaCl) or 
Xenin-25[Lys13PAL] (each at 25 nmol/kg b.w) in lean mice. 
Values are mean ± S.E.M for 6 mice. *p< 0.05, **p< 0.01 


























































































































































































Figure 5.15 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
(A) body weight (B) % fat mass and (C) total lean mass in 






































                                                                                                   
 
(A) Body weight was measured for 3 days before and 42 days 
during (indicated by black horizontal bar) once daily treatment 
with saline vehicle (0.9% w/v NaCl), Xenin-25[Lys13PAL] and 
Xenin-25[Lys13PAL]-Asp (each peptide at 25 nmol/kg bw). (B) 
% fat mass and (C) lean mass as measured by DEXA scanning 
in high fat fed mice on day 42. Values represent means ± SEM 























































Figure 5.16 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
cumulative energy intake in high fat fed mice  
 































Cumulative energy intake was measured for 3 days before and 
42 days during once daily treatment with saline vehicle 
(0.9%w/v NaCl), Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp (each peptide at 25 nmol/kg bw). Values 
















Figure 5.17 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
non fasting (A) blood glucose and (B) plasma insulin in high 







































(A) Blood glucose and (B) plasma insulin were  measured for 3 
days before and 42 days during once daily treatment with saline 
vehicle (0.9%w/v NaCl), Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp (each peptide at 25 nmol/kg bw). Values 
represent means ± SEM for 5 mice. *p < 0.05, **p < 0.01, 
***p< 0.001 compared with high fat fed control.   
  
 






































Figure 5.18 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
(A) glucose tolerance and (B) plasma insulin response in 
high fat fed mice 
  
 









                                   
 
Tests were conducted after once daily treatment with saline, 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each 
peptide at 25 nmol/kg bw) for 42 days. (A) Blood glucose (C) 
plasma before and after i.p injection of glucose (18 mmol/kg 
bw) alone in 18 hour fasted mice. (B, D) AUC values for 0-120 
min are shown.  Values are mean ± S.E.M for 5 mice per 
group. *p< 0.05, **p< 0.01, ***p < 0.001 compared with high 






































































































Figure 5.19 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on insulin 












(A) Insulin (25 U/kg bw) was injected intraperitoneally (at t=0) 
in non-fasted mice following 42 days treatment with saline, 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each 
peptide at 25 nmol/kg bw). (B) Blood glucose and blood glucose 
AUC values for 0-120 min are shown in inset. Values represent 
means ± SEM for 5 mice. *p < 0.05, **p < 0.01 compared to 








































































Figure 5.20 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
(A) whole body bone mineral density (BMD), (B) whole body 
bone mineral content (BMC), (C) femur BMD and (D) 
femur BMC in high fat fed mice 
 

















(A) Whole body bone mineral density (BMD) and (B) whole 
body bone mineral content (BMC) as measured by DEXA 
scanning in high fat fed mice following 42 days treatment with 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp.  (C) Femur 
BMD and (D) femur BMC as measured by DEXA scanning in 
high fat fed mice following 42 days treatment with Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each peptide at 25 
nmol/kg bw). Values represent means ± SEM for 5 mice. *p < 





































































Figure 5.21 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
lumbar spine (A) bone mineral density (BMD) and (B) 
bone mineral content (BMC) in high fat fed mice 
                                                                 








(A) Bone mineral density (BMD) and (B) Bone mineral 
content (BMC) of lumbar spine as measured by DEXA 
scanning in high fat fed mice following 42 days treatment with 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each 
peptide at 25 nmol/kg bw). Values represent means ± SEM for 

















































Figure 5.22 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
tibia (A) bone mineral density (BMD) and (B) bone mineral 
content (BMC) in high fat fed mice           
                                                             








(A) Bone mineral density (BMD) and (B) Bone mineral content 
(BMC) of tibia as measured by DEXA scanning in high fat fed 
mice following 42 days treatment with Xenin-25[Lys13PAL] and 
Xenin-25[Lys13PAL]-Asp (each peptide at 25 nmol/kg bw). 
Values represent means ± SEM for 5 mice. *p < 0.05 compared 



















































Figure 5.23 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp on trabecular 



























Parameters were obtained from a microtomography scan of tibia 
following 42 days once daily administration of saline (0.9%, 
w/v, NaCl), Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp 
(each peptide at 25 nmol/kg bw). Values are means ± SEM for 5 












































































Figure 5.24 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp on cortical 
























Images of cortical bone were obtained from a 
microtomography scan of tibia following 42 days once daily 
administration of saline (0.9%, w/v, NaCl), Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each at 25 
nmol/kg b.w). Cortical bone was located 3 mm below growth 
plate and total area (A), cortical area (B), bone marrow 
diameter (C) cortical thickness (D), bone mineralisation (E) 
and moment of inertia (F) were measured. Values are mean ± 

































































































Figure 5.25 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp for 42 days on 
whole-bone mechanical properties of femoral cortical bone 































Parameters were obtained following 3-point bending tests after 
42 days once daily administration of Xenin-25[Lys13PAL] and 
Xenin-25[Lys13PAL]-Asp (each peptide at 25 nmol/kg b.w) in 







































































































Figure 5.26 Effects of Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp on nanomechanical properties of cortical 
bone matrix in high-fat fed mice  
 
 





















Parameters were measured by nanoindentation following 42 
days once daily administration of saline (0.9%, w/v, NaCl), 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each at 25 

























































































Figure 5.27 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp on cortical 





















Bone mineralisation at cortical bone was measured by 
quantitative backscattered electron imaging following 42 days 
once daily administration of saline (0.9%, w/v, NaCl), Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each at 25 
































































Figure 5.28 Effects of once daily administration of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp on bone tissue 






























































































































































































(A) Collagen maturity-mean, (B) collagen maturity width, (C) 
crystallinity-mean, (D) crystallinity-width, (E) phosphate/amide 
ratio mean, (F) phosphate/amide ratio-width, (G) 
carbon/phosphate ratio-mean, (H) carbon/phosphate ratio-width 
(I) acid phosphate mean and (J) acid phosphate with were 
measured by infrared spectroscopy following 42 days once daily 
administration of saline (0.9%, w/v, NaCl), Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp (each at 25 
nmol/kg b.w). Values are mean ± S.E.M for 5 mice. *p< 0.05, 



























































































































Impact of bone-specific GIP/Xenin 
hybrid peptides on metabolic control 
as well as bone quality and strength 









 6.1 SUMMARY 
There is now compelling evidence indicating that the gut 
hormones, such as glucose-dependent insulinotropic polypeptide 
(GIP) and glucagon-like peptide-1 (GLP-1), play important role 
in the maintenance of bone strength and quality in addition to 
their more recognised benefits on metabolic control. Xenin is 
chiefly considered as a gut peptide that potentiates the biological 
action of GIP. Therefore, the possibility that xenin might have 
important effects on the bone is likely. This study was 
undertaken to assess the effect of bone-specific GIP/Xenin 
hybrid analogues on metabolism and bone health in high-fat fed 
mice model. High-fat fed mice received once-daily i.p injections 
of saline (0.9% w/v NaCl), GIP/Xenin and the bone-specific 
GIP/xenin hybrids, namely GIP/Xenin-Asp and GIP/Xenin-Glu 
(each at 25 mmol/kg bw) for 42 days.  GIP/Xenin, GIP/Xenin-
Asp and GIP/Xenin-Glu had no significant effect on body 
weight or composition, food intake or circulating glucose and 
insulin. Glucose tolerance was improved (p<0.001) in all 
treatment mice on day 42, and this was accompanied by 
enhanced insulin secretion in GIP/Xenin-Asp and GIP/Xenin-
Glu treated mice. Insulin sensitivity was similar in all groups, 
but GIP/Xenin-Glu did induce a significant (p<0.05) 
enhancement compared to controls. DEXA analysis at the end of 
the study revealed no significant difference in whole body or 
femoral bone mineral density (BMD) and content (BMC). 
However, lumbar BMC was enhanced (p<0.05) by GIP/Xenin, 
and tibial BMD increased (p<0.05 and p<0.01, respectively) by 
GIP/Xenin-Asp and GIP/Xenin-Glu treatment. More detailed 
bone analyses revealed that GIP/Xenin-Glu reduced femoral 
cortical bone ultimate load (p<0.01) and stiffness (p<0.05). 
However, the number of trabeculae and trabecular bone volume 
was increased (p<0.05) following GIP/Xenin treatment for 42 
days in high fat fed mice. Interestingly, cortical bone thickness 
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was reduced (p<0.05) by GIP/Xenin-Glu. None of the 
treatments impacted upon cortical bone matrix, bone mineral 
density distribution and bone tissue material properties. In 
conclusion, administration of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Glu to high fat fed mice improved metabolic control but 
had variable effects on bone health. 
 
6.2 INTRODUCTION 
Bone is highly sophisticated mineralised material consisting of 
mineral phase (hydroxyapetite), collagen, non-collagenous 
proteins, lipids and water (Boskey 2001). These constituents are 
variable depending on age, tissue type, diet and health status 
(Boskey et al. 2006). Bone is continuously remodelled in mass 
and architecture and undergoes constant deterioration due to 
number of factors such as growth, aging and mechanical stress. 
Bone remodelling occurs through spatio-temporal coupling 
between osteoclasts and osteoblasts and is a complex process 
regulated by local, hormonal and neuronal factors (Ikeda & 
Takeshita 2014, Sims & Martin 2015, Florencio-Silvia et al. 
2015). In this regard, gut hormones play an important role in 
bone remodelling (Elneanaei et al. 2010, Quach & Britton 2017, 
Collins et al. 2017, Yan & Charles 2017).  
Glucose-dependent insulinotropic polypeptide (GIP), a 42- 
amino-acid incretin hormone secreted by enteroendocrine K 
cells, plays an important role in regulation of glucose 
homeostasis as well as enhancing glucose stimulated insulin 
secretion (Jonvall et al. 1981). Unlike its sister incretin, 
glucagon-like peptide-1 (GLP-1), GIP has received much less 
attention in terms of physiological and therapeutic importance. 
However, GIP receptors are found in adipose tissue, small 
intestine, adrenal cortex, lung, pancreas, heart, testis, bone and 
brain (Usdin et al. 1993). As such, there is substantial evidence 
indicating GIP plays dual role in bone formation and inhibiting 
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bone resorption making it potential candidate for treatment of 
bone fractures (Zhong et al. 2007).  However, native GIP is 
rapidly degraded by the ubiquitous enzyme DPP-4 and is subject 
to efficient renal clearance (Mentlein et al. 1993). 
Recently, it has been shown that xenin, a hormone co-secreted 
with GIP from enteroendocrine K cells, potentiates the insulin-
secretory action of GIP (Althage et al. 2008, Taylor et al. 2010, 
Wice et al 2010, Chowdhury et al. 2014).  The major metabolic 
actions of xenin include effects on gut motility, glucose 
homeostasis, insulin secretion, reducing food intake and 
promoting satiety (Cline et al. 2007, Cooke et al. 2016).  
Therefore, combination of biological actions of GIP and xenin 
to treat metabolic diseases and potentially combat bone fractures 
is a real possibility.  
In this regard, there has been increased interest in designing 
hybrid peptides that can target multiple regulatory pathways 
(Gault et al 2013, Irwin et al 2015).  Previous reports suggest 
that it is possible to design hybrid peptides through addition of 
key bioactive amino acid sequences (Yan et al. 2016, Fan et al. 
2017,). Indeed, a GIP/xenin hybrid peptide has recently been 
described and characterised (Hasib et al 2017). Moreover, it is 
already reported that use of amino acid oligopeptide tagging 
(Glu and Asp) can help deliver peptides to bones, due to 
preferential peptide deposition in hydroxyapatite (Takahashi-
Nishioka et al. 2008). This would enhances therapeutic 
applicability of peptides, such as the GIP/xenin hybrid (Hasib et 
al. 2017), for bone related disorders. Use of acidic oligopepties 
tagging is an innovative approach where repetitive L-Asp and L-
Glu acidic amino acid sequences will rapidly bind to 
hydroxyapaptite in bone (Teitelbaum & Ross 2003 and Lips 
2001). With this in mind, the present project has created 
GIP/xenin hybrids with either six C-terminal aspartic acid and 
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glutamic acid amino acid residues extensions, potentially 
making the peptide highly specific and selective to bone.  
Studies were conducted in high fat fed mice that have 
recognised bone defects associated with poor metabolic control 
(Kerckhofs et al. 2016, Koks et al. 2016, Yan et al. 2016). As 
well as assessing metabolic control, highly advanced imaging 
techniques were employed for assessment of bone quality and 
strength following 42 days administration of each peptide. These 
techniques included bone three-point bending, nanoindentation, 
quantitative backscattered electron imaging (QBEI) and fourier 
transformed infrared microscopy (FTIR) imaging. The findings 
of this study reveal that GIP/xenin hybrid peptides with C-
terminal L-Asp and L-Glu extensions have retained biological 
activity and possess distinct effects on diabetes control and bone 
health in high fat fed mice. 
 
6.3 MATERIALS AND METHODS 
6.3.1 Synthesis of peptides  
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu were purchased 
from EZ Biolabs Ltd. (Carmel, IN, USA). The peptides were 
identified and characterised by mass spectrometry as described 
in Section 2.1.2.  
6.3.2 Animals and study design 
Young male NIH Swiss mice (8 weeks old) were maintained on 
high-fat diet for three months. All the mice were housed 
separately in air conditioned room with 12 hour light and 12 
hour dark cycle. Mice were grouped (n=7) according body 
weight and blood glucose. Prior to commencing the experiment, 
all mice were injected with saline solution (0.9% NaCl) for 3 
days to acclimatise to the injection regimen. Group of high fat 
fed mice then received saline injection (0.9% NaCl), GIP/Xenin, 
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GIP/Xenin-Asp or GIP/Xenin-Glu (each at 25 nmol/kg bw) once 
daily for 42 days. Body weight, food consumption, non-fasting 
glucose and insulin concentrations were measured at regular 
intervals. Intraperitoneal glucose tolerance test (18 mmol/kg bw, 
18 hour fast) and non-fasting insulin sensitivity test (25 U/kg 
bw) were performed at the end of the study as described in 
Section 2.3.2 and 2.3.3 respectively. Bones were then collected 
and processed as noted in Sections 2.5.1 to 2.5.5, and described 
below. All experiments were carried out according to UK Home 
Office Regulations (UK Animals Scientific Procedures Act 
1986).  
6.3.3 Measurement of plasma insulin 
An insulin RIA was carried out as described in Section 2.4.2 to 
determine plasma insulin concentrations.   
6.3.4 Measurement of body composition, bone density and 
mineral content by DEXA scanning 
Isoflurane was used to anesthetize the mice before being placed 
on a specimen tray of the DEXA scanner. Bone mineral density 
(BMD), bone mineral content (BMC), lean mass, fat mass were 
determined as explained in Section 2.4. 
6.3.5 Three-point bending test 
 
Mechanical properties of the femur were assessed using three-
point bending. The properties examined were ultimate load, 
ultimate displacement, stiffness and work to failure ratio. 
Femurs were kept in vials containing saline (NaCl, 0.9%) so that 
they remained hydrated. Three- point bending was carried out as 







6.3.6 X-ray microcomputed tomography (µCT) 
 
Tibias were also processed for microcomputed tomography. 
Scanning of the tibias was carried out to assess trabecular bone 
mass, trabecular bone thickness, number of trabeculae, cortical 
bone diameter, cortical thickness, diameter of bone marrow and 




Nanoindentation was performed on bone as described in the 
Section 2.5.1 and following parameters were assessed: 
maximum force, hardness, indentation modulus and dissipated 
energy. Polymethylacrylate blocks were polished with three 
times with diamond particles to obtain smooth surface. 
Following this, blocks were left in saline (NaCl, 0.9%) solution 
for overnight and processed next morning.   
6.3.8 Quantitative backscattered electron imaging (qBEI) 
The polymethylmethacrylate blocks were polished three times, 
as above, and then subjected to carbon coating for 4 hrs. After 
carbon coating, the polymethylacrylate blocks were observed 
under scanning electron microscope as described in Section 
2.5.2 to assess bone mineral density distribution.  
6.3.9 Fourier transformed infrared (FT-IR) imaging and 
micro spectroscopy 
Following embedding of bone, as described in Section 2.x.x, 
sections (4 µm) were cut using a micrtome equipped with 
tungsten carbide knife and sandwiched between BaF2 optical 
windows. Spectral analysis was performed using Bruker Vertex 
70 spectrometer interfaced with Bruker Hyperion 3000 infrared 
microscope equipped with mercury cadmium telluride detector. 
Infrared spectra were recorded with an average of 32 scans in 
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transmission mode in the same locations as for qBEI and 
nanoindentation.  
 6.3.10 Statistical analysis 
Data were analysed using one-way or two-way ANOVA with 
two-tailed t-tests using PRISM 5.0. Data are expressed as mean 






6.4.1 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on body weight, fat mass, lean mass and food intake in 
high-fat fed mice  
 
Once daily administration of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu did not cause any significant changes in body 
weight (Figure 6.1 A), fat mass (Figure 6.1 B), lean mass 
(Figure 6.1 C) or food intake (Figure 6.2) in high fat fed mice.    
6.4.2 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on circulating blood glucose and plasma insulin in high-
fat fed mice  
There was no significant differences between groups of high at 
fed mice in terms of blood glucose (Figure 6.3 A) or plasma 
insulin (Figure 6.3 B) concentrations. 
6.4.3 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on glucose tolerance and insulin sensitivity in high-fat 
fed mice  
After injecting glucose intraperitoneally (18 mmol/kg bw) on 
day 42, blood glucose was significantly (p<0.001) reduced in all 
treatment groups when compared to saline controls at 60 mins 
post-injection (Figure 6.4A). In addition, GIP/Xenin-Asp treated 
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mice had lowered blood glucose levels at the 15 and 30 minute 
observation points, which corresponded with significantly 
(p<0.05) decreased AUC values in these mice (Figure 6.4B). No 
effect of the treatments was seen on plasma insulin 
concentrations at the time points examined (Figure 6.4C), 
however both GIP/Xenin-Glu and GIP/Xenin-Asp treated mice 
had a reduced (p<0.05) overall insulin secretory response 
(Figure 6.4D). Mice treated with GIP/Xenin, GIP/Xenin-Asp or 
GIP/Xenin-Glu had significantly (p<0.05 to p<0.001) deceased 
blood glucose values following injection of insulin at 15, 30, 60 
and 120 min when compared to saline controls (Figure 6.5A). In 
addition, GIP/Xenin-Glu mice had a reduced (p<0.05) overall 
glycaemic excursion (Figure 6.5B). 
 
6.4.4 DEXA analysis of whole body, femur, tibia and lumbar 
spine in in high-fat fed mice  
 
DEXA analysis on day 42 revealed that there was no difference 
in whole body or femoral BMD and BMC between all groups of 
high fat fed mice (Figure 6.6A-D). However, whilst lumbar 
BMD was also not different (Figure 6.7A) GIP/Xenin enhanced 
(p<0.01) lumbar BMC compared to saline controls (Figure 
6.7B). In addition, tibial BMD assessment (Figure 6.8.A) 
revealed that GIP/Xenin-Asp and GIP/Xenin-Glu both increased 
(p<0.01 and p<0.05, respectively) this parameter in high fat fed 
mice, BMC was similar in all groups (Figure 6.8.B).  
6.4.5 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on whole-bone mechanical properties in high-fat fed 
mice    
Three-point bending analysis revealed a reduction (p<0.01) in 
ultimate load bearing of femoral cortical bone following 42 days 
treatment with GIP/Xenin-Glu (Figure 6.9A). However, no 
significant changes in ultimate displacement were observed with 
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any of the treatment regimens (Figure 6.9B). Despite this, 
GIP/Xenin-Glu mice also presented with reduced (p<0.05) 
femoral cortical bone stiffness (Figure 6.9C). Interestingly, 
work-to-failure ratio was not significantly different within the 
groups of high fat fed mice (Figure 6.9D).  
6.4.6 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on trabecular bone morphology and cortical bone 
geometry in high-fat fed mice  
Microcomputed tomography (MicroCT) was performed to 
analyse trabecular bone volume, thickness, separation and 
number of trabeculae. Notably, none of the bone-specific 
GIP/Xenin hybrids affected these parameters (Figure 6.10A-C). 
However, GIP/Xenin treatment for 42 days increased (p<0.05) 
trabecular bone volume and the number of trabeculae (Figure 
6.10A,B). Cortical bone geometry was similar in all high fat fed 
mice, apart from those treated with GIP/Xenin-Glu (Figure 
6.11A-F). As such, cortical area (p<0.01), thickness (p<0.01) 
and moment of inertia (p<0.05) were reduced by GIP/Xenin-Glu 
treatment (Figure 6.11B, D,F). No changes in tibial overall area, 
bone marrow diameter and mineralisation were noted (Figure 
6.11A, C, and E). 
6.4.7 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on nanomechanical properties of cortical bone matrix in 
high-fat fed mice  
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu did not induce 
any significant changes in hardness (Figure 6.12A), indentation 
modulus (Figure 6.12B), force (Figure 6.12C) and dissipated 
energy (Figure 6.12D) of cortical bone matrix.  
6.4.8 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-




All the three variables analysed relating to bone mineral density 
distribution including Capeak, Camean and Cawidth at cortical parts 
of the tibia in high-fat fed mice were similar in all treatment 
groups when compared to high-fat fed controls (Figure 6.13A-
C) 
6.4.9 Effects of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-
Glu on bone at tissue level in high-fat fed mice 
Different parameters relating directly to the bone tissue were 
analysed using infrared spectroscopy. These parameters 
included collagen maturity, crystallinity, phosphate amide ratio 
and acid phosphate ratio (Figure 6.14A-J).  However, none of 
these factors were affected by 42 days once daily treatment with 






Bone resorption biomarkers have been shown to undergo a rapid 
change following food ingestion (Henrikson et al. 2003, Cross 
et al. 2017, Chandran 2017, Kline et al. 2017). This suggests 
that gastrointestinal hormones play a role in bone remodelling. 
Glucose dependent insulinotrpic polypeptide (GIP) is released 
by entero-endocrine K cells and GIP receptors are present on 
bone cells (Bollag et al.2000, Zhong et al 2007). Whilst there 
are many GIP-related studies focusing on diabetes and glucose 
dependent insulin secretion (Ramsey et al. 2017, Seino & Yabe 
2013, Li et al. 2016) less attention has been given to the fact that 
GIP has direct positive beneficial effects on bone. It has also 
been well established recently that xenin, co-secreted with GIP 
from K-cells, can potentiate the action of GIP (Martin et al. 
2016, Gault et al. 2015). Therefore, recently a GIP/xenin hybrid 
peptide has been characterised, that incorporates the benefits of 
204 
 
combined GIP and xenin activity into one single molecule 
(Hasib et al. 2017). Although highly effective, this hybrid 
peptide would have no specificity for bone tissue. Therefore, in 
this study bone-targeting GIP/xenin hybrid forms were created, 
through addition of six C-terminal acidic L-Asp and L-Glu 
amino acid residues by using acid oligopeptide tagging that 
encourages binding to mainly hydroxyapatite (Ulbrich et al. 
2016).  
Once daily administration of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu for 42 days had no effect on body weight or 
food intake in high-fat fed mice. Thus, any potential effect of 
the peptides on bone would not be linked to altered body weight, 
that can affect bone physiology (Harper et al. 2016, Meier et al. 
2016, MacDonell et al. 2016, Shanbhogue et al. 2016). In 
addition, we did not see any changes in non-fasted plasma 
glucose and insulin levels in high-fat fed mice. This is in 
contrast to previous studies with GIP/Xenin (Hasib et al. 2017), 
but could be due to frequency of peptide administered and type 
of diabetic model employed here. However, insulin is a known 
anabolic hormone in bone (Krishnan & Muthusami 2016, 
Bortolin et al. 2016, Anderson et al. 2017) and therefore 
changes in bone properties by each of the peptides can be 
viewed independently of altered insulin levels. In agreement 
with previous studies (Hasib et al. 2017), administration of 
GIP/Xenin and related bone-specific analogues improved 
glucose tolerance and enhance insulin sensitivity. This is 
encouraging, as it suggests that the C-terminal additions in 
GIP/Xenin-Asp and GIP/Xenin-Glu do not adversely affect 
biological activity. 
 
In terms on bone related analyses, DEXA analysis revealed that 
no difference in whole body and femoral BMD and BMC. 
However, lumbar BMC was enhanced by GIP/Xenin and tibial 
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BMD by GIP/Xenin-Asp and GIP/Xenin-Glu. This differential 
effect of the peptides on bone BMD and BMC is interesting and 
merits further detailed study. However, type 2 diabetic patients 
are noted to have increased or unchanged BMD (Vestergaard, 
2007), which may also be true for the high fat fed mice used in 
this study. Nonetheless, bone quality does not merely depend on 
BMD and BMC, and there are many other factors such as 
microarchitecture, bone matrix composition, biomechanical 
strength that play an important role in overall bone quality and 
integrity (Mieczkowska et al. 2013). Therefore, the current 
study assessed these parameters in more detail, in an attempt to 
separate the effects of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu on bone health in high fat fed mice. 
MicroCT was carried out to analyse trabecular bone volume, 
thickness, separation and number of trabeculae in the bone. It 
was found that the number of trabeculae and trabecular bone 
volume was increased in GIP/Xenin treated mice. In harmony 
with this, Gaudin-Audrain and colleagues reported that GIP 
receptor deficiency leads to modification of trabecular bone 
volume and reduction in number of trabeculae (Gaudin-
Audrain et al. 2013). The reason behind the lack of significant 
effect of GIP/Xenin-Asp and GIP/Xenin-Glu is intriguing, and 
perhaps more deposition in bone and reduced circulating 
peptide levels may explain this, although detailed studies 
would be required to confirm this. However, cortical bone 
geometry seemed to be detrimentally altered by GIP/Xenin-
Glu that could possibly be linked to the observed decrease in 
overall cortical bone strength noted from three-point bending 
studies. The reason why GIP/Xenin-Glu, but not GIP/Xenin-
Asp, should induce such effects is intriguing and suggests 
altered biological action and/or pharmacokinetics of these 
modified GIP/xenin hybrid molecules. Further studies would 
certainly be required, and of major interest, to resolve this 
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conundrum. Interestingly, Mieczkowska et al. in 2015 carried 
out study in double incretin receptor knock-out mice, where 
both GIP and GLP-1 receptors have been removed, and 
demonstrated reduced cortical bone mass and cortical bone 
strength. In our study, we found that cortical thickness was 
reduced by GIP/Xenin-Glu indicating that it might have 
deleterious effects on the cortex.  
 
Further assessment of cortical bone parameters was also 
conducted, in an attempt to further ascertain possible differential 
actions of GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu on 
bone. However, treatment of high fat fed mice for 42 days with 
each of the peptides had no obvious effect the nanochemical 
properties or cortical bone or mineral density distribution. 
Infrared spectroscopy was performed to analyse collagen 
maturity, crystallinity, phosphate amide ratio and acid phosphate 
ratio.  This analysis revealed that collagen maturity, crystallinity 
of the bone tissue, phosphate/amide ratio, carbon/phosphate 
ratio and acid phosphate was not significantly affected by any of 
the treatment regimens. Lack of clear effects could be due to the 
timing of injections, length of the study, age of mice at onset 
and the strain of mice employed. Indeed, it is worth bearing in 
mind that bone quality and strength determines overall bone 
integrity (Miller et al. 2017). As such, the strength of bone and 
its ability to resist fracture is not only dependent on bone 
geometry and bone mass but also on intrinsic material properties 
of the bone, microstructure, morphology, mineralisation and 
bone mass (Vennin et al. 2017). This is a complex process, and 
dependent upon many interlining variables. However, it seems 
clear that GIP/Xenin-Glu imparted detrimental effects on bone 
strength and quality in the current study. 
 
In conclusion, GIP/xenin, GIP/Xenin-Asp and GIP/Xenin-Glu 
all possessed beneficial metabolic effects in high fat fed mice. 
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Both GIP/xenin and GIP/Xenin-Asp appeared to have a positive 
impact on bone health. Considering that diabetes is linked to 
increased bone fractures and lower quality bone (Sosa & 
Eriksen 2017, Sheu et al. 2017, Nilsson et al. 2017) these hybrid 
peptides may merit further study as potential therapeutic 
candidates for diabetes, and particularly diabetic patients who 
























Figure 6.1 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on (A) body 





















(A) Body weight was measured for 3 days before and 42 days 
during (indicated by black horizontal bar) once daily treatment 
with saline vehicle (0.9%w/v NaCl), GIP/Xenin, GIP/Xenin-Asp 
and GIP/Xenin-Glu (each peptide at 25 nmol/kg bw). (B) %Fat 
mass and (C) Lean mass as measured by DEXA scanning in 
high fat fed mice on day 42 Values represent means ± SEM for 
7 mice.  
 
A 












































































Figure 6.2 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on 
cumulative energy intake in high fat fed mice 
   
































Cumulative energy intake was measured for 3 days before and 
42 days during (indicated by black horizontal bar) once daily 
treatment with saline vehicle (0.9% w/v NaCl), GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu (each peptide at 25 nmol/kg 















Figure 6.3 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on non 
fasting (A) blood glucose and (B) plasma insulin in high fat 
fed mice 
 



























    



























(A) Blood glucose and (B) plasma insulin were  measured for 3 
days before and 42 days during once daily treatment with saline 
vehicle (0.9%w/v NaCl), GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu (each peptide at 25 nmol/kg bw). Values 







Figure 6.4 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on (A) 
glucose tolerance and (C) plasma insulin response to glucose 




















Tests were conducted after once daily treatment with saline, 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu (each peptide at 
25 nmol/kg bw) for 42 days. (A) Blood glucose (C) plasma 
before and after i.p injection of glucose (18 mmol/kg bw) alone 
in 18 hour fasted mice. (B,D) AUC values for for 0-105 min are 
shown.  Values are mean ± S.E.M for 7 mice per group. *p< 
0.05, **p< 0.01, ***p< 0.001 compared with high fat fed 
control.  
A B 





























































































































Figure 6.5 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on insulin sensitivity 












Following 42 days treatment with saline, GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu (each peptide at 25 nmol/kg 
bw), insulin (25 U/kg bw) was injected intraperitoneally (at t=0) 
in non-fasted mice to assess insulin sensitivity. (A) Blood 
glucose and (B) blood glucose AUC values for 0-105 min are 
shown. Values represent means ± SEM for 7 mice. *p< 0.05, 















































































Figure 6.6 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on (A) whole 
body bone mineral density (BMD), (B) whole body bone 
mineral content (BMC), (C) femur bone mineral density 
(BMD) and (D) femur bone mineral content (BMC) in high 




















(A) Whole body bone mineral density (BMD) and (B) whole 
body bone mineral content (BMC), (C) femur BMD and (D) 
femur BMC as measured by DEXA scanning in high fat fed 
mice following 42 days treatment with GIP/Xenin, GIP/Xenin-
Asp and GIP/Xenin-Glu (each peptide at 25 nmol/kg bw). 






































































Figure 6.7 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on lumbar 
spine (A) bone mineral density (BMD) and (B) bone mineral 












Lumbar Spine (A) Bone mineral density (BMD) and (B) bone 
mineral content (BMC) as measured by DEXA scanning in high 
fat fed mice following 42 days treatment with GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu. Values represent means ± 














































Figure 6.8 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu for 42 days on tibia (A) 
bone mineral density (BMD) and (B) bone mineral content 











    
Tibia (A) Bone mineral density (BMD) and (B) bone mineral 
content (BMC) as measured by DEXA scanning in high fat fed 
mice following 42 days treatment with GIP/Xenin, GIP/Xenin-
Asp and GIP/Xenin-Glu. Values represent means ± SEM for 7 















































Figure 6.9 Effects of once daily administration of GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin- Glu for 42 days on whole-
bone mechanical properties of femoral cortical bone in high 




















Parameters were obtained following 3-point bending tests after 
42 days once daily administration of GIP/Xenin, GIP/Xenin-Asp 
and GIP/Xenin- Glu (each at 25 nmol/kg b.w) in high fat fed 
mice. Values are mean ± S.E.M for 7 mice. *p< 0.05, **p< 0.01 





































































































Figure 6.10 Effects of once daily administration of 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu on 























Parameters were obtained from a microtomography scan of tibia 
following 42 days once daily administration of saline (0.9%, 
w/v, NaCl), GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu 
(each at 25 nmol/kg b.w).  Values are mean ± S.E.M for 7 mice.  


























































Figure 6.11 Effects of once daily administration of 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu on cortical 




















Images of cortical bone were obtained from a microtomography 
scan of tibia following 42 days once daily administration of 
saline (0.9%, w/v, NaCl), GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu (each at 25 nmol/kg b.w). Cortical bone was 
located 3 mm below growth plate and Total area (A), cortical 
area (B), bone marrow diameter (C) cortical thickness (D), bone 
mineralisation and moment of inertia (F) were measured. Values 
are mean ± S.E.M for 7 mice. *p<0.05, **p<0.01 compared to 











































































































Figure 6.12 Effects of GIP/Xenin, GIP/Xenin-Asp and 
GIP/Xenin-Glu on nanomechanical properties of cortical 









            
 
 







Parameters were measured by nanoindentation following 42 
days once daily administration of saline (0.9%, w/v, NaCl), 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu (each at 25 































































































Figure 6.13 Effects of once daily administration of 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu on cortical 
bone mineral density distribution (BMDD) in high-fat fed 
mice 
 























Bone mineralisation at cortical bone was measured by 
quantitative backscattered electron imaging following 42 days 
once daily administration of saline (0.9%, w/v, NaCl), 
GIP/Xenin, GIP/Xenin-Asp and GIP/Xenin-Glu (each at 25 
































































Figure 6.14 Effects of once daily administration of 






















































































































































































(A) Collagen maturity-mean, (B) collagen maturity width, (C) 
crystallinity-mean, (D) crystallinity-width, (E) phosphate/amide 
ratio mean, (F) phosphate/amide ratio-width, (G) 
carbon/phosphate ratio-mean, (H) carbon/phosphate ratio-width 
(I) acid phosphate mean and (J) acid phosphate with were 
measured by infrared spectroscopy following 42 days once daily 
administration of saline (0.9%, w/v, NaCl), GIP/Xenin, 
GIP/Xenin-Asp and GIP/Xenin-Glu (each at 25 nmol/kg b.w). 








































































































7.1 Overview  
Diabetes mellitus is characterised by high blood glucose levels 
during which the pancreas is unable to synthesise sufficient 
insulin, or the body is unable to effectively utilise it (Moon et al. 
2017). Diabetes mellitus is metabolic syndrome and it is a 
chronic, progressive incompletely understood disease (Chaudhury 
et al. 2017).  Diabetes causes huge economic burden to the 
society (Pradeepa & Mohan 2017). The two main forms of 
diabetes include type 1 diabetes mellitus (T1DM) and type 2 
diabetes mellitus (T2DM). T1DM is mostly seen in young 
individuals and is mainly characterised by inability of pancreatic 
beta cells to produce sufficient insulin and accounts for 10 % of 
cases of diabetes worldwide (International Diabetes Federation, 
2014). T2DM is mainly seen in aged individuals, but also now 
increasingly in the young, and it is mainly characterised by 
ineffective utilisation of insulin and accounts for 90% of the cases 
of diabetes (Powers et al. 2017).  Several complications of 
diabetes are very well known along with severe bone impairments 
and an increase in fracture risk (Sanches et al. 2017). However, 
there are inconsistencies in bone mineral content (BMC) and bone 
mineral density (BMD) measurements in T1DM and T2DM 
patients (Oei et al. 2015, Moayeri et al. 2017). Nonetheless, there 
is no doubt that diabetes plays an important role in increasing 
bone fracture risk (Russo et al. 2016).   
 
In the recent years, there has been growing interest in 
understanding impact of diabetes on bone fractures and develop 
new therapeutic approaches for treatment of fractures (Morley et 
al. 2017). The major factors responsible for bone fractures risk are 
discussed in Section 1.1.3. Several studies have identified the 
insulinotropic incretin hormones, GIP and GLP-1, to have 
beneficial effects on bone (Hu et al. 2016, Hansen et al. 2017, 
Mabilleau et al. 2013, Mabilleau et al. 2014, Meiczkowska et al. 
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2015, Mabilleau 2017) opening a new arena of incretins and bone 
biology.   
 
In this thesis, the potential of incretin based therapies as a 
treatment option against bone fractures was assessed. In 
particular, the impact of acidic olgionucleotide tagging of these 
peptides was employed (Dalal & Jana 2017), in order to 
preferentially direct the peptides towards bone.  Bone-specific 
peptides (D-Ala2)GIP, (D-Ala2)GIP-Asp, (D-Ala2)GIP-Glu, (D-
Ala2)GLP-1, (D-Ala2)GLP-1-Asp, (D-Ala2)GLP-1-Glu, Xenin-
25[Lys13PAL], Xenin-25[Lys13PAL]-Asp, GIP/Xenin, 
GIP/Xenin-Asp, GIP/Xenin-Glu were designed and tested.  
 
 The main experiments in this thesis includes, in vitro studies in 
sarcoma osteogenic SAOS-2 cells as well as assessing effects of 
the peptides in glucose homeostasis and bone quality in a high-fat 
fed diabetic mouse model. Bone quality was assessed using 
sophisticated imaging techniques to examine bone 
microarchitecture, tissue material properties, bone mass and bone 
strength to gain deeper understanding of bone mechanics.  
 
7.2 In vitro studies with GIP, GLP-1, xenin and GIP/Xenin 
hybrid analogues  
GIP, secreted from enteroendocrine K-cells and GLP-1, secreted 
from L-cells, although primarily regarded as insulin-releasing 
hormones (Kim & Sandoval 2017), are both known to play 
important roles in bone remodelling (Mabilleau et al. 2016, Seino 
& Yabe 2013, Lepsen et al. 2015, Zhao et al. 2017). There is no 
published evidence of an action of xenin on bone however; xenin 
is known to potentate biological action of GIP (Martin et al. 
2016).  Hence, there is a possibility that xenin might have some 
effect on bone, either directly or indirectly through GIP. Initially 
the insulinotropic activity of all peptides was examined in BRIN 
BD11 cells to confirm retention of bioactivity. The results were in 
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harmony with the previous studies that have reported similar 
findings (Holst et al. 2016, Martin et al. 2016, Hasib et al. 2017, 
Parthsarthy et al. 2016).  As it is widely reported that GIP 
receptors are present on the bone (Garg et al. 2015), the sarcoma 
osteogenic SAOS-2 osteoblast cell line was used.  Alkaline 
phosphatase activity was increased from 24 to 72 h after 
incubation with GIP analogues. The results were in agreement 
with previous studies which showed direct effects of GIP on 
osteoblasts (Pujari-Palmer et al. 2016, Lee et al. 2016, Mabilleau 
et al. 2013). Similar results were obtained with regards to GLP-1 
and GIP/Xenin hybrid peptides. These peptide also enhanced 
TGF-β and IGF-1 release from SAOS-2 cells. Xenin did not show 
any activity regarding alkaline phosphatase, TGF-β and IGF-1 
release. As such, further investigation is needed regarding effects 
of xenin on bone. IGF-1 is known for its dual action as it helps in 
proliferation and differentiation of bone cells. For example, 
positive effects of IGF-1 on bone mineralisation have been 
reported (Giustina et al 2008, Xian et al. 2012). Regarding the 
cAMP assay, direct effects of GIP and GLP-1 on SAOS-2 cells 
were observed indicating activation of cAMP signaling pathways, 
as seen in other cell lines (Hansen et al. 2017). In GIP/Xenin 
hybrid peptides, cAMP production was seen but that could be 
mainly due to activation of GIP receptors (Hasib et al. 2016). 
Importantly, bone-specific tagged oligopeptides retained their 
biological activity in BRIN BD11 and SAOS-2 cell lines. The 
findings from strongly reiterate the possibility of using these 
analogues as potential therapeutic option for bone fractures.  
 
 
7.3 In vivo and bone assessment studies with GIP family 
peptides  
Glucose dependent insulinotrpic polypeptide (GIP) is secreted by 
entero-endocrine K cells (Yamane et al. 2016). It is already 
known that GIP receptors are present on bone cells (Bollag et 
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al.2000, Zhong et al 2007).  GIP has direct positive beneficial 
effects on bone (Hansen et al. 2017). Various studies have been 
carried out which focus on the aspect of using GIP as a 
therapeutic option for treatment of fragility fractures (Mabilleau 
et al. 2015, Mansur et al. 2016).   
There was no effect on body weight and food intake in high-fat 
fed mice. Glucose was significantly reduced by day 42. Tolerance 
towards glucose was enhanced by (D-Ala2)GIP-Asp. DEXA 
analysis was performed on all the mice and revealed no difference 
in overall, femoral and lumbar BMD and BMC. However, BMC 
assessment of tibia, revealed that BMC was increased (p<0.01) 
suggesting the potential benefits of (D-Ala2)GIP-Asp. These 
findings are in harmony eith the previous study (Varela et al. 
2017).   
MicroCT was performed to determine cortical area, bone 
mineralisation, moment of inertia and cortical thickness. Cortical 
thickness and total area was enhanced in the mice treated with (D-
Ala2)GIP-Asp.  The rest of the parameters remain unchanged in 
the mice treated (D-Ala2)GIP and (D-Ala2)GIP-Asp. Previous 
studies highlighted similar findings backing the idea of positive 
effects of GIP on bone (Mansur et al. 2015, Lee et al. 2016). A 
recent review suggested GIP has dual action on bone, to improve 
bone strength and bone integrity (Mabilleau 2017).  Cortical 
thickness was reduced in the mice treated with (D-Ala2)GIP-Asp, 
and interestingly it has been reported that hyperglycemia causes 
alterations and modifications in bone collagen (Poundarik et al. 
2015).   
Infrared spectroscopy was used to perform analysis of collagen 
cross-linking, crystallinity of hydroxyapaptite, degree of 
mineralisation, degree of carbonate substitution and content of 
acid phosphate.  Out of which collagen cross-linking was 
enhanced significantly in the mice treated with (D-Ala2)GIP and 
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(D-Ala2)GIP-Asp.  Positive effects of GIP on collagen cross-
linking suggest GIP plays an important role in improving bone 
strength at tissue level (Mieczkowska et al. 2015, Mansur et al. 
2016).  The rest of the parameters were not affected by the 
treatment.  These findings reveal that bone biology is goverened 
by different factors andfurther assessment of bone biomechanics 
is necessary.  
 
7.4 In vivo and bone assessment studies with Xenin family 
peptides   
Xenin is co-secreted with GIP from K-cells and it is already 
reported that xenin augments the biological activity of GIP 
(Martin et al. 2016, Hasib et al. 2017). Based on this fact, there is 
a possibility that xenin might affect bone metabolism because it is 
well known that GIP has positive effects on bone metabolism 
(Garg et al. 2015, Mantelmacher et al. 2017). However, to date, 
there is absolutely no evidence that demonstrates direct effects of 
xenin on bone. Indeed, data reported in Chapter 3 in this thesis 
might also suggest lack of direct effects. 
In these studies, we found that both the xenin peptides had no 
impact on body weight or food intake in lean and high-fat fed 
mice. Xenin-25[Lys13PAL] did not show any effect on glucose or 
insulin levels in lean mice, but significantly reduced circulating 
glucose in high fat fed mice. DEXA analysis revealed interesting 
findings regarding Xenin-25[Lys13PAL] and Xenin-
25[Lys13PAL]-Asp in lean and high-fat fed mice. In high-fat fed 
mice, Xenin-25[Lys13PAL] increased whole body BMC, with no 
effect of Xenin-25[Lys13PAL]-Asp. Lumbar BMC was increased 
by Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp, whereas 
tibial BMC was increased only by Xenin-25[Lys13PAL] 
treatment. In lean mice, lumbar BMD was decreased while tibial 
BMC was increased by Xenin-25[Lys13PAL]. These differences 
regarding BMC and BMD reveal that xenin possibly differentially 
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affects each bone region, indicating the need for further detailed 
study. However, it should be remembered that inconsistencies are 
observed in T2DM patients as BMD is unchanged, or slightly 
elevated, in these patients despite increased bone fracture risk 
(Asokan et al. 2017). However, bone quality does not merely 
depend upon BMC and BMD but on many other factors such as 
microarchitecture, bone matrix composition and biomechanical 
strength that play an important role in overall bone quality and 
integrity (Christiana Zidrou 2016).  
In this regard, the number of trabeculae and trabecular bone 
volume were reduced by Xenin-25[Lys13PAL] in lean control 
mice, with increased trabecular separation suggesting a negative 
impact of xenin on bone under normal physiological conditions. 
Regarding high fat fed mice, microcomputed tomography results 
revealed reduction in bone volume and number of trabeculae with 
increased trabecular separation after treatment with Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp. Cortical bone 
parameters did not show any changes after treatment with both 
Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp. Xenin-
25[Lys13PAL] induced significant benefits on the nanomechanical 
properties of cortical bone including increase in hardness, 
indentation modulus and force. Based on the results, it is evident 
that Xenin-25[Lys13PAL]-Asp did not possess any real positive 
effects on the bone rather, it decreased collagen maturity in high-
fat fed mice. However, fatty acid derivation of Xenin-
25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp, might obstruct the 
actions of acidic oligopeptide tagging to deposit the peptide in 
bone, likely through stearic hindrance (Narayana et al. 2015). 
Despite this, Xenin-25[Lys13PAL] and Xenin-25[Lys13PAL]-Asp 
did possess beneficial metabolic effects and most importantly 
Xenin-25[Lys13PAL] showed some positive effects in diabetic 
bone, even though the results were inconsistent under normal 
physiological conditions. Detailed studies are still required to 
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fully understand the effects of xenin on bone biology, and 
whether related analogues can be used as potential therapeutic 
options for treatment against bone fractures.  
 
7.5 In vivo and bone assessment studies with GIP/Xenin 
hybrid family peptides   
There is compelling evidence that suggests glucose-dependent 
insulinotropic polypeptide (GIP) has positive effects on bone 
(Mabilleau et al. 2016, Christensen et al. 2017).  Xenin is known 
to potentiate the action of GIP (Martin et al. 2016, Gault et al. 
2015), and a GIP/Xenin hybrid peptide has recently been 
characterised (Hasib et al. 2017). This hybrid peptide combines 
GIP and xenin activity into one molecule making it very unique 
and use it as a therapeutic option for diabetic disorders. The 
addition of six C-terminal acidic L-Asp and L-Glu amino acid 
residues by using acid oligopeptide tagging is believed to make 
peptides more specific towards bone by encouraging its binding to 
hydroxyapaptite (Ulbrich et al. 2016). No changes were seen in 
non-fasted plasma glucose and insulin levels in high-fat fed mice 
with these drugs. The results somewhat contradict findings from 
the previous study with GIP/Xenin (Hasib et al. 2017). The 
possible explanation could be due to number of factors such as 
frequency of the peptide administration, dose of the peptide and 
type of diabetic model. Bone-specific analogues- GIP/Xenin-Asp 
and GIP/Xenin-Glu did improve glucose homeostasis and insulin 
sensitivity, which is in harmony with the previous studies (Hasib 
et al. 2017). These results suggested that the C-terminal additions 
(GIP/Xenin-Asp and GIP/Xenin-Glu) did not alter the 
pharmacological activity of GIP/Xenin. DEXA analysis revealed 
that GIP/Xenin enhanced lumbar BMC while GIP/Xenin-Asp and 
GIP/Xenin-Glu increased tibial BMD. Again, some small 
inconsistencies were observed regarding BMC and BMD, as 
reported in the Chapter 5. However, the importance of these 
measurements in diabetes is questionable (Asokan et al. 2017).  
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Microcomputed tomography revealed that GIP/Xenin treated 
mice had increased trabeculae number and trabecular bone 
volume. These results were in accordance with the previous 
studies with GIP (Gaudin-Audrain et al. 2012). Interestingly, 
GIP/Xenin-Asp and GIP/Xenin-Glu did not have any significant 
effect on trabecular parameters. This might be because either the 
peptide was deposited excessively in bone, or reduced circulating 
levels of the peptides. GIP/Xenin-Glu evoked deleterious effects 
on cortical bone geometry, suggesting altered biological action of 
GIP/Xenin hybrid molecules. Infrared spectroscopy analysis 
revealed no significant changes regarding collagen maturity, 
crystallinity of the bone tissue, phosphate/amide ratio, 
carbon/phosphate ratio and acid phosphate.  The possible 
explanation could be duration of the study, age of the mice, strain 
of the mice and timing of injections. There are many factors that 
govern overall bone integrity and bone quality such as 
microarchitecture, bone mineralisation and bone mass. Taken 
together, GIP/Xenin and GIP/Xenin-Asp demonstrated a positive 
impact on bone health in diabetic high fay fed mice. Hybrid 
peptides have opened up a whole new frontier in terms of 
therapeutics, and future studies are required to look into the 
potential therapeutic options for diabetic bone disorders. 
 
7.6 Overall impact of oligopeptide tagging on bone 
parameters 
The effects of oligopeptide tagging were encouraging. Diabetic 
mice treated with tagged peptide- (D-Ala2)GIP-Asp had 
augmented bone marrow diameter and cortical thickness 
alongwith total area. These results were in harmony with the 
previous studies which report a positive impact of gastric 
inhibitory polypeptide (GIP) on bone biology (Mabilleau et al. 
2016). No positive effect of Xenin tagged peptides was seen on 
different bone parameters. On the contrary, xenin tagged peptide- 
Xenin-25[Lys13PAL]-Asp, showed reduction in number of 
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trabeculae as well as increase in tibial separation suggesting xenin 
might have negative effects on bone biology. However, more 
studies are needed to be performed in order to confirm this effect. 
The hybrid peptide- GIP/xenin-Asp increased bone marrw 
diameter and cortical thickness. MicroCT analysis revealed that 
trabecular bone volume and number of trabeculae were also 
augmented in the mice treated with GIP/Xenin peptide. However, 
there are some contradictions in the results with these tagged 
peptides, with some positive some negative findings findings. 
One thing is clear, that bone biology is extremely complex 
process with many players in the game, making it difficult for 
researchers to draw a perfect strategy to combat bone fractures. 
Nonetheless, one cannot deny the fact that diabetes does impact 
bone biology with increase risk in bone fractures (Nilsson et al. 
2017), suggesting further studies are required to assess tagged 
oligopeptides (Narayana et al. 2015) as potential therapeutic 
option for treatment of bone fractures.   
There are different labeling and statining techniques to assess 
molecular activities in the bone. Resorption, bone formation and 
mineralisation can be studied with the help of staining techniques 
(Erben et al. 2017).  Established techniques include fluorochrome 
labeling with alizarin red S to analyse calcium deposition and 
sirus red stainin to determine presence pof collaen in the bone 
(Segnani et al. 2015).  A study carried out by Takahashi-Nishioka 
in 2008 demonstrated that fluorescein-labeled L-Asp hexapeptide 
localised only in the bone and not any other tissue in mice. 
Indeed, the peptide was detected in the bone even after 14 days of 
administration suggesting specificity and affinity of tagged 
peptides to hydroxyapaptite making them strong contenders as 
potential therapeutic treatment for bone (Takahashi-Nishioka et 




7.7 Oligopeptide tagging and its impact on blood glucose, 
body weight, food intake and insulin sensitivity  
(D-Ala2)GIP and (D-Ala2)GIP-Asp tagged peptides did not have 
any any effect on body weight and food intake in high-fat fed 
mice but did have reduced blood glucose at the end of 
experiment. (D-Ala2)GIP-Asp enhanced tolerance.  Similar 
findings were seen with xenin treated mice with no effect on body 
weight and food intake. It is already reported that xenin induces 
appetite suppression (Kaji et al. 2017) but only with higher dose 
than the dose used in the study. Xenin-25[Lys13PAL] showed 
improved glucose tolerance and insulin sensitivity in accordance 
with the previous studies (Gault et al. 2015, Martin et al. 2016 
and Hasib et al. 2017).  Xenin did not have any effect on bone 
biology suggesting there is a need for further investigation.  
However, no changes were observed in insulin and non-fasted 
plasma glucose levels in high-fat fed mice. These findings were 
contradictory to the previous studies (Hasib et al. 2017).  There 
are many factors such as dose and frequency of the peptide 
administered as well as type of the diabetic model used in the 
study. GIP/Xenin analogues improved glucose tolerance and 
enhanced insulin sensitivity. These findings were in harmony with 
previous studies (Hasib et al. 2017).  Overall, bone-targeting 
peptides designed through addition of six C-terminal acidic L-Asp 
and L-Glu amino acid residues, did not impede upon the 
metabolic benefits of the parent peptides.  
7.8 Role for oligopeptides peptides for bone disorders beyond 
diabetes  
Targeted drug delivery to the bone can be achieved by acidic 
homopeptides (Nishioka et al. 2006).  It was reported that 
fluorescence-labelled acidic amino acid (L-Asp & L-Glu) 
containing six amino acid residues show strong affinity towards 
hydroxyapatite which is major component of bone (Takahasi-
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Nishioka et al. 2008).  Osteoporosis is common problem in aged 
women, particularly after menopause (Kling et al. 2013). 
Estrogen has anabolic efects on bone through estrogen-receptor 
mediated mechanisms (Manolagas et al. 2013). Tagging of 
estradiol with L-Asp hexapeptide exerted positive osteogenic 
effects on the bone without adverse effects on any other organ 
(Stapelton et al. 2017). In case of levofloxacin, which is used in 
treating chronic osteomyelitis; similar results were obtained when 
levofloxacin was tagged with L-Asp hexapeptide suggesting 
positive beneficial effects of oligopeptide tagging (Philips et al. 
1988, Mader et al. 1990). Tissue-nonspecific alkaline phosphatase 
(TNSALP) is present in bone, kidney, liver and adrenal tissue 
(Michael P White 2016). The deficiency of TNSALP results in 
hypophosphatasia and leads to defective bone minealisation 
(Meaah et al. 2017).  Studies conducted previously showed that 
enzyme replacement therapy was not suitable option because of 
the adverse effects on other vital organs (Whyte et al. 1984, 
Whyte et al. 1986). Another study recommended continous 
delivery of high doses of TNSALP to initiate bone minelisation 
process (Murshed et al. 2005).  L-Asp tagging of TNSALP 
induced positive effects on bone quality wih enhanced bioactivity 
and increase in bone minealsation (Orimo 2010). It is clear from 
these different studies that acidic oligopeptide tagging is efficient 
for achieving bone specific targeted drug delivery.  There are 
concerns related to the use of tagged peptides mainly because of 
alterations in pharmacokinetic and biological properties (Saeui et 
al. 2017). Other factors such as biological activity, blood 
clearance and distribution to visceral organs could also be 
important, especially due to their increased hydrophilicity 
(Takahashi-Nishioka et al. 2008).   However, taken together these 
observations suggest a promising future for tagged acidic 




Future prospects and conclusion 
The data in this thesis includes in-vitro studies with bone specific 
GIP, GLP-1, xenin and GIP/Xenin analogues in sarcoma 
osteogenic SAOS2 cells as well as use of high-fat fed mice model 
to study in-vivo effects of these bone specific analogues. This 
thesis also includes bone assessment results which were 
performed using highly sophisticated and advanced imaging 
techniques such as QBEI, nanoindentation, three-point bending 
and FTIRI. The findings of this thesis highlight beneficial effects 
of incretin-based mimetics on bone. Further assessment is 
necessary to develop potential therapeutic treatment options 
against bone impairements.  
The summary of future work is as follows:   
 
1. More studies need to be carried out to highlight the 
safety, efficacy and tolerability of GIPR agonists, 
GLP-1R agonists, and hybrid analogues.   
 
2. Clinical trials need to be undertaken in order to study 




3.  As diabetes is multifactorial in nature. Several 
pathways come into play indiabetes. In order to target 
these pathways, double or triple-acting agonists, 
cocktails or hybrid stable analogues need to be 
developed.  
 
4. Deeper understanding is required regarding mechanism 





In conclusion, the findings of this thesis highlights the use of 
incretin-based mimetics as new therapeutic approach for the 
treatment of fragility fractures associated with type 2 diabetes. 
This thesis will provide valuable information that can be used to 
design future studies and provide deeper insight in diabetes and 
bone biology. Very few clinical tirlas have been carried out to 
understand impact of type 2 diabetes on bone. Hence, this work 
will serve as platform to deisgn clinical trials to study effects of 
different incretin-based drugs on bone and help people who are 
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